62nd ASH Annual Meeting and Exposition: Author Index L

La Barba, G.

50 - Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study

La Clair, J.

116 - Selective Targeting of Alternative Splicing Deregulation in Pediatric Acute Myeloid Stem and Progenitor Cells

La, L.

3244 - Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect^® MM Registry

La Nasa, G.

2156 - Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

La Rosa, C.

1482 - Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients

La Spina, E.

2175 - Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients
3161 - The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells

La Starza, R.

469 - In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

La Torre, I.

Labanieh, L.

556 - CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering

LaBarge, S.

566 - Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

LaBelle, J.

191 - Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)

Labianca, R.

886 - Thrombin Generation and D-Dimer Significantly Predict for Early Disease Progression and Mortality in Patients with Gastrointestinal Cancer

Labkoff, S. E.

1327 - A Next Generation Liquid Biopsy Approach for Multiple Myeloma
2266 - Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients

Labopin, M.

79 - Personalized Risk-Profiling for Acute Leukemia Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the EBMT
562 - Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT
614 - Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2386 - Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
2425 - Use of Post-Transplant Cyclophosphamide in One-Antigen Mismatched Unrelated Donor Transplantation Results in Similar Transplant Outcomes Than Haploidentical Hransplantation: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the EBMT
2429 - Impact of Donor Kinship on Non-T-Cell Depleted Haploidentical Stem Cell Transplantation (haploHCT) with Post Transplantation Cyclophosphamide (PTCy): From the ALWP of the EBMT
3344 - Outcomes of Hematopoietic Stem Cell Transplantation from Non T– Cell Depleted Haploidentical Versus Matched Sibling Donor in Adult Patients with Acute Lymphoblastic Leukemia in Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrowtransplantation
3355 - Reduced Intensity Vs. Non-Myeloablative Conditioning Regimens for Haploidentical Transplantation in Complete Remission Acute Myeloid Leukemia: A Study from the ALWP of the EBMT

Laborde, S.

845 - Patients’ Reported Perceptions on Satisfaction with Immune Thrombocytopenia Treatments: Results from the ITP World Impact Survey (I-WISh)
1760 - A Patient’s Perspective on Impact of Immune Thrombocytopenia on Emotional Wellbeing: ITP World Impact Survey (I-WISh)
2668 - Higher Symptom Burden in Patients with Immune Thrombocytopenia Experiencing Fatigue: Results from the ITP World Impact Survey (I-WISh)

Labotka, R. J.

1381 - Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial
2318 - Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Labrador, J.

634 - Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry
1033 - Comparison of Azacitidine and Decitabine for the Treatment of Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
1082 - Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19
2850 - Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The Pethema Registry Experience

Labropoulou, S.

2648 - Rapid Reduction of Anti–Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study

Labrune, P.

1735 - How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry

Labudde, E. J.

3474 - Frequency and Timing of Palliative Opportunities in Pediatric Patients with Hematologic Malignancies

Labussière, H.

422 - Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program
462 - Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
496 - Viral Reactivation in Acute Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: Stimulation of the Immune System

Labussière-Wallet, H.

562 - Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT

Lacagnina, M. J.

2613 - Validation of a Peripheral Blood-Derived Microglia-like Cell System

LaCasce, A. S.

531 - Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
2216 - Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
2936 - Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Lacayo, N. J.

397 - Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia
466 - Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
1233 - Comparison of the Transcriptomic Signatures in Pediatric and Adult CML
1975 - A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children
2781 - Genetic Modulators of Niclosamide Sensitivity and Resistance in Acute Myeloid Leukemia

Lacerda, J. F.

1006 - Disseminated Intravascular Coagulation Score Evolution in 48 Hours Predicts Early Death in Newly-Diagnosed Chemotherapy-Treated Acute Promyelocytic Leukemia Patients

Lacey, S. F.

2224 - Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Lachance, S.

1485 - UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Lachey, J.

769 - Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants
771 - Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron
2582 - Ker-050, a Modified Actriia Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies
2736 - Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation

Lachica, C. A.

1870 - Novel Target Genes and Epigenetic Pathways Involved in High Risk Acute Lymphoblastic Leukemia

Lachmann, H. J.

1332 - The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

Lachota, M.

826 - Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells

Lachowiez, C.

332 - Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Lacombe, C.

1994 - IDH Mutations Identify a Subgroup of NPM1 Patients with a More Favorable Prognosis. a Retrospective Multicenter Study of the Filo Group

Lacy, M. Q.

1141 - Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes
1302 - Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis
1336 - A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
1508 - Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents
1516 - Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis
2244 - MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
2248 - Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma
2257 - The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma
2280 - Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
2306 - Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
2312 - Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis
2420 - Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation
3160 - Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
3165 - Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma
3184 - Assessing the Utility of Monitoring IgA Multiple Myeloma Patients with Quantitative Serum IgA Levels
3196 - Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
3228 - Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients
3231 - Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia
3246 - Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis
3341 - Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation

Laderas, T.

567 - A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Ladetto, M.

525 - Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)
2217 - Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study
3325 - Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Ladha, A.

1034 - Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All “Non-Adverse” Risk AML

Ladines-Lim, J.

101 - Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience

Ladogana, S.

1586 - Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus

Ladon, D.

949 - A Novel Human Fetal Model of CRISPR-Cas9-Induced MLL-AF4 Leukemia Faithfully Recapitulates Infant ALL and Can be Used to Unravel MLL-AF4 Function

Laetsch, T. W.

1936 - Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Laetsch, T. W.

466 - Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
468 - Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Laetsch, T. W.

269 - Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Lafaro, P.

3297 - Reduction of Clostridium Difficile Infection in an Academic Medical Center Blood and Marrow Transplant Population

Lafaurie, M.

2584 - Autoimmune Hemolytic Anemia: A Disease of the Elderly and the Very Elderly with Increased Mortality and Increased Rates of Hospitalization for Thrombosis and Infection
2662 - Eltrombopag for Immune Thrombocytopenia in Adult Patients in the Real-World in France. Final Results of the Elextra Study

Laferriere, N. B.

413 - A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Laffan, M.

1372 - Prospective Study Reveals Increased Platelet Function Associated with Multiple Myeloma and Its Treatment

Lafiatis, I.

1702 - An Epidemiological, Retrospective Cross-Sectional Study to Capture the Real-World Complication Burden, and Disease Management Paradigms in Transfusion-Dependent Beta-Thalassemia Adults in Greece: Interim Results of the Ulysses Study

Lafioniatis, S.

1702 - An Epidemiological, Retrospective Cross-Sectional Study to Capture the Real-World Complication Burden, and Disease Management Paradigms in Transfusion-Dependent Beta-Thalassemia Adults in Greece: Interim Results of the Ulysses Study

Laframboise, T.

259 - Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
284 - Characterization of the Blood and Bone Marrow Microbiome of MDS Patients and Associations with Clinical Features
929 - Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence
2776 - Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

LaFramboise, T.

257 - Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia
3100 - Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA

Lagana, A.

1103 - Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model
3154 - Patient Similarity Network of Multiple Myeloma Identifies Patient Subgroups with Distinct Genetic and Clinical Features

Lagana, S. M.

734 - Glucagon-like Peptide-2 (GLP-2) Treatment Reduces Gvhd-Related Mortality in a Pre-Clinical Transplant Model Via Expansion of Macrophages with Tolerogenic Potential

Lagarkova, M. A.

1113 - The Altered Functional Status of Bone Marrow Stromal Progenitor Cells in Patients with Diffuse Large B-Cell Lymphoma without Bone Marrow Involvement Does Not Recover Many Years after Treatment

Lagarrigue, F.

829 - Differential Use of Rap1 Effectors for Integrin Activation in Platelets and Lymphocytes

Lage, L. A. D.

2085 - GATA3 Gene - a Potential New Biomarker Associated with Adverse Outcomes in ALK1-Negative Anaplastic Large Cell Lymphoma: Preliminary Results from a Retrospective Cohort of 80 South American Cases of Nodal Peripheral T Lymphoma
2134 - Overexpression of the OCT-1 Gene Is a Biomarker Associated with Poor Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) - Data from a Retrospective Cohort from Latin America: Defining a Very High-Risk Clinical-Molecular Subgroup

Lagerlöf, I.

3033 - Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Lähdesmäki, H.

711 - Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia

Lahiry, A.

3028 - A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Lahoud, O. B.

470 - Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
1369 - Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
2097 - Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
3204 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Lähteenmäki, P. M.

467 - NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Lahue, B. J.

2518 - Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Lahuerta, J. J.

62 - Discordances between Immunofixation (IFx) and Minimal Residual Disease (MRD) Assessment with Next-Generation Flow (NGF) and Sequencing (NGS) in Patients (Pts) with Multiple Myeloma (MM): Clinical and Pathogenic Significance
415 - Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)
1329 - A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform
2252 - Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma
2261 - Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Lai, B. S.

2461 - Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

Lai, C.

431 - Impact of Treatment Facility Chracteristics on Patient (Pt) Outcomes in Acute Myeloid Leukemia (AML) Using Data from the National Cancer Database (NCDB)
1650 - Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
2001 - TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
2110 - Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma
2570 - Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
2943 - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Lai, C. M.

2041 - R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Lai, D.

2219 - Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Lai, G.

1175 - Identification of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Lai, G.

37 - Modeling Marginal Zone Lymphomagenesis

Lai, H. C.

619 - Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study
2435 - An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation
3363 - Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Lai, J.

94 - Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Lai, K.

303 - 10-Year Mortality in Patients with Sickle Cell Disease from a Large Population-Based Cohort
1727 - Healthcare Utilization Among Children and Adolescents with Sickle Cell Disease during the COVID-19 Pandemic

Lai, L.

1547 - Discovery of GT19077, a c-Myc/Max Protein-Protein Interaction (PPI) Small Molecule Inhibitor, for Targeting c-Myc-Driven Blood Cancers

Lai, M.

2127 - Association of Circulating Tumor DNA from the Cerebrospinal Fluid with High-Risk CNS Involvement in Patients with Diffuse Large B-Cell Lymphoma

Lai, S.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Lai, X.

2394 - Salvage Therapy with Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem Cell Transplantation
2398 - Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Lai, X.

601 - Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lai, Y. S.

566 - Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

Laidou, S.

2215 - Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy

Laina, A.

1415 - Protective Effects of Daratumumab on Carfilzomib-Related Cardiac Dysfunction in Patients with Relapsed Multiple Myeloma: Results from an Observational Study

Laine, W.

1885 - Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells
2005 - Mitochondrial Spare Reserve Capacity : A New Predictive Metabolic Biomarker for Aggressiveness of Acute Myeloid Leukemia

Lainey, E.

3102 - JMML Fetal Identity Results Either from Retention of a Physiologic Signature or Aberrant Activation of Master Oncofetal Regulators

Laing, S.

1441 - Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)

Lajkosz, K.

301 - Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Lakhani, N.

3016 - ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma

Lakhmapurkar, U.

2676 - Efficacy and Safety of Biosimilar Romiplostim in Immune Thrombocytopenic Purpura : Single Centre Retrospective Data Analysis

Lakhotia, R.

598 - Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
1137 - Preliminary Results from a Phase II Study of Response-Adapted Therapy with Copanlisib and Rituximab for Untreated Follicular Lymphoma
2110 - Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma
3025 - Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Lakhwani Lakhwani, S.

1241 - Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
2673 - Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Lakkaraja, M.

1480 - Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Laks, D.

1604 - Brazilian Real-World Multiple Myeloma (MM) Electronic Platform Register Project

Lal, A.

154 - Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia
1697 - Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the BELIEVE Trial
1699 - Response of Patients with Transfusion-Dependent β-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers
2600 - Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Thalassemia: Interim Results from an Ongoing, Phase 2, Open-Label, Multicenter Study
- Chronic Transfusion for Patients with Hemoglobinopathies

Lal, I.

2220 - Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)

Lal, L. S.

1224 - The First Retrospective Commercial Claims-Based Analysis of CAR T Treated Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

Lala, D. A.

2784 - Predicting Resistance to the Combination of ATO and ATRA in APL Patients with PML-Rara Fusions, Using a Computational Biology Modeling Approach: Mycare-021-01

Lalama, C.

2700 - Weight-Based Dosing in Hemophilia a: A Randomized, Controlled, Open-Label, Crossover Trial to Measure Factor VIII Recovery Following Factor VIII Concentrate Dosing Based on Total Body Weight, Ideal Body Weight, and Lean Body Mass

Lalayanni, C.

1245 - Long Term Survival of Chronic Myeloid Leukemia Patients with Chromosomal Aberrations in Philadelphia Negative Cells Treated with Tyrosine Kinase Inhibitors
2369 - Allogeneic Hematopoietic Cell Transplantation with Myeloablative Conditioning Regimen of Reduced Toxicity Is Associated with Favorable Survival in Patients with Secondary Acute Myeloid Leukemia

Lalezari, S.

575 - The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Lam, A.

266 - Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-LL): Results of Children’s Oncology Group (COG) Trial AALL1231

Lam, A.

3429 - Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma
3475 - Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Lam, D.

1543 - Adenine Base Editing of the Sickle Allele in CD34⁺ Hematopoietic Stem and Progenitor Cells Eliminates Hemoglobin S
1545 - Adenine Base Editing of Gamma Globin Gene Promoters Shows No Detectable Off-Target RNA or DNA Editing

Lam, D.

2626 - Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease

Lam, H. P. J.

1729 - Thrombosis and Risk Management in Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with Sars-CoV2 (PIMS-TS)

Lam, N.

498 - Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Lam, S.

3428 - A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Lam, S.

939 - Acquired Amegakaryocytic Thrombocytopenic Purpura Associated with a Paroxysmal Nocturnal Hemoglobinuria Clone: A Case Report and Review of the Literature

Lam, V.

1174 - Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
1180 - Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Lam, V.

2024 - TRAF3 Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma

Lam, W. A.

368 - STEM Education for Children with Sickle Cell Disease: Unique Educational Outreach Program Taught By Near-Peer Undergraduate Students
804 - Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies
2008 - Incorporating Hemoglobin Levels to Map Leukostasis Risk in Acute Leukemia Using Microvasculature-on-Chip Technologies

Lam, W.

1530 - Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Lam, W.

1498 - Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment
1565 - Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre – a Prospective Observational Study
2428 - ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Lamanna, N.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Lamanna, N.

117 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
125 - Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
542 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
1314 - Early Results from a Phase 1 Dose Escalation Study Evaluating MS-553, a Novel, Selective Pkcβ Inhibitor, in Relapsed or Refractory CLL/SLL Patients
2942 - Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
3145 - A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- Managing Toxicities of Bruton Tyrosine Kinase Inhibitors

Lamb, Jr., L. S.

3260 - First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated Γδ T Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide

Lamba, J. K.

978 - Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia
2904 - An Ara-C, Daunorubicin, and Etoposide microRNA (ADEmiR) Score As a Prognostic Tool to Predict AML Treatment Outcomes

Lamba, M.

2295 - Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel CELMoD Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma

Lambert, A.

1059 - Investigating the Dual Targeting of BCL-2 and CD38 in Models of Acute Myeloid Leukemia

Lambert, F.

582 - NUTM1-Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Lambert, H.

3222 - Daratumumab Dose Analysis Among Patients with Multiple Myeloma in a US Community Oncology Setting: A Retrospective Observational Study in Integra Connect Network

Lambert, J.

3112 - Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Lambert, M. P.

380 - Transcription Factor RUNX1 Regulates Factor FXIIIA Subunit (F13A1) Expression in Megakaryocytic Cells and Platelet F13A1 Expression is Downregulated in RUNX1 Haplodeficiency
830 - Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation
1771 - Anxiety in Adult Patients Living with ITP Stratified across Different Treatment Types and Groups
2672 - Impact of Therapy Choice on Fatigue in Adults with Immune Thrombocytopenia
3405 - Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method
- Improving Interpretation of Genetic Testing for Hereditary Hemorrhagic, Thrombotic, and Platelet Disorders

Lambert, P.

3476 - Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

Lambertini, A.

3039 - Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL

Lamble, A. J.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome
269 - Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival
1020 - CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Lambrecht, N.

2615 - Prenatal Cannabinoid Exposure Impacts Offspring's Health in Sickle Mice

Lammens, T.

384 - Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-Cell Acute Lymphoblastic Leukemia
582 - NUTM1-Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Lammoglia Cobo, M. F.

2254 - Clonally Expanded Bone Marrow T Cells Show Effector Differentiation and Rarely Recognize Disease-Associated Antigens in Multiple Myeloma

Lamothe, T. L.

1044 - A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)
2330 - Single Agent CD45-Targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model

Lamparelli, T.

3288 - Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia

Lamprou, S.

3193 - Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α

Lampson, B. L.

531 - Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
569 - Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders
2216 - Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
2936 - Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy

Lamrani-Ghaouti, A.

3018 - First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

Lamy De La Chapelle, T.

1161 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Lamy, T.

819 - Lenograstim and Filgrastim Have a Similar Efficacy and Safety Profile in the Treatment of Chronic Neutropenia. a Study for the French SCN Registry:
1735 - How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry

Lamy, T.

2040 - Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Lan, L.

182 - An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Lan, X.

156 - ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

Lan, Y.

109 - RNA Binding Protein CELF2 Mutation Cooperates with MLL-AF9 in Driving Acute Myeloid Leukemia Development

Lan, Y.

156 - ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

Lance, A.

2641 - Complex CSF3R Protein Isoform Interactions Dictate Cytokine Responsiveness

Lancelot, M. M.

897 - Effective Erythropoiesis from Human iPSC-Derived RBC in Immunodeficient Mice

Lancelot, M. M.

86 - Characteristics of in Vitro Differentiated Erythrocytes Derived from Human Bmi-1 Extensively Expanded Erythroblasts (E3)

Lancet, J. E.

344 - Characteristics of Different Splicing Factor Mutation Hotspots in Myelofibrosis
635 - Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
1013 - Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant
1455 - Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia
1670 - Analysis of Practice Patterns Among Experts and Community Healthcare Providers for the Treatment of Acute Myeloid Leukemia
1946 - Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
2806 - PTPN11 Mutations Are Associated with Poor Outcomes across Myeloid Malignancies
2864 - A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
3122 - SF3B1 Mutations and Not TP53 Are Associated with Poor Outcomes in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
3346 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Lancman, G.

1404 - Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab

Landa, J.

2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Landau, D. A.

107 - Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation
283 - Robust Discovery of Candidate DNA Methylation Cancer Drivers
348 - Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK^C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia
2208 - Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Landau, H. J.

728 - A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)
730 - TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response
1342 - Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
1369 - Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
3204 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Landecho, M.

824 - Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance

Landesman, Y.

965 - CRISPR/Cas9 Chemogenetic Profiling Identifies Candidate Biomarker Genes That Modulate Sensitivity to Selinexor
1385 - Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
2125 - A Six-Protein Activity Signature Defines Favorable Response to Selinexor Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Landfors, M.

384 - Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-Cell Acute Lymphoblastic Leukemia

Landgraf, K.

2095 - The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells In Vitro
3008 - Blockade of the CD47/SIRPα Checkpoint Potentiates the Anti-Tumor Efficacy of Tafasitamab

Landgraf, R.

3046 - Use of Medium Potency Statins Is Associated with Improved Outcomes after Frontline RCHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Landgren, O.

436 - Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
548 - Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
602 - Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease
1342 - Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001
1344 - Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients
1361 - The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data
1369 - Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
2240 - Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls
2256 - Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma
2282 - Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
2325 - Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study
3159 - The Role of ¹⁸f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
3204 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study
3304 - Duration of Post-Autologous Hematopoietic Cell Transplant Anemia and Thrombocytopenia Are Associated with Prolonged Hospital Length-of-Stay for Multiple Myeloma Patients

Landin, A. M.

1455 - Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Landman-Parker, J.

822 - Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up

Landry, C.

2482 - Risk Factors for Iron Deficiency in Very Preterm Infants at 4-6 Months Corrected Age

Lands, R. H.

2212 - Detection of Systemic AL Amyloidosis and Differentiation of AL from Attr Using ¹²⁴I-p5+14 PET Imaging

Landsburg, D. J.

473 - Everolimus Plus Itacitinib in Relapsed/Refractory Classical Hodgkin Lymphoma: Results of a Phase I/II Investigator Initiated Trial (EVITA Study)
478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
701 - A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
703 - Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
1210 - Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
1213 - Anti-CD19 CAR-T for Treatment of Double Expressor and Double Hit Large B-Cell Lymphomas: A Single Institution Real-World Analysis
1218 - Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma
2126 - A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma
2945 - A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
2978 - Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Lane, A.

1705 - Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment
1801 - Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy
2619 - Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience
2620 - Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience
2623 - Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia

Lane, A. A.

167 - Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Lane, H.

2870 - Trials in Progress: A Phase I Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High-Risk Myelodysplastic Syndrome

Lane, H.

1463 - Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients

Lane, P. A.

303 - 10-Year Mortality in Patients with Sickle Cell Disease from a Large Population-Based Cohort
1727 - Healthcare Utilization Among Children and Adolescents with Sickle Cell Disease during the COVID-19 Pandemic

Lane, T. A.

1273 - Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Laneuville, P.

1234 - BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
1247 - Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
2114 - Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Lang, F.

650 - Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial

Lange, C.

1539 - First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A – BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Lange, E.

1313 - Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Lange, P.

2011 - MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential

Langemeijer, S.

1279 - Longitudinal Study on Determinants of Health-Related Quality of Life in Patients with Myelodysplastic Syndromes

Langenskiöld, C.

467 - NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Langer, A. L.

2543 - Team-Based Learning in Medical School Hematology Course Improves Immediate Understanding but Not Long-Term Retention
- Choosing Wisely Champions

Langer, C.

1337 - Characterization of Rare Germline Variants in Familial Multiple Myeloma

Langerbeins, P.

1313 - Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials
1316 - Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Langerhorst, P.

3156 - Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Langerman, S. S.

1641 - Real-World Validity of the Revised International Staging System in Multiple Myeloma By Race

Langlais, B. T.

1257 - Analysis of Free-Text Responses in an International Myeloproliferative Neoplasms Patient Survey to Assess Impact of the COVID-19 Pandemic on Clinical Care
1628 - Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
2535 - Clinical Trial Design Features of Myelofibrosis Trials during the Last Decade: Comprehensive Review of Clinicaltrials.Gov Data 2010-2019
3400 - Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients

Langridge, A.

2659 - Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP)

Langston, A.

1514 - Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
1747 - Potent Interaction between CMV Reactivation and Gvhd: Immunologic Evidence for Blunting of CMV-Driven Immune Reconstitution in the Setting of Gvhd
2389 - Predicting Immune Pathology after Hematopoietic Stem Cell Transplant with Transcriptomics: Naïve CD4 T Cell Expansion at Day 100 Predicts Patients with De Novo Chronic Gvhd

Lanieri, L.

1044 - A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)

Lanikova, L.

83 - Mutation of EPO 5`UTR Facilitates Interaction with HIF2 and Causes Autosomal Dominant Erythrocytosis

Lankford, A.

2864 - A Phase 1/1b Safety Study of Prgn-3006 Ultracar-T™ in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome

Lannert, K. W.

231 - A Multi–Omics Approach to X-Chromosome Inactivation (XCI) Identifies Severe Xci Skewing in Female Genetic Carriers of Hemophilia

Lannes, R.

603 - The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Lannutti, B. J.

121 - VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
2786 - Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma

Lanpher, B.

1284 - Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study

Lansigan, F.

340 - Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R² Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
1123 - Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R² Followed By Maintenance
3136 - Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen

Lanza, F.

392 - Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

Lanzkron, S. M.

15 - Hydroxyurea Is a Potential Risk Factor for Diminished Ovarian Reserve in Young Adults with Sickle Cell Anemia
798 - Young Adults with Sickle Cell Disease (SCD) Have Low Interest in Genetic Counseling and Sickle Cell Trait Testing for Sexual Partners
1730 - The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD
2634 - Low Rates of Transfusion Transmitted Infection Screening in Chronically Transfused Adults with Sickle Cell Disease

Lapan, M.

7 - IRF5 Regulates the Balance between Erythropoiesis and Myelopoiesis during Aging

Lapeyre-Mestre, M.

2584 - Autoimmune Hemolytic Anemia: A Disease of the Elderly and the Very Elderly with Increased Mortality and Increased Rates of Hospitalization for Thrombosis and Infection
2662 - Eltrombopag for Immune Thrombocytopenia in Adult Patients in the Real-World in France. Final Results of the Elextra Study

Lapietra, G.

3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’
3147 - Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Lapillonne, H.

816 - Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry
931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients
1076 - Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
1735 - How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry

Lapinski, J.

1608 - Premedication Prior to Peg-Asparaginase Is Cost-Effective for Pediatric Leukemia Patients

Laplant, B.

1192 - Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E
2285 - Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data
3196 - Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
3246 - Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

Lapping, S. D.

815 - Nanoparticle-Directed Targeting of Clustered PSGL-1 Mitigates Neutrophil-Derived Thrombosis in Antiphospholipid Antibody Syndrome

Lapteva, N.

3268 - A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Lara, B. H.

968 - BET Protein Antagonist-Based Therapy of Novel Models of Richter Transformation-Diffuse Large B-Cell Lymphoma (RT-DLBCL)
1864 - Preclinical Efficacy of a Novel Omacetaxine-Based Therapy for AML Expressing Somatic or Germline Mutant RUNX1
1879 - Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Laraque, L.

119 - Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study
2097 - Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Larcher, M. V.

462 - Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Larcher-Senn, J.

3027 - Phase II Single-Arm “Window-of-Opportunity” Study of a Combination of Obinutuzumab and Venetoclax in Early Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) – First Results of the AGMT NHL15B Study

Large, K.

646 - Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Largeaud, L.

931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients

Laribi, K.

1161 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1214 - R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers
1300 - Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization
1377 - Real-Life-Setting Effectiveness of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: The Remix Study
2195 - A Molecular-Based Response Prediction Model to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome and Severe Thrombocytopenia
3126 - Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement

Lario, A.

1063 - Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia

Lario Arribas, A.

1226 - Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma NOS Diagnosis: Comparative Study between PET, Histology and Flow Cytometry

Larkin, K.

1499 - Survival Implications of Opioid Use after Blood and Marrow Transplantation
1668 - A Retrospective Analysis of Outcomes Following Allogeneic Stem Cell Transplantation for Patients from Appalachian Counties
2427 - Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience
2441 - Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality
3360 - Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience
3362 - Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant

Larkin, S. K.

2616 - Differential Acetone Extraction of Total and Hemoprotein-Unbound Heme to Quantify Heme Binding Capacity of Plasma in Patients with Sickle Cell Disease: The Role of Heme Scavengers

Larkin, T.

978 - Identification of Pharmacogenomic Single Nucleotide Polymorphism Variants As Contributors to Toxicity Phenotype in the Treatment of Acute Childhood Leukemia

Larocca, A.

1329 - A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform
1379 - Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial
2293 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma—Age Subgroup Analysis of Elderly Patients
2321 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy—Subgroup Analysis
2360 - On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)
2564 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)—Analysis of Adverse Events Related to Hospitalizations
3175 - High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling
3214 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)—Subgroup Analysis
3237 - HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics—Subgroup Analysis
3239 - Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial
3477 - HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) — Health-Related Quality of Life (HRQoL) Analysis

Larocca, L. M.

2124 - IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study

Larochelle, A.

1688 - Long-Term Eltrombopag for Bone Marrow Failure Depletes Total Body Iron
1833 - Notch-Mediated Expansion of Human Hematopoietic Stem and Progenitor Cells By Culture Under Hypoxia

Laros-Van Gorkom, B. A.

571 - Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease

Larose, M. I.

2978 - Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis

Larrayoz, M. J.

489 - Waldenström’s Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Larrayoz, M.

489 - Waldenström’s Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Larripa, I.

3078 - Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina

Larsen, E. C.

1090 - Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children’s Oncology Group (COG) Report
1094 - Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group (COG)
1095 - Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children’s Oncology Group
2794 - Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children’s Oncology Group (COG) Report

Larsen, J.

179 - Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma
181 - A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE^®(bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
724 - First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
1328 - Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma
1358 - Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001
1359 - Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations
3198 - Daratumumab Plus Lenalidomide and Dexamethasone (DRd) Compared to Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Relapsed Lenalidomide-Exposed or Refractory Multiple Myeloma (MM) Patients: The Mayo Clinic Experience
3246 - Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

Larsen, K.

1335 - Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Larsen, S.

LBA-5 - ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine

Larsen, S. R.

2435 - An Australasian Bone Marrow Transplant Registry (ABMTR) Study of the Trends and Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Hodgkin Lymphoma between 2009-2019: Relapse Remains the Most Common Cause of Death Post Transplantation
3354 - Allogeneic Stem Cell Transplantation for Mantle Cell Lymphoma Can Achieve Durable Remission and Myeloablative Conditioning Is Associated with Inferior Survival: An Australasian Bone Marrow Transplant Recipient Registry Study
3363 - Allogeneic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma Can Achieve Durable Remissions: An Australasian Bone Marrow Transplant Recipient Registry Study

Larsen, T. S.

3033 - Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial

Larson, A.

1545 - Adenine Base Editing of Gamma Globin Gene Promoters Shows No Detectable Off-Target RNA or DNA Editing

Larson, D.

2497 - Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX)

Larson, M. C.

371 - Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas
1654 - Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study
2022 - Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment
2950 - Body Mass Index and Survival of Patients with Lymphoma

Larson, M. L.

217 - The Role of Structural Violence in Acute Myeloid Leukemia Outcomes
1117 - High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles
2132 - The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma

Larson, M. L.

205 - Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Larson, R. A.

163 - Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
191 - Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)
330 - The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results
391 - Molecular Landscape and Prognostic Impact of FLT3 Internal Tandem Duplication Insertion Site in Acute Myeloid Leukemia (AML): Results from the Ratify Study (Alliance 10603)
1920 - Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only
2796 - Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results
2999 - Molecular Characteristics and Patterns of Progression of IDH2-Mutated, Philadelphia-Chromosome Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib

Larson, S.

1071 - Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia
3272 - Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia

Larson, T.

471 - Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Larsson, R.

2274 - Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Lasa, M.

884 - Peripherally Inserted Central Catheter (PICC) Related Deep Venous Thrombosis: A Retrospective Cohort Study on Incidence and Risk Factors in a Single Center

Lasa, M.

1324 - Predictive Biomarkers of Response to Venetoclax in Combination with Cobimetinib in Relapsed/Refractory Multiple Myeloma (RRMM)

Lasho, T.

1 - Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
669 - Developing Novel Targeted Therapies Using the High-Risk Vq Myeloma Model
1275 - ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility
1284 - Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study
2182 - Gene Body Methylation and Transcriptional Activity in ASXL1-Mutant Chronic Myelomonocytic Leukemia
2188 - Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Lasica, M.

1130 - Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies
2944 - Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Laskin, B. L.

830 - Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation

Lasky, III, J. L.

868 - Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Lasso, J. F.

3036 - COVID-19 in Patients with Lymphoma: A Grupo De Estudio Latinoamericano En Linfoproliferativos (GELL) Retrospective Study

Latagliata, R.

2167 - Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival
2990 - First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria
2994 - Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome
3077 - Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the “Registro Italiano LMC & Campus CML”

Latchford, T.

1788 - Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

Latham, T.

92 - Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia
243 - Genetic Basis of Erythrocyte Alloimmunization Among Children with Sickle Cell Anemia in the Dominican Republic
1705 - Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment
2619 - Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience
2620 - Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience
2623 - Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia

Latif, A. L.

522 - A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Latif, H.

2495 - Using Virtual Reality to Promote Mindfulness Among Medical Trainees; A Study of Feasibility and Acceptance

Latimer, K.

1044 - A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)

Latimer, M.

591 - Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Latour, S.

SCI-47 - The Complete Spectrum of IKZF1 Defects: Immunodeficiency, Immune Dysregulation, Abnormal Hematopoiesis and Leukemia

Latremouille-Viau, D.

216 - Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy
1665 - Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Lattenist, R.

745 - Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients

Lattimore, S. U.

672 - Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial
870 - Dosing, Patient Satisfaction and Other Patient-Reported Outcomes after Switching to Rurioctocog Alfa Pegol in Athn 2: A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Coagulation Replacement Factor Products
LBA-6 - First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Lau, B. W.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Lau, C.

3478 - Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Lau, V.

1433 - Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors

Laubach, C.

2969 - SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Laubach, J. P.

292 - Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
1398 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
2712 - Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study
3201 - Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study
3211 - Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Laubach, J. P.

549 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Laude, M. C.

3044 - Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
3052 - Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Laulicht, B.

238 - Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect

Launonen, A.

3042 - Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Laurance, S.

224 - Fetal Hemoglobin Rescues Ineffective Erythropoiesis in Sickle Cell Disease

Laurell, A.

2038 - Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial
2956 - Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Laurence, J.

853 - Higher Tissue Factor (TF) Expression in the Lungs of COVID-19 Pneumonia Patients Than Patients with Acute Respiratory Distress Syndrome: Association with Thrombi Formation
1579 - Triggers in Patients with Atypical Hemolytic Uremic Syndrome: An Observational Cohort Study Using a US Claims Database

Laurent, A. P.

1101 - Expression of Vav1-Myo1F Fusion Affects T-Cell Differentiation and Induces T-Cell Lymphoma

Laurent, C.

2118 - Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Laurent, D.

1923 - SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Laurent, E. M.

5 - Divergent Levels of CD112 and INKA1 Define a Subset of Human Hematopoietic Stem Cells That Resists Regenerative Stress to Preserve Stemness

Laurent-Rolle, M.

101 - Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience

Laurenti, L.

663 - Combined Genetic Lesions in TP53 and CDKN2A/CDKN2B Drive B Cell Receptor-Dependent/Costimulatory Signal-Independent Proliferation in Richter Syndrome
1306 - Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’

Laurenti, L.

1319 - Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax
1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19
2030 - Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial
2217 - Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study
3147 - Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Lauri, B.

144 - A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Lauritzen, B.

2680 - A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys

Lausch, E.

1768 - Novel Splice-Site Mutation in RASGRP2 Leading to Caldag-GEFI Deficiency

Lausen, B.

399 - Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
1246 - Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study

Lausman, A.

424 - Suboptimal Screening for Iron Deficiency in Pregnancy in a High Resource Setting

Lauten, M.

255 - RPA1 Gain of Function Causes Human Short Telomere Syndrome with Revertant Somatic Mosaicism

Lauwers-Cances, V.

143 - Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial
1338 - The Discriminatory Ability of the R-ISS Is Equivalent to the ISS in a Large Cohort of Newly Diagnosed Multiple Myeloma (NDMM) Patients

Lavasseur, C. M.

1853 - Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies

Lavau, C. P.

698 - The SIX1 homeobox Gene Is a Novel Therapeutic Target in CALM-AF10 Leukemogenesis

Laveille, C.

3273 - Population Pharmacokinetic Analysis of Emapalumab, a Fully Human, Anti-Interferon Gamma Monoclonal Antibody, in Children with Primary Hemophagocytic Lymphohistiocytosis

Lavelle, D.

89 - Cathepsin B, a Negative Regulator of Autophagy, Identified As a Novel Therapeutic Drug Target in Sickle Cell Disease
1701 - Effect of Nicotinamide, 1-Methylnicotinamide, and N’-Methylnicotinamide on Erythroid Colony Formation and γ-Globin Expression in Cultured Baboon CD34+ Cells
2603 - Combinatorial Administration of Pharmacological Inhibitors Targeting DNMT1 and KDM1A Produces Synergistic and Additive Increases in F Retiulocytes and γ-Globin Expression in Normal Baboons

Laverdiere, C.

271 - Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Lavi, N.

727 - A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Lavie, D.

545 - Safety and Efficacy of CD19-CAR T Cells in Richter’s Transformation after Targeted Therapy for Chronic Lymphocytic Leukemia
2141 - Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma
2570 - Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
2824 - First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1^st Line Therapies in Patients with Acute Myeloid Leukemia (AML) – Revive Study

Lavilla, E.

634 - Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry
1082 - Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Lavin, M.

- Session Introduction

Lavoie, M. W.

311 - Health Care Utilization and End of Life (EOL) Outcomes in Patients Receiving CAR T-Cell Therapy

Lavorgna, S.

392 - Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol
2890 - Clinical Relevance of– Limit of Detection (LOD) – Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

Lavrova, T.

1315 - The Prosid Study: Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIG) 10% in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia– Study Design

Law, A.

1498 - Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment
1530 - Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission
1565 - Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre – a Prospective Observational Study
2396 - Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment
2428 - ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Law, J.

1537 - Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC)

Law, J. Y.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
2351 - Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2934 - Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
3487 - Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Law, K. M.

674 - Gene Therapy for Fanconi Anemia, Complementation Group a: Updated Results from Ongoing Global Clinical Studies of RP-L102
675 - A Phase 1/2 Study of Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): Results from Phase 1
2446 - Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Law, M.

1225 - The Role of Lymphomas in Subsequent Primary Cancers in People with HIV/AIDS: An Australian National Population-Based Data Linkage Study

Law, S. C.

642 - Neoantigens Are Typically Associated with Intact HLA Class I Presentation in Early-Stage Follicular Lymphoma

Law, S.

1332 - The Impact of Longitudinal Strain on Haematological and Cardiac Response and Survival in Patients with Systemic AL Amyloidosis

Lawitschka, A.

419 - Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Lawrence, C. E.

868 - Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Lawrence, H.

355 - Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Lawrence, N.

355 - Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Lawrenz, M.

1175 - Identification of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies

Lawson, J.

3487 - Impact of Cardiovascular Disease on Clinical Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Layedra, L.

898 - Use of Convalescent Plasma in COVID-19 Patients: Guayaquil, Ecuador Experience.

Layton, D. M.

1679 - Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency
2583 - Baseline Characteristics of Patients in Peak: A Global, Longitudinal Registry of Patients with Pyruvate Kinase Deficiency
2600 - Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Thalassemia: Interim Results from an Ongoing, Phase 2, Open-Label, Multicenter Study

Lazar, A.

1649 - Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Lazar, I.

2885 - RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Lazareth, A.

3044 - Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
3052 - Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Lazarevic, V.

2903 - DNA-Based Methods for Measurable Residual Disease Detection in NPM1-Mutated Acute Myeloid Leukemia; Establishment of Cut-Offs for qPCR, Digital Droplet PCR and Targeted Deep Sequencing

Lazarian, G.

941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
1304 - IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia

Lazarini, M.

917 - Reduction of ARHGAP21 Alters Platelet Biogenesis in Vitro and Accelerates Hemostatic Response In Vivo

Lazaroiu, M.

3086 - Momelotinib’s Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia
3238 - Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Lazarovici, J.

475 - PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
1108 - High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
1214 - R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers
2019 - Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?
2069 - Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups

Lazarski, C.

3270 - Tumor Associated Antigen Specific T Cells Given in Combination with Nivolumab for the Treatment of Hodgkin Lymphoma

Lazarus, H.

934 - Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study

Lazarus, H. M.

135 - High Doses of Targeted Radiation with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
186 - Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)
193 - Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Lazaryan, A.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
1451 - Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
1494 - High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease
2397 - Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease

Lazo-Langner, A.

429 - Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability
1612 - Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?
3446 - Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Lazzareschi, I.

1586 - Influenza Vaccination in Asplenia: Improving Quality of Care in Time of Coronavirus

Lazzarino, G.

2175 - Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients

Le, A.

1457 - First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency

Le, B. V.

1052 - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Le, B.

911 - The RNA Splicing Factor U2AF1 Controls Hematopoietic Stem Cell Survival and Function

Le Beau, M. M.

360 - Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies
1920 - Therapy-Related Myeloid Neoplasms in 108 Patients Following Radiation Therapy Only

Le Bescop, C.

3406 - Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy

Le Bihan, Y. V.

3153 - Mutations in CRBN and Other Cereblon Pathway Genes Are Only Associated with Acquired Resistance to Immunomodulatory Drugs in a Subset of Patients and Cell Line Models

Le Bourgeois, A.

422 - Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program
1483 - Gut Microbiota-Induced Regulatory T Cells in Patients with Hematological Malignancies Receiving Allogeneic Hematopoietic Stem Cell Transplantation: Towards Deciphering a Role for These Tregs in aGVHD
2436 - Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases
3300 - Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Le Bris, Y.

2118 - Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Le Calvez, B.

3300 - Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Le, C.

1673 - Lyn Kinase Activity Is Required for Akt Mediated Erythroleukemia Cell Differentiation

le Coutre, P. D.

46 - Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
650 - Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
2155 - Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR^4.5: Results from ENESTfreedom
3066 - Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)
3074 - Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION
3076 - Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial
LBA-4 - Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Le Du, K.

1214 - R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Le, D. D.

731 - MHC Class II on Ccl19⁺ Reticular Cells Mitigates Graft-Versus-Host Disease Via Maintenance of Regulatory T Cells

Le Gal, G.

429 - Deep Vein Thrombosis Diagnosis with D-Dimer Adjusted to Clinical Probability

Le Gall, J.

2103 - ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi‑Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

Le Gouill, S.

117 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
120 - Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group
475 - PET-Guided Strategy Improves the Safety of Beacopp-Based Treatment in Advanced Hodgkin Lymphoma: Prolonged Follow-up of the Lysa Ahl 2011 Phase 3 Study
1139 - Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial
1161 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
2040 - Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study
2081 - Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial
2118 - Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project
2436 - Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases
3029 - A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
3032 - Pre-Planned Interim Safety Analysis of the Niveau Trial, a Randomized Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma
3300 - Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Le Guennec, S.

2289 - Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Soft-Tissue Plasmacytomas: Icaria-MM Subgroup Analysis

Le, H.

1595 - How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?
1660 - Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings

Le Marchand, L.

3186 - Characteristics of and Risk Factors for Monoclonal Gammopathy of Undetermined Significance (MGUS) in the Multiethnic Cohort Study

Le, Q.

1993 - Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia
2344 - Generation of CAR-NK Cells Using a Notch-Mediated Cell Expansion and Differentiation Platform

Le, Q.

1959 - Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Le Roux, N.

1413 - Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib (V) Lenalidomide (R) and Dexamethasone(d) Combined Therapy for Newly Diagnosed Multiple Myeloma (NDMM): Results from a Phase 1b Feasibility/Safety Study
2288 - Updates from a Phase Ib Study of Isatuximab, Bortezomib and Dexamethasone Plus Cyclophosphamide or Lenalidomide in Transplant Ineligible Newly Diagnosed Multiple Myeloma

Le, T.

432 - Understanding Barriers to Hematopoietic Cell Transplantation Among Patients with Acute Myeloid Leukemia

Le, T.

359 - Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial
453 - Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Le Van Kim, C.

799 - Persistance of Inflammatory Phenotype of Neutrophils in Sickle Cell Disease Children Despite Chronic Exchange Transfusion Program: A Cause of the Progression of Cerebral Vasculopathy?

Leabman, M.

1142 - Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Leadbetter, J.

591 - Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Leader, A.

1901 - D-Dimer As a Predictor of Thrombotic Events during Early Acute Lymphoblastic Leukemia Therapy
2481 - Risk Assessment and Management of Venous Thromboembolism in Cancer Patients: A Population-Based Cohort Study

Leaf, D. E.

581 - Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States

Leaf, R. K.

1259 - Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk

Leak, L.

2000 - Clonal Architecture and Variant Allele Frequency Predict Clinical Outcomes and Drug Response in Acute Myeloid Leukemia

Leal, J.

2416 - Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Lear, S.

3213 - Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Leary, A.

920 - Therapy Related Myeloid Neoplasm Post PARP Inhibitors: Potential Clonal Selection.

Leary, G.

1436 - Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment

Leary, H.

3203 - Panobinostat in Combination with Bortezomib and Dexamethasone for Heavily Pre-Treated Myeloma: A UK Real-World Multi-Centre Cohort

Leary, K.

3209 - Predictive Markers of High-Grade or Serious Treatment-Emergent Infections with Daratumumab-Based Regimens in Newly Diagnosed Multiple Myeloma (NDMM)

Leavitt, A. D.

671 - Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a

Lebedinsky, C.

1251 - A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Lebel, E.

2141 - Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma

Lebensburger, J. D.

1626 - Outcomes of Hydroxyurea Dose Adjustment Via Telehealth
2630 - Steadfast: A Randomized, Multicenter, Open-Label, Phase II Study Comparing the Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Chronic Kidney Disease Due to Sickle Cell Nephropathy

Leber, B.

56 - CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study
1050 - Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS
1230 - Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
1234 - BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
1247 - Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
1280 - MDS Iron Road: An Internet-Based Algorithm for the Diagnosis, Workup and Management of Iron Overload (IOL) in Patients with Myelodysplastic Syndromes (MDS) from the Canadian Consortium on MDS (CCMDS)
1291 - Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study
1989 - Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA
2197 - High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

Leber, X. C.

1475 - Pre-Clinical Characterization of MAU868, a Novel Neutralizing Antibody Targeting BK Virus

Lebioda, A.

1382 - Management of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Novel Therapies in Routine Clinical Practice in Germany

Leblanc, M. L.

2969 - SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Leblanc, R.

2417 - Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database
3241 - Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis

LeBlanc, R.

726 - Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
1366 - Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma
1393 - Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
1607 - Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Leblanc, R. M.

2092 - R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Leblanc, T.

822 - Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up
931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients
1735 - How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry

Leblanc, T. W.

1595 - How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?
2547 - Financial Burden Is Associated with Postponing Care and Decreasing Physical and Emotional Quality of Life Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia
2572 - Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial
3437 - Indirect Treatment Comparison of CC-486 Versus Azacitidine (AZA) As Maintenance Therapy for Acute Myeloid Leukemia (AML)
3491 - Decisional Involvement, Information Preferences, and Prognostic Optimism Among Patients with Hematologic Malignancies

LeBlanc, T. W.

218 - Comparison of End-of-Life Care Quality Outcomes and Indicators of Palliative Needs between Medicare Beneficiaries with Solid and Hematologic Malignancies
433 - Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia
3493 - Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Leblay, N.

719 - Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy

Leblebjian, H.

2712 - Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Leblond, V.

36 - Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group
336 - Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom’s Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATE^TM Study
1300 - Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization

Leblond, V.

337 - Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial
2462 - The Role of PET-MRI in Multiple Myeloma Patients

Leboeuf, C.

84 - The Pyruvate Kinase Activator Mitapivat Ameliorates Anemia and Prevents Iron Overload in a Mouse Model of Hereditary Spherocytosis

Lebon, D.

114 - Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
462 - Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
2386 - Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation

Lebowitz, S.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Lebras, L.

1214 - R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Lebrecht, D.

2181 - NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up

Lech-Marańda, E.

54 - Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
542 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
2098 - Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa
2934 - Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
2973 - Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study
3166 - PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium
3201 - Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study

Lechman, E. R.

256 - Erythropoiesis Failure in Diamond-Blackfan Anemia Starts at the Oligopotent Common Myeloid and Megakaryocyte-Erythroid Progenitor Stage
519 - A Human Model of Down Syndrome Associated Leukemia Reveals Different Cell of Origins for Initiation and Progression
2777 - Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism

Lechman, E. R.

1839 - Functional Investigation of the Argonaute Proteins in Human Hematopoietic Stem and Progenitor Cells

Lechman,, E. R.

454 - Elevated Expression of Mir-130a in t(8,21) AML Reinforces the Aberrant Molecular Program of AML1-ETO
1865 - Mir-125b Regulates the Self-Renewal of Acute Myeloid Leukemia Stem Cells through PTPN18 and GSK3

Lechner, K.

3211 - Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma
3269 - Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma

Lechowicz, M. J.

1155 - A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma
1514 - Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Leclair, P.

2011 - MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential

Leclerc, J. M.

271 - Frequency and Prognostic Significance of Recurrent Gene Mutations in Pediatric B-ALL: Report from the DFCI ALL Consortium

Lecourt, H.

1108 - High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 - Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Lecumberri, R.

2308 - Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis’ Survey

Ledda, A.

1331 - Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial

Ledesma, C.

2357 - Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma
3308 - Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies

Ledesma, C.

3323 - Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma
3359 - Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy

Ledet, G. A.

2592 - Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis

Ledraa, T.

2379 - Stable Pulmonary Function after Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide: A Single Center Experience

Ledwidge, J.

2482 - Risk Factors for Iron Deficiency in Very Preterm Infants at 4-6 Months Corrected Age

Lee, A.

1793 - Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry
2655 - Platelet Membrane Procoagulation in Preeclampsia

Lee, A. Y.

887 - Efficacy and Safety of Tinzaparin in CAT Patients with Metastatic Disease

Lee, A. G.

1233 - Comparison of the Transcriptomic Signatures in Pediatric and Adult CML

Lee, A. I.

427 - Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
579 - Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
1572 - The Impact of COVID-19 on Hematology-Oncology Fellowship Programs: Program Director Perspectives
2473 - Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment
2690 - VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
3173 - Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma
3391 - Factors Associated with Burnout Among Hematology & Oncology Physicians

Lee, A.

1780 - Lyophilized Human Platelets Restore Hemostasis in the Presence of the P2Y12 Inhibitors Cangrelor, Ticagrelor and Clopidogrel

Lee, A.

3454 - Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Lee Bazaldua, E. E.

2596 - Compared to Normal-Weight Pregnant Women, Overweight Pregnant Women Fail to Upregulate Iron Absorption in the Third Trimester Despite Iron Deficiency and Their Infants Are Born with Lower Body Iron Stores

Lee, B. C.

383 - Macaque CRISPR/Cas9 Age-Related Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Mutated Clones and Applicability for Testing Mitigation Approaches

Lee, C.

1543 - Adenine Base Editing of the Sickle Allele in CD34⁺ Hematopoietic Stem and Progenitor Cells Eliminates Hemoglobin S

Lee, C.

1663 - Patient-Reported Outcomes and Frailty Among Participants in the NHLBI MDS Natural History Study

Lee, C.

3475 - Real-World Use of Maintenance Therapy and Associated Outcomes Following Autologous Stem Cell Transplant in US Patients with Newly Diagnosed Multiple Myeloma

Lee, C. C.

1098 - Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia
2905 - Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm

Lee, C.

20 - Soluble Platelet Agonists Expand the Procoagulant Surface in Heparin-Induced Thrombocytopenia

Lee, C. W.

3096 - Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Lee, C.

1419 - DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
3037 - Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance

Lee, C. H.

619 - Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

Lee, D. D.

1463 - Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients

Lee, D. J.

330 - The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results
1045 - Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Lee, D. W.

1896 - ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Lee, D. A.

68 - Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia
825 - Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)
2347 - A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
2442 - Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching
2650 - Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Lee, D. G.

1122 - Rituximab Monotherapy Compared to Observation in Patients with Newly Diagnosed Asymptomatic Advanced Stage Follicular Lymphoma: A Retrospective Population-Based Analysis

Lee, D. H.

1443 - Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lee, E. J.

2671 - Clinical Outcomes in Patients with Immune Thrombocytopenia Treated with All 3 Approved Thrombopoietin Receptor Agonists

Lee, G.

- Surgical splenectomy and Autosplenectomy when Treating Non-Malignant Hematologic Disorders: Infection Risk, Immunization Recommendations, Antimicrobial Prophylaxis Needs

Lee, G. M.

19 - Complement Regulates the Procoagulant Effects of HIT Immune Complexes
2639 - Variation in Neutrophil Function Among Healthy Subjects Influences Response to Bacteria

Lee, H. C.

181 - A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE^®(bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
485 - Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma
552 - Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
668 - The Anti-B-Cell Maturation Antigen (BCMA) Antibody-α-Amanitin Conjugate Hdp-101 Induces Immunogenic Cell Death and Immunologic Memory in Models of Multiple Myeloma
1371 - Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
1394 - Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM)
1417 - DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) – 1-Year Outcomes By Prior Therapies
1453 - PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy
1506 - African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis
1512 - Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation
1640 - Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
2055 - A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM)
2413 - Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance
2419 - Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation
2422 - Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation
2423 - Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation
3216 - Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)
3221 - Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3244 - Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect^® MM Registry

Lee, H.

676 - Ex-Vivo Autologous Stem Cell Gene Therapy Clinical Trial for Mucopolysaccharidosis Type IIIA: Trial in Progress - NCT04201405

Lee, H. H.

2838 - Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model

Lee, H.

641 - Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination

Lee, H.

3229 - Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients

Lee, H. M.

3252 - A Murine Immunocompetent Acute Myeloid Leukemia (AML) Model for Testing Immunotherapies

Lee, H.

638 - Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma
1511 - Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience

Lee, H. J.

645 - A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)
1128 - Treatment and Outcome of Patients with Follicular Lymphoma Relapsed or Progressed after Frontline Lenalidomide and Rituximab
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
1172 - Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center
2037 - Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma
2119 - Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy
2128 - Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
2357 - Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma
2942 - Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
2983 - Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma
3053 - Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival
3063 - The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Lee, I. Y.

3216 - Hyperfractionated Cyclophosphamide-Dexamethasone (HyperCy-Dex) with or without Carfilzomib (Car) in Patients (pts) with Multiple Myeloma (MM)

Lee, J. H.

1389 - Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study
3140 - Acalabrutinib Vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Ascend Final Results
3238 - Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Lee, J.

841 - A Phase II Study to Assess the Sustained Response Off Treatment in Patients with ITP Receiving Eltrombopag, Who Had a Previous Insufficient Response to Corticosteroids (TAPER): A Recruitment Update

Lee, J.

2154 - Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

Lee, J.

2714 - A Low Dose Heparinized Saline Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Lee, J.

2391 - Secondary Graft-Versus-Host Disease (GVHD) Prophylaxis with Oral Proteasome Inhibitor Ixazomib Is Associated with Low Incidence of Recurrent, Late Acute and Chronic GVHD and Facilitated Calcineurin Inhibitor Taper within the First Year Post Allogeneic Stem Cell Transplantation

Lee, J. T.

3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet

Lee, J. H.

27 - Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3^mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy
1527 - Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies
1914 - Real-World Treatment Patterns and Clinical Outcomes in Unfit Patients with AML Receiving First-Line Systemic Treatment or Best Supportive Care (CURRENT): Final Analysis

Lee, J. J.

1389 - Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Lee, J.

700 - Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Lee, J.

1264 - Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

Lee, J.

830 - Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation

Lee, J. M.

794 - Cerebral Metabolic Stress Is Increased in Children with Sickle Cell Anemia Compared to Anemic Controls

Lee, J. S.

2415 - Autologous Stem Cell Transplantation (ASCT) for T-Cell Non Hodgkin Lymphoma (T-NHL) Patients Who Achieve Complete Remission with First-Line Treatment: A Systematic Review and Meta-Analysis

Lee, J.

LBA-1 - Driver Mutation Acquisition in Utero and Childhood Followed By Lifelong Clonal Evolution Underlie Myeloproliferative Neoplasms

Lee, J. W.

756 - Phase 3 Study of Danicopan, an Oral Complement Factor D Inhibitor, As Add-on Therapy to a C5 Inhibitor in Patients with Paroxysmal Nocturnal Hemoglobinuria with Clinically Evident Extravascular Hemolysis
1686 - Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks
1913 - Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients
2457 - Risk Factors for Thrombotic Events in Patients with PNH: A Nested Case-Control Study in the International PNH Registry
2586 - Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies
3330 - A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Lee, J. S.

2967 - A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Lee, J.

608 - Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial

Lee, J. S.

2885 - RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Lee, J.

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Lee, J.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Lee, J. H.

3388 - Diagnostic Validation of a Clinical Laboratory-Oriented Targeted RNA Sequencing System As a Comprehensive Assay for Hematologic Malignancies

Lee, J. Y.

2725 - Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization

Lee, J. H.

1527 - Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Lee, K. P.

314 - CD28 Expression Distinguishes Plasma Cell Fate in Pediatric Patients Suffering from COVID-19/Kawasaki's Disease Vs MIS-C
722 - Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Lee, K. (.

3464 - Association of Blood Type on Clinical Outcomes in Black/African Americans Hospitalized for COVID-19 Infection

Lee, K.

2314 - Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial

Lee, K. H.

998 - HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study
1527 - Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Lee, L. H.

879 - Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses

Lee, L.

2592 - Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis
2594 - Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models

Lee, L.

2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution

Lee, L.

866 - Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis
1786 - A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Lee, M.

1167 - Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas

Lee, M. T.

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Lee, M.

1674 - Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up

Lee, M.

2768 - Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Lee, M.

696 - Obesity-Induced Chemoresistance in B-Cell Acute Lymphoblastic Leukemia Cells Is Mediated By Reduced Chemotherapy Uptake and Interleukin-9 Signaling
1023 - Obesity Attenuates T-Cell Function Which Impacts the Efficacy of T-Cell Based Immunotherapies in Acute Lymphoblastic Leukemia

Lee, P. P.

2035 - Tnfα Promotes an Immunosuppressive Microenvironment in Cutaneous T Cell Lymphoma and Regulates PD-L1 Expression

Lee, R. W.

205 - Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Lee, R. H.

1818 - Impact of Platelet Count on Bleeding in the Setting of Anti-Platelet Therapy

Lee, S. J.

1125 - Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma

Lee, S. Y.

1443 - Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lee, S.

1051 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)
2986 - A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Lee, S.

1913 - Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients
3330 - A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Lee, S. T.

598 - Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Lee, S. Y.

3388 - Diagnostic Validation of a Clinical Laboratory-Oriented Targeted RNA Sequencing System As a Comprehensive Assay for Hematologic Malignancies

Lee, S. Y.

804 - Assessment of Cerebral Blood Flow and Oxygen Extraction in Pediatric Sickle Cell Disease with Non-Invasive Diffuse Optical Spectroscopies

Lee, S. T.

2351 - Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Lee, S.

394 - Genome-Wide Association Study Identifies Novel Risk Variants in BCL11A-PAPOLG for TCF3-PBX1 Acute Lymphoblastic Leukemia

Lee, S. Y.

2549 - Malignant Progression of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review and Meta-Analysis

Lee, S. J.

3096 - Ifnα Attenuates the Disease Phenotype and Extends Survival in Mouse Models of MPN

Lee, S.

2303 - A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)

Lee, S.

3459 - A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Lee, S.

526 - Inhibiting the Nuclear Exporter XPO1 and the Antiapoptotic Factor BCL2 Is Synergistic in XPO1 Mutant and Wildtype Lymphoma

Lee, S. J.

77 - Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
137 - High-2-Low Risk Assessment Model to Predict Venous Thromboembolism in Allogeneic Transplant Patients after Platelet Engraftment
353 - Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213)
358 - Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment
423 - Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation
561 - Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis
1496 - Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-Term Survivors
1518 - Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching
1849 - Towards Identifying the Target of Autoimmunity in Aplastic Anemia
3356 - Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant
3491 - Decisional Involvement, Information Preferences, and Prognostic Optimism Among Patients with Hematologic Malignancies

Lee, S. J.

397 - Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia
699 - DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia

Lee, S. E.

1243 - Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study
1913 - Effects of Delayed Treatment on Patients with Acute Myeloid Leukemia; Treatment Delay Matters in Younger Patients
3101 - Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade
3330 - A Phase 3 Trial of Thymoglobuline for Prevention of Chronic Gvhd in Transplantation from an HLA-Matched Sibling

Lee, S. T.

597 - Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Lee, T.

3398 - Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Lee, T.

2493 - Patient Adherence to Medication within a New Multidisciplinary Thrombosis Service

Lee, T. K.

2679 - Characterization of Protein Unable to Bind Von Willebrand Factor in Recombinant Factor VIII Products: Can We Reduce Their Immunogenicity?

Lee, T.

67 - Engineered iPSC-Derived NK Cells Expressing Recombinant CD64 for Enhanced ADCC
93 - CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma
566 - Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse
613 - Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy
1402 - FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
1434 - Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor
1947 - Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML
3263 - Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment
3279 - cGMP Mass Production of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line

Lee, T.

748 - Roxadustat Lowers Risk of RBC Transfusion in Patients with Anemia of CKD
749 - Pooled Efficacy and Cardiovascular Safety Results of Roxadustat Compared with Epoetin Alfa in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
1671 - Pooled Efficacy and Cardiovascular Analysis of Roxadustat Compared with Placebo in Anemia Correction in Chronic Kidney Disease Patients Not on Dialysis

Lee, W. I.

2645 - Correlation of Hemophagocytosis with Clinical Criteria of Hemophagocytic Lymphohistiocytosis and Recommendations for Screening Bone Marrow Samples in Adult Patients

Lee, W.

2789 - Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Lee, W. S.

1243 - Second Imatinib Discontinuation Outcomes in Patients Regaining Durable Deep Molecular Response in the Korean Imatinib Discontinuation Study; KID Study
2154 - Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia
2967 - A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Lee, X. Y.

1566 - Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch

Lee, Y. M.

2479 - Maximising Capacity and Saving Cost in an Outpatient Chemotherapy Centre during a Pandemic: A Quality Improvement Project
3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Lee, Y.

2938 - Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Lee, Y. G. G.

554 - CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells

Lee, Y.

2779 - JAK/STAT Inhibition Targets TP53 altered Primary Human Acute Myeloid Leukemia Stem Cells

Lee, Y.

1527 - Machine Learning-Based Approach to Predict Survival after Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies

Lee, Y. S.

3026 - Phase I/II Dose-Escalation Study of Lenalidomide in Combination with R-GDP for Treatment of Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Followed By Maintenance Lenalidomide

Lee-Sundlov, M. M.

322 - Plasmacytoid Dendritic Cells Surveil Megakaryocyte Sialic Acid to Regulate Thrombopoiesis
909 - Sialylated Glycans Regulate MUC13 and the Proto-Oncogenes Pim-1 and Myc to Control Hematopoietic Stem and Progenitor Cell Numbers

Leebeek, F. W.

571 - Semiautomatic VWF Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease
573 - Low Von Willebrand Factor: Cut-Off Value for Diagnosis and Risk Score to Predict Bleeding Incidence
672 - Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial
3373 - AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years
LBA-6 - First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Leef, R.

2477 - Clinical & Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice in Israel

Leeies, M.

899 - Red Blood Cell Transfusion and the Use of Intravenous Iron in Iron Deficient Patients Presenting to the Emergency Department
2667 - Platelet Count Trajectory and Mortality in Septic Shock: A Retrospective Cohort Study

Leeming, A.

638 - Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma
2094 - AZD4320 Is a Novel and Potent BCL-2/X_L Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma
2786 - Targeting ROR1 Using the Antibody Drug Conjugate Vls-101 in Aggressive Mantle Cell Lymphoma
2789 - Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Leen, A. M.

609 - Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study
612 - Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Lefebure, M.

125 - Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)
3139 - Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study

Lefevre, C.

12 - Whole Exome Sequencing of a Patient with Atypical Congenital Pure Red Cell Aplasia Has Enabled the Identification of a Novel Key Actor of Erythropoiesis That May be Involved in CDAI Physiopathology

Lefkou, E.

3387 - Profile of Thrombin Generation Assay and Thromboelastometry in Women with Moderate and Severe Preeclampsia. the Roadmap-Preeclampsia Study

LeFleur, D. W.

3199 - Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Legg, A.

1929 - Analysis of Treatments and Outcomes for Patients with De Novo AML, Therapy-Related AML, and Secondary AML (Prior MDS and CMML) Diagnosed in England between 2011 and 2016 Using Hospital Episode Statistics^®

Legrand, F.

422 - Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program
816 - Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry
1459 - Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Legrand, F.

3018 - First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

Legrand, O.

632 - Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

Legros, L.

3112 - Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Legros, M.

3338 - High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

Lehle, M.

1800 - Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Lehman, A.

699 - DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia

Lehman, J. H.

1070 - FLT3 Internal Tandem Duplication Quantitation and Length Analysis By Digital PCR Paired with High-Speed AFM

Lehmann, A. K.

467 - NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Lehmann, A.

1742 - COVID-19: B-Cell Depletion and Sepsis Related Changes in Bone Marrow and Spleen

Lehmann, F. F.

990 - First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
993 - Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
1428 - Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Lehmann, F.

1360 - Melflufen Shows Efficacy Against Bortezomib-Resistant Multiple Myeloma Models
1364 - Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma
1892 - Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model
2274 - Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Lehmann Mendoza, R.

246 - Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2

Lehmann, T.

2997 - Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Lehner, S.

1774 - Von Willebrand Factor (VWF) Deficiency Leads to Altered Angiogenesis in the Gastrointestinal Tract

Lehrer-Graiwer, J.

1716 - Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis

Lehrnbecher, T.

1919 - Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group
2804 - Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome

Lehtiö, J.

565 - Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Lei, B.

2304 - Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Lei, X.

522 - A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

LEI, Y.

1486 - Interleukin-7 Receptor Gene Heterozygous Mutations in Recipients Significantly Increase Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
2407 - Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies

Leiba, M.

727 - A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Leiderman, K.

SCI-22 - A Systems Biology Approach to Identifying Modifiers of Bleeding in Hemophilia

Leifer, E.

75 - A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Leighton, J.

2897 - Mapping the Architecture of Adverse Risk AML Using Single-Cell RNA Sequencing

Leip, E.

46 - Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
2152 - Bosutinib for Previously Treated Patients with Philadelphia Chromosome-Positive Leukemia: ≥8-Year Update of a Phase 1/2 Study
2158 - Efficacy and Safety of Bosutinib By Age and Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 Byond Study
3076 - Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Leis, J. F.

126 - A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter’s Transformation and De Novo Diffuse Large B-Cell Lymphoma
1317 - Adverse Events in Clinical Trials of Ibrutinib and Acalabrutinib for B-Cell Lymphoproliferative Disorders: A Systematic Review and Network Meta-Analysis
2086 - Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia
2206 - Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma
2211 - Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter’s Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL)
3127 - Distinct Gene Expression Signatures in Patients with Richter’s Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib
3143 - Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia
3144 - Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL)
3150 - Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience

Leisenring, W.

370 - Prevalence and Predictors of Neurocognitive Impairment in Long-Term Survivors of Childhood Hodgkin Lymphoma: A Report from the Childhood Cancer Survivor Study

Leisner, C.

2269 - Local Activator and T Cell Engager (αBCMA x αPD-L1 x αCD3) with Enhanced Tumor Killing and Minimal Cytokine Release for the Treatment of Multiple Myeloma

Leissinger, C. A.

868 - Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices
1790 - PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Leitch, H. A.

1280 - MDS Iron Road: An Internet-Based Algorithm for the Diagnosis, Workup and Management of Iron Overload (IOL) in Patients with Myelodysplastic Syndromes (MDS) from the Canadian Consortium on MDS (CCMDS)
1291 - Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study
2197 - High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS

Leitges, M.

967 - Overcoming Multidrug Resistance in B Cell Malignancies By Antagonism of Stromal Mediated TGF-β Signalling

Leiva, J. A.

1814 - Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation

Leiva, O.

1259 - Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk

Leivonen, S. K.

2034 - Clinical Impact of Tumor-Associated Macrophage and T-Cell Contents in Diffuse Large B-Cell Lymphoma

Lejeune, D.

3415 - Real-World Treatment Patterns and Healthcare Resource Utilization (HRU) of Patients (Pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population

Lejeune, J.

3112 - Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Lekah, A.

1808 - Acute Deep Vein Thrombosis and Association with Popliteal Fossa (Baker’s) Cysts in Patients with Lower Extremity Duplex Ultrasound Examination

Lekakis, L. J.

600 - Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL

Lekakis, L. J.

1187 - Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
1463 - Pharmacokinetics and Safety of KRN7000 Following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients
2100 - Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product
3342 - Is There an Unequal Benefit of Autologous Stem Cell Transplant in Different Cytogenetic Groups of High Risk Patients with Multiple Myeloma: The University of Miami Experience

Leksa, N.

857 - Mechanistic Studies of Thrombin Generation Assay to Evaluate Procoagulant Potential of Fitusiran
862 - Reducing Antithrombin in Plasma to Levels Observed in Fitusiran-Treated Patients Does Not Interfere with Coagulation Assays

Lekstrom-Himes, J.

4 - Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9–Modified CD34+ Hematopoietic Stem and Progenitor Cells

Leleu, X.

Lema, E.

771 - Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron
2736 - Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation

Lemaistre, C. F.

3427 - Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Lemarie, C.

1459 - Successful Clearance of Donor Specific Anti-HLA Antibodies after Desensitization with Rituximab, Velcade and Plasma-Exchange Followed By a Haploidentical Stem Cell Transplantion with Post-Transplantation Cyclophosphamide

Lemasle, E.

2857 - Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Lemieux, C.

1507 - Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma
3322 - Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant

Lemieux, S.

1485 - UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Lemoli, R. M.

461 - Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations
1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)
2167 - Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival
2360 - On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)
2994 - Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome

Lemoli, R. M.

2990 - First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria

Lemoli, R. M.

588 - Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Lemon, B.

1408 - HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Lemonier, N.

1709 - Drepadom – Home Care Services and Hospitalizations for Sickle Cell Disease Patients during the Covid-19 Pandemic

Lemons, R. S.

LBA-6 - First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Lemos, M.

1081 - Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Lemvigh, C. K.

1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome

Lenain, P.

3325 - Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Lenco, M.

3414 - Costs and Adverse Events Associated with Ibrutinib or Ruxolitinib in Chronic Graft-Versus-Host Disease

Lendvai, N.

436 - Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Leng, C.

1206 - Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Leng, S.

3029 - A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lengerke Diaz, P. A.

2136 - Management of Patients with Aggressive B Cell Non-Hodgkin Lymphoma after Relapse from Axicabtagene Ciloleucel: Single Center Real-World Experience
2226 - Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Lengfellner, J.

436 - Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients

Lengline, E.

1237 - Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line

Lenhammar, L.

2274 - Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Lenhoff, S.

2445 - Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT

Lenk, L.

2834 - Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Lennon, N.

80 - DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant
1327 - A Next Generation Liquid Biopsy Approach for Multiple Myeloma

Lentz, S. R.

1810 - COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19

Lentzsch, S.

291 - REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
723 - Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Lentzsch, S.

181 - A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE^®(bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)
726 - Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
1366 - Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma
1393 - Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma
2275 - Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Lenz, A.

1768 - Novel Splice-Site Mutation in RASGRP2 Leading to Caldag-GEFI Deficiency

Lenz, G.

267 - First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)
1048 - Impeding DNA Repair Offers a Novel Possibility for Personalized Therapy in AML Patients, Who Are Carrier of the Growth Factor Independence 1 Variant “GFI1-36N”
1049 - AML Associated Mesenchymal Stroma Cells Support Growth of AML Cells As a Result of Activated Notch Signaling and This Can be Targeted By Dexamethasone
1206 - Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)
3311 - Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for the Assessment of Acute Intestinal GvHD and Prediction of Response to Immunosuppressive Therapy

Lenze, A.

565 - Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

León-Basantes, G.

1903 - Minimal Residual Disease Assessment and Allogeneic Transplantation As Consolidation Therapy in Acute Lymphoblastic Leukemia

León-Peña, A. A.

2412 - Early Response Predicts Long-Term Improvement or Stabilization of Persons with Multiple Sclerosis Treated with Hematopoietic Stem Cell Transplantation

Leonard, E. J.

1026 - Ponatinib Versus Imatinib with Reduced-Intensity Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Phallcon Study
2842 - A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Leonard, J. P.

40 - Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
704 - Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study
1195 - Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]
1205 - Evaluation of the Prognostic Utility of Bone Marrow Biopsy in Diffuse Large B-Cell Lymphoma: A SEER-Medicare Linked Database Analysis
2018 - XPO1 Relieves MYC-Induced Replication Stress Limiting the Immunogenicity of DLBCL Cells
2052 - A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
2104 - A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas
2501 - Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations
2969 - SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
3030 - Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Leonardi, A.

1779 - Plasminogen Eye Drops Are Effective in Preventing Recurrence of Pseudomembranes in Ligneous Conjunctivitis: Results from the Phase 2/3 KB046 Trial

Leonel, R. B.

3286 - “Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose”
3293 - Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients

Leonetti Crescenzi, S.

3077 - Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the “Registro Italiano LMC & Campus CML”

Leong, H.

3489 - Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Leong, K.

450 - In Situ Fate Mapping of Native and Stress Myelopoiesis Reveals a Unique Niche for Mono- and Dendritic Cell –Poiesis

Leong, R.

749 - Pooled Efficacy and Cardiovascular Safety Results of Roxadustat Compared with Epoetin Alfa in the Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis
766 - Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
1277 - Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels
1671 - Pooled Efficacy and Cardiovascular Analysis of Roxadustat Compared with Placebo in Anemia Correction in Chronic Kidney Disease Patients Not on Dialysis

Leongamornlert, D. A.

602 - Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Myeloma Precursor Disease

Leonidakis, A.

1370 - Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study
2279 - Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Leonti, A. R.

274 - Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts
388 - Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
593 - Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol
689 - Integrated Stem Cell Signature and Cytomolecular Risk Determination in Pediatric Acute Myeloid Leukemia
1087 - The Transcriptomic Landscape of NUP98-Rearranged Pediatric Acute Myeloid Leukemia
1959 - Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy
1985 - Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia
2003 - Target-Informed Repurposing of Immunotherapies in AML – a Transcriptome Based Approach for Identifying Immediately Available Therapeutics

Lepik, K.

1152 - The Outcomes of Nivolumab Fixed Dose 40 Mg Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
1292 - Profile of Checkpoint Molecules Expression on Bone Marrow Cell Populations in Patients with High-Risk Myelodysplastic Syndrome
1492 - Safety of Allogeneic Stem Cell Transplantation after PD-1 Blockade for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Focus on Immune-Related Adverse Events

Lepik, K.

467 - NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity

Leporace, A.

3077 - Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the “Registro Italiano LMC & Campus CML”

Leppa, S.

1162 - Outcome of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Finnish Nationwide Population-Based Study
2034 - Clinical Impact of Tumor-Associated Macrophage and T-Cell Contents in Diffuse Large B-Cell Lymphoma

Lepretre, S.

337 - Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Lequang, T.

681 - Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Lequesne, J.

1214 - R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers

Lequeu, H.

3044 - Diagnosis-to-Treatment Interval Is an Important Prognostic Factor with a Time-Dependent Effect Predicting Event-Free Survival after 12 Months from First-Line Treatment in Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma
3052 - Retrospective Evaluation of Rituximab, Methotrexate, Procabazine, Vincristine and Etoposide Followed By Consolidation with Rituximab, Aracytine and Ifosfamide for Elderly Patients with Newly Diagnosed Primary CNS Lymphoma

Leray, E.

3337 - Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Lercher, A.

3374 - Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities

Lerman, M.

679 - FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

Lerman, Y.

2102 - A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma

Lerner, A.

2322 - Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Lesegretain, A.

2775 - Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Leshchenko, V.

1103 - Aberrant Cell Cycle Programming Confers Rapid Lethality in the EuSOX11+ CCND1 MCL Mouse Model

Leshchiner, I.

1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome

Lesley, R.

181 - A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE^®(bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Leslie, C.

523 - Transcriptional Control of HP1a By the RNA Binding Proteins Rbmx/L1 Maintain Chromatin State in Myeloid Leukemia
1429 - Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes

Leslie, K.

1070 - FLT3 Internal Tandem Duplication Quantitation and Length Analysis By Digital PCR Paired with High-Speed AFM

Leslie, L. A.

372 - Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study
700 - Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
703 - Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
2934 - Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial
2942 - Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
2943 - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
3136 - Venetoclax Re-Treatment of Chronic Lymphocytic Leukemia (CLL) Patients after a Previous Venetoclax-Based Regimen

Leslie, L. A.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19
2553 - COVID-19 Impact on Lymphoma Patients’ Clinical Outcomes – an Observational Cohort Study
2945 - A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Lesmana, H.

317 - Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells

Lesnick, C. E.

3132 - Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Lesokhin, A. M.

177 - CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
436 - Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
1191 - Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
1369 - Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
2240 - Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
3204 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study
3206 - Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lesprit, E.

799 - Persistance of Inflammatory Phenotype of Neutrophils in Sickle Cell Disease Children Despite Chronic Exchange Transfusion Program: A Cause of the Progression of Cerebral Vasculopathy?

Lessard, S.

1703 - Catalytic Activity of Heme-Regulated eIF2 Alpha Kinase (HRI) Regulates Fetal Hemoglobin
2608 - Genetic Silencing of KEAP1 Induces NRF2 Mediated Oxidative Stress Pathway in Human Erythroid Cells

Lessene, G.

263 - Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Lessi, F.

2763 - Germline GATA2 Mutations (R986Q and R398W) Inhibit Endothelial Development and Augment Myeloid Differentiation during Early Human Hematopoiesis

Letai, A.

190 - Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies
362 - Dynamic BH3 Profiling As Pharmacodynamic Biomarker for the Activity of BH3 Mimetics
1038 - Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
1904 - Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
2209 - CCR2 Expression Signature Can Classify and Predict Outcome in a Subpopulation of Chronic Lymphocytic Leukemia (CLL) Patients
2273 - Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Letterio, J.

2840 - Targeting NLRP3 Inflammasome-Induced Therapy Resistance in ALL

Lettre, G.

- Using Mendelian Randomization to understand clinical heterogeneity in sickle cell disease
- Omics Approaches to Erythrocyte Biology in Sickle Cell Disease - Live Q&A and Panel Discussion

Leung, N.

1302 - Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis
1336 - A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
1391 - A Single-Center Phase 2 Open-Label Trial Evaluating the Safety and Efficacy of Daratumumab in Treatment of Patients with Monoclonal Gammopathy of Renal Significance
1508 - Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥ 75 Treated with Novel Agents
1675 - Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review
2244 - MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
2257 - The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma
2280 - Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
2306 - Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
2312 - Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis
3160 - Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
3165 - Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma
3196 - Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
3228 - Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients
3229 - Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients
3246 - Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis

Leung, W. H.

3306 - HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies: Three-Year Follow-up of Multicenter Study in Singapore

Levato, L.

50 - Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study
3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’

Leventaki, V.

1996 - Genomic Analysis of Congenital Myeloid Sarcoma Identifies Significant Bone Marrow Involvement in the Absence of Morphologic Blasts

Leventhal, J. R.

1204 - Prognosis and Outcomes of Patients with Post-Transplant Lymphoproliferative Disorder: A Single Center Retrospective Review

Leverett, D.

1782 - Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Leverger, G.

1076 - Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
1246 - Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study

Leverger, G.

822 - Pediatric-Onset Evans Syndrome Is Associated with Broad Immunopathological Manifestations, High Treatment Burden and Mortality in Long-Term Follow-up
931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients

Levi, I.

401 - Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B‑Cell Lymphoma
1958 - Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation
2824 - First Results from a Nationwide Prospective Non-Interventional Study of Venetoclax-Based 1^st Line Therapies in Patients with Acute Myeloid Leukemia (AML) – Revive Study

Levi, M.

2477 - Clinical & Economic Implications of Hydroxyurea Intolerance in Polycythemia Vera in Routine Clinical Practice in Israel

Levie, S. E.

2836 - Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Levin, M. D.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Levin, M.

3143 - Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia

Levin, N.

701 - A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Levine, B. L.

2224 - Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Levine, M.

386 - Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis

Levine, R. L.

1 - Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms
273 - Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
386 - Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis
387 - Germline Contributions to Clonal Hematopoiesis in Solid Cancer Patients
388 - Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
636 - Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
713 - Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms
1265 - Analysis of the Global Methylation Profile of Accelerated and Blast Phase Myeloproliferative Neoplasms and Its Association with Response to Decitabine-Based Therapy
2204 - Immunophenotypic Lineage Assessment By Multiparameter Flow Cytometry Provides More Precise MDS Prognosis
2746 - Clonal Hematopoiesis and COVID-19 Severity in Cancer Patients
2843 - Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors
3093 - LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation
- Opening Remarks

Levis, M.

24 - A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
272 - The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
333 - Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study
334 - Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
591 - Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
1025 - V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
1525 - Transplant Outcomes for IDH-Mutated AML: Good Outcomes Thanks to Keeping Good Company
1534 - Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)
2402 - A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation
2443 - Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use
2461 - Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia
2797 - Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2^nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

LeVoir, A. C.

3055 - IVAC +/- R for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era

Levovitz, C.

1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome

Levy, C.

2595 - Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist

Levy, D.

2085 - GATA3 Gene - a Potential New Biomarker Associated with Adverse Outcomes in ALK1-Negative Anaplastic Large Cell Lymphoma: Preliminary Results from a Retrospective Cohort of 80 South American Cases of Nodal Peripheral T Lymphoma

Levy, E. R.

610 - CRISPR Gene-Editing of Chemokine Receptors As a Novel Strategy to Redirect NK Cell Trafficking In Vivo

Levy, E.

3069 - In Pursuit of Surrogate Markers for Treatment-Free Remission in Patients with Chronic Myeloid Leukemia from Argentina Stop Trial

Levy, G.

1800 - Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1–4)

Levy, H.

1795 - The Crimson 1 Study: A Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptocog Alfa (activated) for on-Demand Treatment and Control of Bleeding Episodes in Subjects with Hemophilia A or Hemophilia B, with Inhibitors

Levy, J. H.

- The Role of the Coagulation Laboratory in Treating the Infectious Disease Patient
- Prevention and Monitoring Panel Discussion and Live Q&A
- Full Panel Discussion and Q&A

Levy, M.

1612 - Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?
3446 - Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Levy, M.

135 - High Doses of Targeted Radiation with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
2297 - Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study
3489 - Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Levy, M. Y.

193 - Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
1385 - Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study
2947 - Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
3206 - Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
3215 - Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study
3245 - Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Levy, R.

641 - Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination
1144 - Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Lew, G.

1900 - Premedication and Longer Infusion Time Do Not Reduce the Incidence of Hypersensitivity Reactions to Pegaspargase
2008 - Incorporating Hemoglobin Levels to Map Leukostasis Risk in Acute Leukemia Using Microvasculature-on-Chip Technologies

Lewalle, P.

993 - Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

Lewandowski, A.

1200 - Ibrutinib before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results from a Phase 1b Study

Lewerin, C.

2951 - Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project

Lewis, A.

1975 - A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Lewis, B.

729 - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis Patients Treated on a Phase 2, Open-Label, Dose Selection Study to Evaluate the Safety and Tolerability of Cael-101 in Patients with AL Amyloidosis
2281 - Outcomes in AL Amyloidosis: A Single Institution Experience

Lewis, D. J.

117 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
402 - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
542 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
1185 - Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
2965 - AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Lewis, D.

65 - GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts
2356 - Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC‑Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Lewis, E.

3221 - Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lewis, H. B.

437 - Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial

Lewis, J.

3436 - Predictors of Healthcare Utilization in Newly Diagnosed Myeloma

Lewis, K. L.

117 - LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
1130 - Clinical Activity of TG-1701, As Monotherapy and in Combination with Ublituximab and Umbralisib (U2), in Patients with B-Cell Malignancies

Lewis, N. M.

2302 - DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Lewis, S.

317 - Germline Gain-of-Function JAK3 Mutation in Familial Chronic Lymphoproliferative Disorder of NK Cells

Lewis, V. A.

419 - Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study
1975 - A Novel Anti-Cancer Vaccine Approach for the Treatment of High-Risk Leukemia in Children

Ley, T. J.

409 - Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
1553 - Comparison of Deep Whole Exome Versus Targeted Gene Sequencing for Assessment of Persistent Molecular Disease in Acute Myeloid Leukemia Samples
2894 - Molecular Profiling of Decitabine Response in MDS and AML Patients

Leyton, C.

21 - Indeterminate Serotonin Release Assays Are Associated with a High Mortality Rate
3460 - Utilization & Barriers to Curative Therapies Among Adult Aplastic Anemia Patients in a Multiethnic Urban Underserved Cohort

Lezhava, T.

3146 - Pooled Analysis of Cardiovascular Events from Clinical Trials Evaluating Acalabrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia (CLL)

Lhermitte, L.

2118 - Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Li, A.

137 - High-2-Low Risk Assessment Model to Predict Venous Thromboembolism in Allogeneic Transplant Patients after Platelet Engraftment
204 - Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
1496 - Thrombotic Microangiopathy Increases the Risk of Chronic Kidney Disease but Not Overall Mortality in Long-Term Survivors
2516 - Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada

Li, B.

727 - A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Li, B.

90 - Salubrinal Mediated Fetal Hemoglobin Induction through the eIF2α-ATF4 Signaling Pathway

Li, B.

3093 - LSD1 Inhibitor CPI-482 Shows Efficacy and Prolongs Survival in Mouse Models of AML and Post-MPN AML in the Context of Constitutive JAK-STAT Pathway Activation

Li, B.

3115 - Clonal Architecture Analysis of TET2 Identified Distinct Origins in Myelodysplastic Syndromes

Li, B.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Li, C.

1350 - Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma
2271 - CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Li, C.

2060 - Shifting Treatment Patterns and Clinical Outcomes in Veterans Diagnosed with Waldenstrom Macroglobulinemia from 2006 to 2018

Li, C.

1542 - In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques
2602 - Mgta-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice
3368 - In Vivo HSC Gene Therapy with Base Editors Allows for Efficient Reactivation of Fetal Globin in Beta-Yac Mice

Li, C.

2740 - Taghi-C Reveals 3D Chromatin Architecture Dynamics during Hematopoiesis

Li, C.

2243 - Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation
3181 - The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Li, C. K.

399 - Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
582 - NUTM1-Rearranged Infant and Pediatric B Cell Precursor Acute Lymphoblastic Leukemia: A Good Prognostic Subtype Identified in a Collaborative International Study

Li, C. C.

702 - Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
2096 - Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Li, C.

1454 - Mobilization of Auto-Stem Cells in the Thalassemia Major and Relationship with Iron Overload
1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors
1992 - High EVI1 Expression Predict Adverse Outcome in Children with Acute Myeloid Leukemia: A Multicenter, Nonrandomized Clinical Study in China
2365 - Outcome of Sibling's and Unrelated Umbilical Cord Blood Stem Cell Transplantation Combined PBSC in Thalassemia Major and Related Factors Analysis:76 Cases Reported in Single Center
2859 - Phase I Clinical Trial of Autologous CLL1 CAR-T Therapy for Pediatric Patients with Relapsed and Refractory Acute Myeloid Leukemia

Li, C.

42 - Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Li, C.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals
2345 - Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

Li, C.

2318 - Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Li, D.

2116 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Li, D.

459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial
1135 - Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Li, E. W.

434 - Development and Evaluation of a Community of Practice to Support Stem Cell Donor Recruitment in Canada

Li, F.

2751 - A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)

Li, G.

1455 - Large Scale Ex Vivo Expansion of Γδ T Cells Using Artificial Antigen Presenting Cells for the Treatment of Acute Myeloid Leukemia

Li, G.

2859 - Phase I Clinical Trial of Autologous CLL1 CAR-T Therapy for Pediatric Patients with Relapsed and Refractory Acute Myeloid Leukemia

Li, H.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Li, H.

2090 - Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Li, H.

2730 - Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life

Li, H.

1218 - Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma

Li, H.

256 - Erythropoiesis Failure in Diamond-Blackfan Anemia Starts at the Oligopotent Common Myeloid and Megakaryocyte-Erythroid Progenitor Stage

Li, H.

2969 - SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
3470 - Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

Li, H.

3022 - A Phase 1, Open-Label Study of MGD013, a Bispecific DART^® Molecule Binding PD‑1 and LAG‑3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Li, H.

957 - CXCL12 Knock-out Enhances Leukemia Stem Cell Response to Combination Chemotherapy Plus Tyrosine Kinase Inhibition in Flt3-ITD Acute Myeloid Leukemia

Li, H.

2607 - Crispra: A Promising Tool for β-Thalassemia Treatment

Li, J. L.

1098 - Prognostic Prediction with Static-Dynamic Clinical and Pathological Parameters By Machine Learning Algorithm in Acute Lymphoblastic Leukemia
2905 - Accurate Prediction of Gene Mutations with Flow Cytometry Immune-Phenotyping By Machine Learning Algorithm

Li, J.

2768 - Highly-Sensitive DNA Hydroxymethylation Analysis in Myelodysplastic Syndromes (MDS)

Li, J.

1602 - Cost-Effectiveness of Polatuzumab Vedotin Plus Bendamustine-Rituximab for Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the United States

Li, J.

521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis
1269 - ZRSR1 Cooperates with ZRSR2 in Regulating Splicing of U12-Type Introns in Murine Hematopoietic Cells

Li, J.

1992 - High EVI1 Expression Predict Adverse Outcome in Children with Acute Myeloid Leukemia: A Multicenter, Nonrandomized Clinical Study in China

Li, J.

592 - Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis
763 - Detection of Myeloid and Clonal Expansion Related Gene Mutations By Whole-Exome Sequencing in Patients with Paroxysmal Nocturnal Hemoglobinuria
1620 - Impact of Hematologists’ Personality and Behavioral Traits on Medical Decision-Making for Elderly Acute Myeloid Leukemia: A National Study in China
2043 - A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease
2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals
2758 - Plasma Concentration of Eltrombopag Correlated with the Efficacy in the Treatment of Refractory Aplastic Anemia: A Single-Center Study in China
2962 - Unicentric Castleman Disease with High Inflammatory State: Surgical Treatment Is a Potential Cure
3171 - A Highly Heterogeneous Mutational Pattern in POEMS Syndrome

Li, J.

3440 - Feasibility of a Decision Support Software to Aid in the Interpretation of Somatic Mutations Detected in Hematologic Malignancies

Li, J.

110 - NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice
944 - Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma

Li, J.

161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, J.

182 - An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial
1320 - Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
1860 - A Novel pH Dependent C5 Monoclonal Antibody with Better Developability
2229 - Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Li, J.

2940 - Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial

Li, J.

644 - Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Li, J. Y.

2262 - An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism
3190 - Adipocyte Fatty Acid Binding Protein Promotes Multiple Myeloma through Regulating Bone Marrow Microenvironment

Li, J.

2450 - Platelet-Targeted Gene Therapy Induces Robust Immune Tolerance Even in a Primed Model Via Peripheral Clonal Deletion of CD4 and CD8 T Cells and Expansion of Treg Cells

Li, J.

291 - REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
400 - Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
3029 - A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Li, J.

159 - Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
270 - A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
1445 - Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, J.

2967 - A Phase I/II Study (JACKPOT8) of DZD4205, a Selective JAK1 Inhibitor, in Refractory or Relapsed Peripheral T- Cell Lymphoma

Li, J.

973 - First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Li, J.

39 - Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma
340 - Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R² Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
1123 - Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R² Followed By Maintenance

Li, J.

1956 - Therapeutic Response and Molecular Mechanisms of Novel Combination Regimen Azacitidine Plus Homoharringtonine in Acute Myeloid Leukemia with Poor Outcome

Li, J.

1944 - Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Li, L.

1107 - Genetic Mutations of Tim-3 Ligand, and Exhausted Tim-3⁺CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma
2031 - Associations of OX40 and Tumor Microenvironment with Outcomes in Diffuse Large B-Cell Lymphoma

Li, L.

1017 - A Feasibility and Safety Study of Non-Viral Genome Targeting Anti-CD19 CAR-T in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, L.

907 - Nuclear Protein DEK Governs Quiescence and Metabolic Homeostasis of Hematopoietic Stem Cells By Shaping Chromatin Accessibility

Li, L.

3083 - Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Li, L.

3376 - PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia

Li, L.

3253 - Endothelial Microparticles Delivering Lncrna NEAT1 Are Involved in the Pathophysiology of aGVHD Following Allogeneic Hematopoietic Stem Cell Transplantation

Li, L.

2849 - Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients

Li, L.

876 - Coagulation Dysfunction and Hematological Changes in 633 Patients with COVID-19
919 - The Role of 5-HT on Proplatelet Formation and Thrombopoietin Production
1807 - Increased Circulating Proplatelets and Elevated Plasma TPO Levels: A Novel Pathological Mechanism of Cerebral Infarction
2658 - Thrombopoietin Protects Neural Cells and Endothelial Cells from Apoptosis Via PI3K/AKT Pathway

Li, L.

710 - Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)
1878 - Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Li, L.

973 - First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Li, L.

1112 - Targeting the Synthetic Lethality Interaction of MTAP and PRMT5 to Overcome Drug Resistance and Enhance Anti-Cancer Immunity in Mantle Cell Lymphoma
1114 - MCL Cells in Tumor Microenvironment Impair T-Cell Metabolic Fitness and Effector Function
1181 - Abemaciclib-Based Combinational Therapies to Overcome Therapeutic Resistance in Mantle Cell Lymphoma

Li, L.

2576 - The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59^-cell from Paroxysmal Nocturnal Hemoglobinuria Patients

Li, L.

178 - Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Li, M.

2188 - Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Li, M.

292 - Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
3213 - Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Li, M.

2334 - Application of Novel T Cell Immunotherapeutics to Drive Antigen-Specific Activation, Expansion, and Differentiation of CD19 Chimeric Antigen Receptor T Cells (CAR T-cells)

Li, M. Y.

639 - The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma
2024 - TRAF3 Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma

Li, M.

204 - Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry

Li, M.

101 - Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience

Li, N.

2452 - A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing
2539 - Examining the Hemophilia Disability Paradox

Li, N.

501 - Novel CoupledCAR^TM Technology for Treating Colorectal Cancer
2453 - AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Li, N.

1884 - FLT3 Ligand-DM1 Conjugate Selectively Targets Acute Myeloid Leukemia Cells with FLT3 Expression

Li, P.

1559 - The Quick Antigen Identification By Tissue Flow Cytometry for CAR-T Therapy in Relapsed/Refractory B-Cell Malignancies without Bone Marrow Involvement or Serous Cavity Effusions
2464 - CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy

Li, P.

2751 - A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)

Li, P.

2210 - CTP Synthase 2: A Novel Prognostic Biomarker and Potential Therapeutic Target in Chronic Lymphocytic Leukemia

Li Pira, G.

560 - Outcome of Children with Different Non-Malignant Disorders Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Li, Q.

1485 - UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Li, Q.

310 - Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California
622 - Treatment Patterns, Type of Front-Line Regimen, and Outcomes Among Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis in the Modern Era
2525 - Intensity of Front-Line Regimen Is Associated with Admissions, in-Hospital Days, and Discharge Destination in Older Adults with Acute Myeloid Leukemia: A Population-Based Analysis
3466 - Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study

Li, Q.

876 - Coagulation Dysfunction and Hematological Changes in 633 Patients with COVID-19

Li, Q.

1941 - CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Li, Q.

113 - Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML

Li, Q.

2841 - Healthcare Utilization and Costs Associated with Different Treatment Protocols for Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: A Population-Based Study

Li, Q.

1199 - Efficacy and Safety of Pemetrexed Combined with Lenalidomide in the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma

Li, Q.

1548 - Induction of Fetal Hemoglobin By FTX6058, a Novel Small Molecule Development Candidate

Li, Q.

681 - Phase 1 Multiple Ascending Dose Study of Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Mitapivat (AG-348) in Subjects with Sickle Cell Disease

Li, R.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Li, R.

1509 - Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies

Li, S.

2155 - Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR^4.5: Results from ENESTfreedom

Li, S.

3100 - Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA

Li, S.

522 - A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Li, S.

94 - Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Li, S.

1881 - Machine Leaning Algorithm on Chemotherapeutic Drug Resistance Related Gene Classifier in Acute Myeloid Leukemia

Li, S.

1119 - Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
1138 - Comprehensive Analysis of Factors Predictive for Time to Transformation and Risk of Transformation in Patients (pts) with Mantle Cell Lymphoma
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2058 - Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma

Li, S.

2743 - Tet2 Deficiency Rejuvenates Hematopoietic Stem and Progenitor Cells during Ageing

Li, S.

723 - Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease
2275 - Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Li, S.

1592 - Role of clonoSEQ^®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma

Li, S.

2402 - A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation
3349 - Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Li, S.

659 - Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter’s Syndrome
941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome
1304 - IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia
2433 - Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation

Li, S.

501 - Novel CoupledCAR^TM Technology for Treating Colorectal Cancer

Li, S.

1386 - A Phase 1 Dose-Escalation Study of LH031, a Kinesin Spindle Protein Inhibitor, in Patients with Refractory/Resistance Multiple Myeloma

Li, T.

972 - Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Li, T.

1263 - A Novel Humanized Animal Model Reveals Clonal Architecture and Therapeutic Vulnerabilities in Myelofibrosis

Li, T.

2790 - Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Li, V. M.

2734 - Transcriptional, Protein-Level and Functional Profiling of Human Fetal Liver (FL)-Derived Hematopoietic Stem Cells (HSCs) at Single Cell Resolution

Li Volti, G.

2175 - Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients
3161 - The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells

Li, W.

416 - Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)
1116 - Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action
2290 - Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Li, W.

2762 - Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Li, W.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Li, W.

161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
270 - A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, W.

2773 - Overexpression of hTLX3 in Association with Mutant IL7Rα Is Sufficient to Generate T-ALL In Vivo and to Transform Thymocytes in Vitro

Li, W.

644 - Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)
1186 - Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory （r/r） Large B-Cell Lymphoma in China
1197 - Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study
1229 - Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma

Li, X.

200 - Detecting 24 Kinds of Cytokines Via Flow Cytometry Aimplex Kit Is an Effective Way to Monitor CRS after CAR-T Cells Infusion

Li, X.

161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, X.

2122 - A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL

Li, X.

973 - First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Li, X.

1941 - CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Li, X.

2747 - Single-Cell Transcriptome of Early Hematopoiesis Guides Arterial Endothelium-Promoted Functional T Cell Generation from Human Pluripotent Stem Cells

Li, X.

2298 - Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) – Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
3218 - Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) – Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Li, X.

1071 - Best Practices for Validation of Measurable Residual Disease Assessments By Multiparameter Flow Cytometry in Emerging Clinical Trials of Acute Myeloid Leukemia

Li, X.

2816 - Fanconi Anemia Gene Associated Germline Predisposition in Aplastic Anemia and Hematologic Malignancies

Li, Y.

2074 - Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Li, Y.

1320 - Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Li, Y.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
1881 - Machine Leaning Algorithm on Chemotherapeutic Drug Resistance Related Gene Classifier in Acute Myeloid Leukemia

Li, Y.

42 - Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial
2048 - Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Li, Y.

2885 - RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Li, Y.

2350 - Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)
2358 - Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Li, Y.

459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Li, Y.

937 - The Role of Lncrna-AF117829.1 in the Immunopathogenesis of CD8+ T Cells in Patients with Severe Aplastic Anemia
2031 - Associations of OX40 and Tumor Microenvironment with Outcomes in Diffuse Large B-Cell Lymphoma

Li, Y.

499 - The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, Y.

947 - Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma
1129 - Complex Karyotype Is a Significant Predictor for Worst Outcomes in Patients with Mantle Cell Lymphoma (MCL) Treated with BTK Inhibitors – Comprehensive Analysis of 396 Patients
2037 - Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma – Phase-II Window-1 Clinical Trial
2042 - Combination of Ibrutinib with Rituximab (IR) in Previously Untreated Older Patients with Mantle Cell Lymphoma (MCL) – a Phase II Clinical Trial
2094 - AZD4320 Is a Novel and Potent BCL-2/X_L Dual Inhibitor in Targeting Aggressive Mantle Cell Lymphoma
3010 - Overcoming CAR T Resistance with Non-Covalent BTK Inhibitor Loxo-305 in Mantle Cell Lymphoma

Li, Y.

952 - Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Li, Y.

2769 - Comprehensive Profiling of the Epitranscriptomic N6-Methyladenosine RNA Methylation in Chronic Lymphocytic Leukemia

Li, Y.

955 - Amot Inhibits Tumorigenesis of Diffuse Large B-Cell Lymphoma By Regulating DNA Damage Response

Li, Y.

1444 - Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Li, Y.

2751 - A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)

Li, Y.

2109 - Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Li, Y.

1883 - NGS-Based Screening to Comprehensively Decipher TKIs Resistant Mutations in BCR-ABL1 Positive Leukemias

Li, Y.

3254 - LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease Via Skewing T Cells Polarization Towards Treg Cells

Li, Y.

162 - CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia
601 - Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Li, Y.

42 - Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial

Li, Y.

162 - CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia
601 - Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Li, Y.

533 - Double-Hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-Cell Lymphoma Treated with R-CHOP
2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution
2926 - VAV1-GFP Fusion Protein Generated By Intron-Based Genome Editing through CRISPR/Cas9 Leads to Spontaneous Activation in TCR Signaling

Li, Y.

1967 - Multi-Omic Based Antigen Discovery for the Immunotherapy of Pediatric Acute T Cell Lymphoblastic Leukemia

Li, Y.

3188 - A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Li, Y. Y.

521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Li, Z.

973 - First-in-Class Autologous CD7-CAR-T Cells Exhibited Promising Clinical Efficacy for Relapsed and Refractory T-Lymphoblastic Leukemia/Lymphoma

Li, Z.

1437 - CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Li, Z.

1937 - Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Acquires Superior CR Rate Than CD19 CAR-T Cells: A Case Controlled Study

Li, Z.

1878 - Repurposing Nelarabine to Induce Differentiation of Acute Myeloid Leukemia

Li, Z.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Li, Z.

750 - Lncrna-Iκbα Promotes Erythroid Differentiation By Inhibiting NF-Κb Pathway As a Cerna Against Mir-24-3p in Polycythemia Vera

Li, Z.

493 - Influence of Inherited and Acquired Hematological and Immunological Gene Variants on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies
1486 - Interleukin-7 Receptor Gene Heterozygous Mutations in Recipients Significantly Increase Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

Li, Z.

2407 - Daratumumab and Venetoclax-Containing Regimens in the Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies

Li, Z.

94 - Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells

Li, Z.

1135 - Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas
1140 - Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
1197 - Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study
2048 - Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
2767 - The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Li, Z.

96 - Role of Mir-29b in T-Cell Development and in Cutaneous T-Cell Lymphoma Pathogenesis

Li, Z.

146 - Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)

Li, Z.

161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Li, Z.

132 - Two-Year Follow-up of Investigator-Initiated Phase 1 Trials of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells (CT053) in Relapsed/Refractory Multiple Myeloma
133 - Results from Lummicar-2: A Phase 1b/2 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Patients with Relapsed and/or Refractory Multiple Myeloma
1396 - Results from Lummicar-1: A Phase 1 Study of Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT053) in Chinese Subjects with Relapsed and/or Refractory Multiple Myeloma

Li, Z.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Liacos, C. I.

2255 - A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias
3168 - A Simple and Robust Real-Time Quantitative PCR Method for the Detection of MYD88 L265P Mutation in Waldenström'smacroglobulinemia.

Lian, J.

172 - Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
638 - Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma
3377 - Targeting Transcription Checkpoint Using a Novel CDK9 Inhibitor in Mantle Cell Lymphoma

Lian, Z.

1052 - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Liang, B.

459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Liang, C.

710 - Microrna-142 Deficiency Promotes Chronic Myeloid Leukemia (CML) Transformation from Chronic Phase (CP) to Blast Crisis (BC)

Liang, E.

919 - The Role of 5-HT on Proplatelet Formation and Thrombopoietin Production

Liang, E.

2164 - Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Liang, H.

366 - Cognitive and Emotional Factors and Pain-Related Outcomes in Youth with Sickle Cell Disease

Liang, Q.

135 - High Doses of Targeted Radiation with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
193 - Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered

Liang, R.

780 - Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn’t Improve Erythroid Maturation
2869 - FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal Hematopoietic Progenitors and AML in Humanized Mouse Models

Liang, S.

1979 - Induced CD25⁺CD127^dim Γδ Tregs in Acute Myeloid Leukemia Suppress the Activity of Normal Αβ T Cells

Liang, X. J.

2919 - Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma

Liang, X.

1859 - The Effectiveness of Rapamycin Combined with Eltrombopag in Murine Models of Immune-Mediated Bone Marrow Failure

Liang, Y.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
1197 - Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study
2262 - An Accurate Prognostic Survival Model of Survival Based on Expression of Genes Involved in Plasma Cell Metabolism
2767 - The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma
3135 - An Immune Score Model of the Bone Marrow Micro-Environment Predicts Survival in Chronic Lymphocytic Leukaemia
3190 - Adipocyte Fatty Acid Binding Protein Promotes Multiple Myeloma through Regulating Bone Marrow Microenvironment

Liang, Y.

1651 - Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Liang, Y.

611 - Engineered Memory-like NK Cars Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia

Liang, Z.

3254 - LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease Via Skewing T Cells Polarization Towards Treg Cells

Liang, Z. Y.

592 - Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Liani, A.

941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model

Lianoglou, B. R.

1698 - In Utero Stem Cell Transplantation in Patients with Alpha Thalassemia Major: Interim Results of a Phase 1 Clinical Trial
2601 - Investigating Zeta Globin Gene Expression to Develop a Potential Therapy for Alpha Thalassemia Major

Liao, A.

2207 - Integrative Transcriptome and Quantitative Proteome Analyses Identify METTL3 As a Key Regulator for Aberrant RNA Processing in Chronic Lymphocytic Leukemia

Liao, C.

2867 - A First-in-Human (FIH) Phase 1 Study of the Anti-LILRB4 Antibody IO-202 in Relapsed/Refractory (R/R) Myelomonocytic and Monocytic Acute Myeloid Leukemia (AML) and R/R Chronic Myelomonocytic Leukemia (CMML)

Liao, C.

2247 - ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application
3182 - Base Excision Repair and Homologous Recombination Pathway Intermediates Drive Genomic Instability and Evolution in Myeloma

Liao, J.

1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors

Liao, L.

1651 - Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Liao, S.

657 - Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
2192 - Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Liao, W.

1611 - Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study

Liao-Zou, H.

1704 - GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model

Libao, B. M.

1397 - Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Libby, E.

552 - Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
1640 - Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
2051 - Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen
2516 - Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada
2964 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Liberati, A. M.

141 - Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial
142 - Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study
648 - Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS)
1252 - The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10⁹/L to < 100 × 10⁹/L) at Baseline
1379 - Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial
1410 - Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis
1554 - Minimal Residual Disease (MRD) at 10^-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication)
3021 - Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
3142 - Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study ‘Veritas’
3238 - Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Libura, M. A.

1051 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Libutti, S.

2478 - Environmental Sars-Cov-2 Surface Testing: Low Incidence of Virus Positivity in Outpatient and Inpatient Hematology/Oncology Settings

Licht, J. D.

110 - NSD2-E1099K Mutation Leads to Glucocorticoid-Resistant B Cell Lymphocytic Leukemia in Mice
944 - Adenylate Kinase 2 Is a Selective Dependency in NSD2-High Multiple Myeloma
1867 - POU2AF1 As a Master Regulator of Oncogenic Transcription Factor Networks in Myeloma
2234 - Interactions with a “Humanized” Mesenchymal Bone Marrow Stromal Niche In Vivo Modify the Patterns of Essential Genes for Myeloma Cells: Therapeutic Implications
2250 - Functional Genomic Characterization of Endoplasmic Reticulum-Associated Dependencies in Multiple Myeloma - Biologic and Therapeutic Implications
2766 - KDM6A Controls Genes Modulating Immune Surveillance in Multiple Myeloma
2792 - Use of Olfactory Receptor Genes As Controls for Genome-Scale CRISPR Functional Genomic Studies to Define Treatment Resistance Mechanisms

Lichtarge, O.

2201 - Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Lidonnici, M. R.

220 - Transferrin Receptor 2 Is a Novel Target to Ameliorate Anemia of Chronic Kidney Disease

Lieber, A.

1542 - In Vivo HSC Gene Therapy for Hemoglobinopathies: A Proof of Concept Evaluation in Rhesus Macaques
2602 - Mgta-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice
3368 - In Vivo HSC Gene Therapy with Base Editors Allows for Efficient Reactivation of Fetal Globin in Beta-Yac Mice

Lieberman, C.

703 - Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
2863 - A Phase 1, Open Label Dose Escalation Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
2945 - A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies

Lieberman, D. B.

952 - Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Lieberman-Cribbin, W.

2585 - Mild Anemia As a Single Independent Predictor of Mortality in Patients with COVID-19

Liebers, N.

565 - Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile
1206 - Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Liebich, A.

389 - IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML

Liebling, E.

830 - Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation

Liebman, H.

3405 - Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Liebman, H. A.

1757 - Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress

Liedl, D.

3455 - Reduced Calf Muscle Pump Function Is a Risk Factor for Venous Thromboembolism and Mortality

Liedtke, M.

129 - Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma
131 - Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
975 - Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study
1034 - Routine Use of Gemtuzumab Ozogamicin in 7+3-Based Inductions for All “Non-Adverse” Risk AML
1507 - Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma
3169 - Response Evaluation Using PET/CT in Multiple Myeloma Patients Undergoing Autologous Transplant
3211 - Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Liegel, J.

2856 - Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial

Lien, P. W.

3479 - Characteristics and Treatment Response of Newly Diagnosed Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study

Liersch, R.

1206 - Polatuzumab Vedotin in Relapsed and Refractory (r/r) Large B-Cell Lymphoma (LBCL): Real-World Data of the German National Compassionate Use Program (CUP)

Liesner, R.

509 - Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A
867 - Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIXFc in Previously Untreated Patients with Haemophilia B

Liesner, R. J.

2681 - Long-Term Prophylaxis with Simoctocog Alfa for the Management of Haemophilia Α: Immunogenicity, Efficacy and Safety Results from the Nuprotect PUP Extension Study

Liesveld, J. L.

112 - SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia
114 - Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
214 - Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial
653 - Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS) from Study P-2001 (NCT02610777)
3137 - A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
3490 - Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Lievonen, J.

3217 - Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Liew, E.

1234 - BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
1247 - Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Liew, H. K.

1697 - Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the BELIEVE Trial

Lightbody, E. D.

1327 - A Next Generation Liquid Biopsy Approach for Multiple Myeloma

Ligon, K. L.

1327 - A Next Generation Liquid Biopsy Approach for Multiple Myeloma

Lihme Egerod, F.

2790 - Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)

Lihong, S.

9 - A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription

Lihou, C.

2166 - A Phase 1 Study of INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis (INCB 57643-103)

Liles, D.

1715 - Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study
2636 - Real World Evidence of Prescription Patterns and Effect of Oxbryta (voxelotor) for Patients with Sickle Cell Disease

Lillicrap, D.

1773 - Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation

Lillie, J.

1729 - Thrombosis and Risk Management in Paediatric Inflammatory Multisystem Syndrome – Temporally Associated with Sars-CoV2 (PIMS-TS)

Lim, A. B.

2374 - Significant EBV Reactivation Is Associated with Poorer Overall Survival Due to Increased NRM Post Myeloablative/Reduced Intensity, T-Cell Deplete Allogeneic Stem Cell Transplant for MDS or Acute Leukaemia

Lim, C. J.

2011 - MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential

Lim, E. D.

3370 - Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma

Lim, E.

1761 - Plasma Proteomic Profile Associated with Platelet Dysfunction after Trauma

Lim, F.

3029 - A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Lim, H. J.

3388 - Diagnostic Validation of a Clinical Laboratory-Oriented Targeted RNA Sequencing System As a Comprehensive Assay for Hematologic Malignancies

Lim, J. Q.

2916 - Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer⁄T Cell Lymphoma

Lim, J.

940 - NSD2 Regulates Pro-Metastatic Gene PTP4A3 through Chromatin Remodeling in Multiple Myeloma

Lim, M. S.

1173 - A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families

Lim, S. W.

3469 - Reducing Time to Chemotherapy Administration in the Outpatient Setting of a Tertiary Cancer Centre Using a Design Thinking Approach

Lim, S. T.

39 - Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma

Lim, S. T.

2916 - Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer⁄T Cell Lymphoma
2979 - Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

Lim, S.

3232 - Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Lim, T. L.

952 - Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Lim, Y. J.

936 - TINF2 Mutations Are Associated with Poor Outcome Post Hematopoietic Stem Cell Transplantation for Dyskeratosis Congenita
1857 - Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry

Lim, Z. Y.

3306 - HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies: Three-Year Follow-up of Multicenter Study in Singapore

Lima, J.

1828 - Caring for Patients with Sickle Cell Disease during a Pandemic: Continuing to Provide Automated Red Blood Cell Exchange Transfusions in Difficult Times

Limerick, E.

505 - Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Limjoco, J.

1787 - Real-World Clinical Outcomes in Previously Untreated and Minimally Treated Patients with Congenital Factor VIII Deficiency: The San Diego Experience

Limón-Palafox, M.

246 - Phase I and Preliminary Results of a Phase II Study (TERAPLASCoV2) of Convalescent Plasma in Patients with Severe and Life-Threatening Pneumonia Caused By Sars-Cov-2

Lin, A. Y.

174 - In Situ Vaccination in Lymphoma Using Photothermal Therapy with CpG Deoxynucleotide Coated Branched Gold Nanoparticles: Analysis of Tumor Growth and Immune Response in a Murine Xenograft Model

Lin, A.

3279 - cGMP Mass Production of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line

Lin, A. J.

32 - High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins

Lin, B.

2745 - Opposing Evolutionary Pressures Drive Clonal Evolution and Health Outcomes in the Aging Blood System

Lin, C. Y.

950 - Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition
2270 - RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Lin, C. C.

3057 - Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Lin, C. H.

2598 - The Dysregulation of Hepcidin-Ferroportin Axis in Childhood Acute Lymphoblastic Leukemia Survivors after Completion of Chemotherapy

Lin, C.

2298 - Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) – Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
3218 - Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) – Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Lin, D.

2909 - DNA Methylation-Mediated Silencing of Mir-204 Enhances the Occurrence of T-Cell Acute Lymphoblastic Leukemia By Upregulating MMP-2 and MMP-9 through the NF-Κb Signaling Pathway

Lin, D.

2405 - Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts

Lin, F. J.

3479 - Characteristics and Treatment Response of Newly Diagnosed Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study

Lin, G. H.

646 - Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies
1191 - Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study

Lin, H.

1208 - Risk Profiling of De Novo DLBCL Patients By Measuring Circulating Tumor DNA

Lin, H.

410 - High-Resolution Binding Atlas of U2AF1 Mutants Uncovers New Complexity in Splicing Alterations and Kinetics in Myeloid Malignancies

Lin, H.

1612 - Reducing Cytogenetic Testing in the Era of Next Generation Sequencing (NGS); Are We Choosing Wisely?
3446 - Identifying Myeloid Mutations By NGS in Patients with Unexplained Erythrocytosis

Lin, H. X.

3135 - An Immune Score Model of the Bone Marrow Micro-Environment Predicts Survival in Chronic Lymphocytic Leukaemia

Lin, H. M.

345 - Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study
1248 - Results from Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent Systemic Mastocytosis
2988 - Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis
3004 - Increased Detection of KIT D816V Mutation in Peripheral Blood Samples from Patients with Indolent Systemic Mastocytosis (ISM) in the Phase 2 Pioneer Study Using a High Sensitivity Droplet Digital (dd) PCR Assay Compared with Next Generation Sequencing (NGS)

Lin, J.

1158 - Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Lin, L.

3188 - A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Lin, L.

1545 - Adenine Base Editing of Gamma Globin Gene Promoters Shows No Detectable Off-Target RNA or DNA Editing

Lin, L.

3095 - Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia

Lin, M.

324 - Identification of Potent Human Hematopoietic Stem Cells (HSCs) Using Mitochondrial Profile Towards Improving HSC Transplantation
780 - Elevated P21 (CDKN1a) Mediates Apoptosis of Beta-Thalassemic Erythroid Cells in Mice but Its Ablation Doesn’t Improve Erythroid Maturation

Lin, M.

330 - The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results

Lin, M.

49 - Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Lin, N.

159 - Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Lin, N.

1163 - Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial

Lin, P. P.

913 - Mdm2 Haplo-Insufficiency in Hematopoietic and Mesenchymal Progenitor Cells Results in Cell Death

Lin, P.

3438 - Health-Related Quality of Life in Heavily Pre-Treated and Renally Impaired Patients with Relapsed/Refractory Multiple Myeloma Receiving Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study

Lin, P.

485 - Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Lin, R.

3258 - Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar T^TM Cell Therapy for the Treatment of Multiple Myeloma

Lin, R.

3319 - Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation

Lin, R.

2466 - Metagenomics Next-Generation Sequencing for Identifying Pathogens in Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Lin, R. J.

1448 - Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Lin, S.

1759 - Relapse Prediction Model for Immune-Mediated Thrombotic Thrombocytopenic Purpura

Lin, S.

2755 - Metformin Upregulates Mir-26a to Improve Erythropoiesis in Preclinical Models of Diamond Blackfan Anemia through Suppression of Nlk Expression

Lin, S.

1140 - Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies

Lin, S.

856 - Evaluating BIVV001, a New Class of Factor VIII Replacement Therapy: A Phase 3 Study (XTEND-1) Design

Lin, T.

24 - A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
635 - Five-Year Final Results of a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML): Outcomes By Age Subgroup and Among Responders
636 - Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
990 - First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
1025 - V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
1946 - Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
1954 - Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2858 - Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
3346 - Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML

Lin, T.

1871 - The RNA Binding Protein IGF2BP3 Is Required for MLL-AF4 Mediated Leukemogenesis

Lin, T. S.

549 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
3243 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin
3424 - Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Lin, T.

1374 - Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT)

Lin, T.

2767 - The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Lin, W. H.

1101 - Expression of Vav1-Myo1F Fusion Affects T-Cell Differentiation and Induces T-Cell Lymphoma

Lin, W.

597 - Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Lin, X.

270 - A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Lin, Y.

Lin, Y. C.

1325 - Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma

Lin, Y.

476 - Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era
706 - Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis
3051 - EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Lin, Y. W.

3479 - Characteristics and Treatment Response of Newly Diagnosed Advanced-Stage and Relapsed/Refractory Hodgkin Lymphoma in Taiwan: A Nationwide Retrospective Study

Lin, Y. C.

3057 - Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Lin, Z.

3233 - RAR Gamma Activation Sensitizes Human Myeloma Cells to Carfilzomib Treatment through OAS-RNase L Innate Immune Pathway

Lin, Z.

660 - The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL
941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model

Lina, B.

496 - Viral Reactivation in Acute Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: Stimulation of the Immune System

Linares, M.

363 - Detection of Emerging Resistant Clones in Philadelphia-Positive Leukemia Patients Exposed to Tyrosine Kinase Inhibitors. Correlation of cDNA and Gdna Approaches
487 - Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma

Linch, D. C.

160 - ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Lind, K.

453 - Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells

Lind, T.

2274 - Anti-Myeloma Drug Melflufen Inhibits RANKL-Stimulated Osteoclastogenesis By Suppressing Proliferation of CD14+ Precursor Cells

Lindberg, III, Å.

2956 - Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience

Linden, M. A.

2235 - Phenotypic and Functional Characterization of Multiple Myeloma By Single Cell Mass Cytometry (CyTOF)

Lindenberg, L.

548 - Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
3159 - The Role of ¹⁸f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
3172 - Evaluation of Whole-Body MRI (WB-MRI) in Smoldering Multiple Myeloma (SMM)

Linderkamp, C.

268 - Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial

Linders, J.

2091 - Discovery of JNJ-67856633: A Novel, First-in-Class MALT1 Protease Inhibitor for the Treatment of B Cell Lymphomas

Lindsay, D.

871 - Experience with Continuous Infusion of Recombinant Porcine FVIII in Patients with Acquired Hemophilia a

Lindsay, J.

2948 - Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis

Lindsey, K.

1133 - Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Lindsley, R. C.

80 - DNMT3A clonal Hematopoiesis in Older Donors Is Associated with Improved Survival in Recipients after Allogeneic Hematopoietic Cell Transplant
170 - Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings
190 - Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies
254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome
540 - Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS
1911 - Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy
2810 - Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
SCI-30 - Germline and Somatic Genomics in Ribosomopathies

Lindstrom-Vautrin, J.

2734 - Transcriptional, Protein-Level and Functional Profiling of Human Fetal Liver (FL)-Derived Hematopoietic Stem Cells (HSCs) at Single Cell Resolution

Linenberger, M.

- Updates on the Diagnosis and Management of the Most Common Porphyrias – AIP and EPP

Lines, J.

2642 - VISTA Targeting Modulates Tumor-Infiltrating Myeloid Cells to Overcome Adaptive Resistance

Ling, F.

568 - Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

Ling, G.

861 - Real-World Clinical and Laboratory Characteristics in Severe Hemophilia a Patients Commencing Emicizumab

Ling, K.

323 - Bleeding Cessation in a Mouse Jugular Vein Puncture Wound Model Is Caused By Extravascular Capping, Not Hole Infill

Ling, T.

1 - Loss of LKB1/STK11 Facilitates Leukemic Progression of the Myeloproliferative Neoplasms

Lingamaneni, P.

1011 - Clostridium Difficile Infection Is Independently Associated with Significantly Worse Outcomes in Acute Leukemia Patients Undergoing Chemotherapy and/or Hematopoietic Stem Cell Transplant
2521 - Nationwide Trends and Outcomes in Neutropenic Acute Leukemia Patients with Invasive Aspergillosis
2629 - Inpatient Outcomes and 60-Day Unplanned Readmissions after Hip Arthroplasty in Sickle Cell Patients with Avascular Necrosis

Lingaraju, C. R.

1482 - Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients

Linhares, Y.

2107 - Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma

Link, B. K.

371 - Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas
534 - Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma
1210 - Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
1654 - Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study
2022 - Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment
2039 - Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era
2056 - Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis
2066 - Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
2129 - Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis
2132 - The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma
2950 - Body Mass Index and Survival of Patients with Lymphoma

Link, D. C.

409 - Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML
695 - Combined Inhibition of CXCR4 Signaling and System x_c^- Transporter Activity Induces Synthetic Lethality in T-ALL Cells By Suppressing Gsh and Inducing Ferroptosis
718 - TGF-β Signaling Contributes to the Clonal Dominance of Jak2^V617F Hematopoietic Stem/Progenitor Cells
1293 - Imaging Mass Cytometry Reveals the Spatial Architecture of Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemias
2835 - Evidence of Synergistic Effect of Idasanutlin and Navitoclax Using T-Cell Acute Lymphoblastic Leukemia Patient-Derived Xenografts
2894 - Molecular Profiling of Decitabine Response in MDS and AML Patients

Linn, S. M.

2396 - Multicenter, Retrospective Evaluation of Therapeutic Efficacy of Ruxolitinib for Chronic Gvhd Treatment
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Linn, Y. C.

94 - Single Cell Immune Profiling Reveals Distinct T Cell Clones and Functional States in in-Vitro Expanded Cord Blood Derived Gamma Delta T Cells
1465 - High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients : A Multicenter Study in Singapore
2370 - Prognostic Value of Refined Disease Risk Index (rDRI) and Conditioning Regimen in Adult Patients Receiving Unrelated Cord Blood Transplantation (UCBT) for Haematological Malignancies – 15-Year Follow-up of Multicenter Study in Singapore
3306 - HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies: Three-Year Follow-up of Multicenter Study in Singapore

Lins, M. M.

2851 - Successful Outcomes of Children Simultaneously Diagnosed with Acute Myeloid Leukemia and Covid-19: The Role of a Mild Chemotherapeutic Induction Regimen

Lintner, N. G.

791 - Sickle Cell Disease Model Mice Lacking 2,3-Dpg Show Reduced RBC Sickling and Improvements in Markers of Hemolytic Anemia

Linton, E.

798 - Young Adults with Sickle Cell Disease (SCD) Have Low Interest in Genetic Counseling and Sickle Cell Trait Testing for Sexual Partners

Linton, K.

339 - Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
707 - Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance
2965 - AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Linton, K. M.

402 - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
2918 - Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Lio, C. W. J.

2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution

Lionakis, M. S.

2110 - Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma
3025 - Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Lionel, A.

653 - Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS) from Study P-2001 (NCT02610777)
654 - Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Lionetti, M.

60 - Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma

Lioure, B.

2830 - Adjunction of a Fish Oil Emulsion to Cytarabine and Daunorubicin Induction Chemotherapy in High-Risk AML. the Famyly Pilot Study from the French Innovative Leukemia Organization (FILO)
3337 - Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Lipato, T.

2627 - Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Lipe, B.

726 - Selinexor in Combination with Pomalidomide and Dexamethasone (SPd) for Treatment of Patients with Relapsed Refractory Multiple Myeloma (RRMM)
1366 - Selinexor in Combination with Carfilzomib and Dexamethasone, All Once Weekly (SKd), for Patients with Relapsed/Refractory Multiple Myeloma
1393 - Selinexor, Lenalidomide and Dexamethasone (SRd) for Patients with Relapsed/Refractory and Newly Diagnosed Multiple Myeloma

Lipes, J.

896 - Thrombotic Complications in a Canadian Population of Critically Ill Patients with COVID-19

Lipof, J. J.

3490 - Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)

Lippert, E.

1256 - An International Multicentric Observational Study on the Use of Ruxolitinib in Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea: Results from Interim Analysis

Lippi, G.

47 - Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations

Lipschitz, M.

2971 - Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Lipsky, A.

348 - Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK^C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Lipton, J. H.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Lipton, J. H.

46 - Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial
48 - Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
647 - Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
1234 - BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
1247 - Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial
1498 - Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment
1530 - Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission
1565 - Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre – a Prospective Observational Study
1857 - Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry
2363 - Incidence, Outcomes and Predictors of Acute Kidney Injury Post Allogeneic Stem Cell Transplant
2428 - ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors
3072 - ENESTop 5-Year Update: Durability of Treatment-Free Remission Following Second-Line Nilotinib and Exploratory Analysis of Molecular Response Regain after Nilotinib Re-Initiation in Patients with Chronic Myeloid Leukemia
3316 - Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Lipton, J. M.

10 - RASA3 Regulates Stage-Specific AKT Signaling and Cell Cycle Progression in Mammalian Erythropoiesis
935 - Clonal Hematopoiesis in Patients with Diamond Blackfan Anemia

Liquori, A.

1543 - Adenine Base Editing of the Sickle Allele in CD34⁺ Hematopoietic Stem and Progenitor Cells Eliminates Hemoglobin S
1545 - Adenine Base Editing of Gamma Globin Gene Promoters Shows No Detectable Off-Target RNA or DNA Editing

Liron, T.

3015 - Anti-CD20-Mediated B Cell Depletion Is Associated with Reduced Osteoclastogenic Signals and Bone Mass Preservation: Clinical Observation in Patients with Follicular Lymphoma Supplemented By Animal Studies in a Murine Model

Lisano, J.

2499 - Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
3418 - Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Lisano, J.

1606 - Economic Assessment of Diagnostic Revision in Peripheral T-Cell Lymphoma

Lisbon, E.

1726 - Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lischuk, A.

3173 - Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Lisignoli, G.

2245 - PD-L1/PD-1 Pattern of Distribution within Bone Marrow Microenvironment Cells in Patients with Smoldering Myeloma and Active Multiple Myeloma

Lissat, A.

469 - In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Lissitchkov, T.

511 - Long-Term Durability, Safety and Efficacy of Fitusiran Prophylaxis in People with Hemophilia a or B, with or without Inhibitors – Results from the Phase II Study
856 - Evaluating BIVV001, a New Class of Factor VIII Replacement Therapy: A Phase 3 Study (XTEND-1) Design
878 - Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIIIFc) in Patients with Severe Hemophilia A

Lista, E.

1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Lister, J.

2137 - Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis
3049 - Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis
3056 - Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy

Lit, L.

2726 - Refining Blood Products Utilization: Every One (unit) Matters. Post-Intervention Study

Litalien, V.

263 - Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Litke, R.

2256 - Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma

Little, C. R.

680 - Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant

Little, D.

761 - Roxadustat Treatment Corrects Anemia to Hemoglobin (Hb) Values ≥10 g/dL in the Majority of Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
766 - Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

Little, J. A.

196 - Computer Vision and Deep Learning Assisted Microchip Electrophoresis for Integrated Anemia and Sickle Cell Disease Screening
506 - Exercise Induced Changes of Vital Signs in Adults with Sickle Cell Disease
787 - Thrombin-Induced Endothelial Cell Damage Is Mitigated By Human Anti-Thrombin III in a Microfluidic Device
1711 - Contribution of Red Blood Cell Derived Extracellular Vesicles to Sickle Red Blood Cell Adhesion Discerned Using an Endothelialized Microfluidic Assay
1730 - The Grndad Registry: Contemporary Natural History Data and an Analysis of Real-World Patterns of Use and Limitations of Disease Modifying Therapy in Adults with SCD
2610 - Assessment of Red Blood Cell-Mediated Microvascular Occlusion in Sickle Cell Disease By a Novel Electrical Impedance-Based Microfluidic Device

Little, L.

398 - Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib
690 - Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy

Little, M.

2973 - Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Little, M.

2523 - Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect^® MDS/AML Disease Registry
- A New Treatment Option for Patients with Acute Myeloid Leukemia

Little, R. F.

1909 - Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)
2110 - Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma
2809 - Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Littlewood, S.

1605 - A Large London District General Hospital Highlights CLL and Bame As Risk Factors for Severe Disease Amongst Haematology-Oncology Patients

Litzow, M.

135 - High Doses of Targeted Radiation with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
193 - Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (¹³¹I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
262 - Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors
299 - Comparison of Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide to Matched-Sibling, Matched-Unrelated, Mismatched-Unrelated, and Umbilical Cord Blood Donor Transplantation in Adults with Acute Lymphoblastic Leukemia: A CIBMTR Study
333 - Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study
388 - Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
636 - Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
934 - Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study
1052 - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
1278 - A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015
1284 - Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study
1536 - Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults
2148 - Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
2188 - Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients
2426 - Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee
3123 - Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias
3364 - Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis
3380 - Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141)

Liu, A.

416 - Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)

Liu, A.

192 - Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Liu, B.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Liu, B.

518 - ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1

Liu, C.

2393 - Quantification of Allele-Specific HLA Expression with Nanopore Long-Read Sequencing

Liu, C.

529 - A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

Liu, C. J.

3339 - The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation: A Nationwide Population-Based Study

Liu, C. L.

281 - Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage

Liu, C.

937 - The Role of Lncrna-AF117829.1 in the Immunopathogenesis of CD8+ T Cells in Patients with Severe Aplastic Anemia

Liu, C.

2611 - Mitochondrial DNA Variation in Individuals with Sickle Cell Disease

Liu, C.

2505 - Racial Differences in Multiple Myeloma Survival and Treatment Using Pooled Clinical Trial and Real-World Electronic Medical Record Data

Liu, D.

1435 - NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Liu, D.

31 - Identification of Chemo-Resistant Residual Cell Population in Pediatric AML of Complete Remission By Single Cell RNA Sequencing

Liu, D.

2919 - Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma

Liu, D.

2592 - Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical Disease Models of Iron Overload and Erythrocytosis
2594 - Mechanism of Systemic Iron Regulation and Hematocrit Control By Hepcidin Peptidomimetics in Pre-Clinical Models

Liu, D. R.

673 - Base Editing Eliminates the Sickle Cell Mutation and Pathology in Hematopoietic Stem Cells Derived Erythroid Cells
3367 - Adenosine Base Editing of γ-Globin Promoters Induces Fetal Hemoglobin and Inhibit Erythroid Sickling

Liu, D.

185 - Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Liu, D.

1445 - Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Liu, E.

613 - Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy

Liu, E.

2219 - Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Liu, F.

1349 - Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11;14), in Patients with Multiple Myeloma

Liu, F. F.

2116 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
2565 - Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy

Liu, F. Q.

733 - Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR⁺ and αvβ3⁺ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT
3313 - PGE₂ Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD

Liu, H.

900 - Demographic, Clinical, and Biochemical Predictors of Pica in a Large Cohort of Blood Donors

Liu, H.

1860 - A Novel pH Dependent C5 Monoclonal Antibody with Better Developability

Liu, H. D.

1451 - Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
3281 - Hematopoietic Progenitor Cell Mobilization and Collection for Autologous Hematopoietic Cell Transplantation in AL Amyloidosis: A Single Center Experience

Liu, H.

2868 - Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Liu, H.

2911 - DDX41 Mutations in Myeloid Neoplasms and Acute Leukemias

Liu, H.

2604 - Loss of Alpha Globin Genes in Human Subjects Is Associated with Improved Nitric Oxide-Mediated Vascular Perfusion

Liu, H.

163 - Preliminary Results of Balli-01: A Phase I Study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor) in Adult Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
191 - Phase I Trial of a Novel Conditioning Regimen Utilizing Total Marrow Irradiation (TMI) with Fludarabine-Melphalan for Patients with Relapsed Hematologic Malignancies Undergoing Second Allogeneic Stem Cell Transplantation (Allo-SCT)
2796 - Expanding Use of a Modified Pediatric Intensive Regimen for Acute Lymphoblastic Leukemia (ALL) into an Older Adult Population: Feasibility and Efficacy Results
2999 - Molecular Characteristics and Patterns of Progression of IDH2-Mutated, Philadelphia-Chromosome Negative, Advanced-Phase Myeloproliferative Neoplasms Treated with Enasidenib

Liu, H.

1083 - Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
1099 - Classification and Quantification of Oncogenic Ikaros Isoforms in B Cell Precursor Acute Lymphoblastic Leukemia By RNA-Seq
1883 - NGS-Based Screening to Comprehensively Decipher TKIs Resistant Mutations in BCR-ABL1 Positive Leukemias
2816 - Fanconi Anemia Gene Associated Germline Predisposition in Aplastic Anemia and Hematologic Malignancies
2911 - DDX41 Mutations in Myeloid Neoplasms and Acute Leukemias
2915 - Fusion Gene Map of Acute Lymphoblastic Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 350 Cases in a Single Center

Liu, H. C.

2598 - The Dysregulation of Hepcidin-Ferroportin Axis in Childhood Acute Lymphoblastic Leukemia Survivors after Completion of Chemotherapy

Liu, H.

625 - Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
2900 - Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Liu, H.

1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors

Liu, H.

1977 - Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia
2466 - Metagenomics Next-Generation Sequencing for Identifying Pathogens in Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Liu, H.

937 - The Role of Lncrna-AF117829.1 in the Immunopathogenesis of CD8+ T Cells in Patients with Severe Aplastic Anemia
1345 - Bone Marrow-Derived Mesenchymal Stem Cells Inhibit CD8⁺t Cell Immune Responses Via PD-1/PD-L1 Pathway in Multiple Myeloma
2576 - The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59^-cell from Paroxysmal Nocturnal Hemoglobinuria Patients

Liu, H.

1163 - Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
1186 - Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory （r/r） Large B-Cell Lymphoma in China

Liu, H.

3254 - LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease Via Skewing T Cells Polarization Towards Treg Cells

Liu, H.

608 - Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial

Liu, H.

128 - Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study
1509 - Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies
2349 - Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Liu, J. J.

540 - Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Liu, J.

178 - Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Liu, J. H.

3057 - Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Liu, J.

1339 - Development and Analysis of a Weighed Prognostic Model in Newly Diagnosed Multiple Myeloma Patients
2239 - Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level
2243 - Novel Insight into Multi-Hit Multiple Myeloma Based on "Two-Hit" Theory of Cancer Causation
2260 - Igh Translocation with Undefined Partners Is Associated with Superior Outcome in Multiple Myeloma Patients
3181 - The Relative Risk of Prognostic Factors of Age Stratified Multiple Myeloma

Liu, J.

1661 - Real-World Outcomes of Patients Treated with Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Systematic Review and Meta-Analysis

Liu, J.

1979 - Induced CD25⁺CD127^dim Γδ Tregs in Acute Myeloid Leukemia Suppress the Activity of Normal Αβ T Cells

Liu, J.

529 - A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies

Liu, J.

955 - Amot Inhibits Tumorigenesis of Diffuse Large B-Cell Lymphoma By Regulating DNA Damage Response
971 - Cfi-400945 Induces Cytokinesis Failure By Activating Hippo Signaling Pathway in Diffuse Large B-Cell Lymphoma
1097 - Single-Cell Transcriptome Reveals the Role of Sting Pathway in Acute B Lymphoblastic Leukemia Bone Marrow Cells
1863 - Targeting Glycosylated Ptgds Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of Wnt Pathway
1888 - CD20-Modified Exosomes Delivered E260 Inhibits Progression of Diffuse Large B-Cell Lymphoma By Restoring Hippo Activity
2028 - Exosomal MiR-107 As Novel Biomarker and Tumor Suppressor By Targeting Ywhah in Diffuse Large B-Cell Lymphoma
2774 - NUSAP1 Promotes Cell Proliferation Via the DNA Damage Response Pathway in Diffuse Large B-Cell Lymphoma

Liu, J.

2304 - Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

Liu, J.

2871 - Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting

Liu, J.

106 - 3D Genomics of Acute Meyloid Leukemia Reveals the Imbalance between DNA Methylation Canyon Interactions and Leukemic Specific Enhancer Network Interactions

Liu, J.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions

Liu, J. H.

3339 - The Influence of High-Efficiency Particulate Air Filtration on Mortality Among Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation: A Nationwide Population-Based Study

Liu, J.

416 - Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)

Liu, J.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Liu, J.

9 - A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription

Liu, J.

471 - Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Liu, J.

3189 - TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Liu, K. Y.

72 - Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation
733 - Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR⁺ and αvβ3⁺ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT
2665 - Risk and Prognostic Factors for Intracranial Hemorrhage in Elderly Patients with Immune Thrombocytopenia
3313 - PGE₂ Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD
3319 - Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation

Liu, K.

1941 - CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Liu, L.

279 - Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma
1346 - Multiple Myeloma Cell Defects Erythropoiesis and Results Anemia Via High Level of CCL3 in Bone Marrow Microenvironment
2239 - Clonal Phylogeny and Evolution of Critical Cytogenetic Aberrations in Multiple Myeloma at Single Cell Level

Liu, L.

178 - Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
416 - Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)

Liu, L.

1012 - Oral Posaconazole or Intravenous-Oral Itraconazole in Preventing Invasive Fungal Diseases for Patients with Acute Leukemia

Liu, L.

3244 - Clinical Features and Survival Outcomes in Diabetic Patients with Newly Diagnosed Multiple Myeloma (NDMM) Enrolled in the Connect^® MM Registry

Liu, L.

926 - ANGPTL2-Containing Exosomes from Vascular Endothelial Cells Promote Leukemia Development

Liu, L.

42 - Safety and Efficacy of Mitoxantrone Hydrochloride Liposome in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma and Extranodal NK/T-Cell Lymphoma: A Prospective, Single-Arm, Open-Label, Multi-Center, Phase Ⅱ Clinical Trial
1140 - Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
1163 - Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
1320 - Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
2048 - Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Liu, L.

2816 - Fanconi Anemia Gene Associated Germline Predisposition in Aplastic Anemia and Hematologic Malignancies

Liu, L. N.

2354 - Siglec-15 Is a Novel Immunomodulatory Protein and Therapeutic Target in Childhood Leukemia

Liu, L.

1067 - A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within AML1-ETO-Positive Acute Myeloid Leukemia
1272 - Prognostic Prediction Clinical-Molecular Model for Allogeneic Transplant Outcomes in Patients with Myelodysplastic Syndrome

Liu, L.

2394 - Salvage Therapy with Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem Cell Transplantation
2398 - Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Liu, L.

962 - Anlotinib Induced Apoptosis and Regulated the Chemosensitivity and Immune-Related Properties of Leukemia Stem Cells By Inhibiting JAK2-STAT3/5 Signaling
1942 - Anlotinib Shows Potent Antileukemia Effects in B-Cell Acute Lymphocytic Leukemia through the Blockage of Angiogenic Related Pathways

Liu, L.

2011 - MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential

LIU, L.

459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Liu, M.

329 - Atlas of Blood Cells

Liu, M.

2873 - DAC+CAG Compared with the Standard 3+7 Regimen for Induction of the Medically Fit Elderly Acute Myeloid Leukemia: An Open-Label, Multicenter, Randomized, Phase III Trial

Liu, M. C.

2206 - Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma
2211 - Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter’s Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL)

Liu, M.

1083 - Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
2915 - Fusion Gene Map of Acute Lymphoblastic Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 350 Cases in a Single Center

Liu, M.

1083 - Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
2915 - Fusion Gene Map of Acute Lymphoblastic Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 350 Cases in a Single Center

Liu, N.

1606 - Economic Assessment of Diagnostic Revision in Peripheral T-Cell Lymphoma
2033 - Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective
2499 - Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
3418 - Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Liu, N.

742 - Frailty Is Associated with Increased One-Year Mortality in Patients with Newly Diagnosed Diffuse Large-B-Cell Lymphoma: A Population-Based Study

Liu, P.

1197 - Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study
2074 - Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study
2767 - The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Liu, P. P.

1838 - Zrsr2 Deficient Zebrafish Display Hematopoietic Defects and U12-Type Intron Retention in mRNA Processing Genes

Liu, P.

2733 - Prdm16 Is a Critical Regulator of Adult Long-Term Hematopoietic Stem Cell Quiescence

Liu, P.

2090 - Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Liu, P.

2153 - Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)

Liu, Q.

1032 - A Stemness-Based Screen Identifies PLK1 Inhibitors for Targeting Leukemia Stem Cells in AML
1865 - Mir-125b Regulates the Self-Renewal of Acute Myeloid Leukemia Stem Cells through PTPN18 and GSK3
2777 - Nicotinamide Phosphoribosyltransferase Inhibitors Induce Apoptosis of AML Stem Cells through Dysregulation of Lipid Metabolism

Liu, Q.

2138 - Is There a Disparity in Oncological Outcomes for Hispanics? Analysis of Burkitt Lymphoma
2515 - Demographic Differences in the Treatment and Mortality of Lymphoplasmacytic Lymphoma in Texas: Does Ethnicity Play Any Role?
2562 - Population Based Analysis of Mantle Cell Lymphoma in Texas: Are Outcomes Any Different in Hispanics?
2959 - Does Hispanic Origin Affect the Repartition and Outcome of Marginal Zone Lymphoma?
2975 - Ethnic Disparities in Hodgkin’s Lymphoma (HL): A Large-Scale Population Based Analysis of Hispanics with HL in Texas
3054 - A First Large Statewide Population Based Study Evaluating Racial Differences in Treatment and Survival between Hispanics and Non-Hispanics with Diffuse Large B Cell Lymphoma (DLBCL)
3468 - Survival and Outcomes for T-Cell Lymphomas in a Ubiquitous Hispanic Community: A Texas Cancer Registry Retrospective Study

Liu, Q.

1533 - Allogeneic Hematopoietic Stem Cell Transplantation Overcomes the Poor Prognosis in MLL-Rearranged Solid Tumor Therapy Related-Acute Myeloid Leukemia

Liu, Q.

1977 - Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed /Refractory Acute Myeloid Leukemia
2405 - Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts
2466 - Metagenomics Next-Generation Sequencing for Identifying Pathogens in Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation
2873 - DAC+CAG Compared with the Standard 3+7 Regimen for Induction of the Medically Fit Elderly Acute Myeloid Leukemia: An Open-Label, Multicenter, Randomized, Phase III Trial

Liu, Q.

2405 - Prophylactic Donor Lymphocyte Infusion Based on Two Different Time for Preventing Relapse in Advanced Acute Leukemia Undergoing Allo-HSCT: Comparison of Two Independent Prospective Cohorts
3319 - Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation

Liu, Q.

707 - Survival Outcomes for Plasmablastic Lymphoma: An International, Multicentre Study By the Australasian Lymphoma Alliance

Liu, Q. H.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Liu, Q.

1680 - Preclinical Characterization of BCX9930, a Potent Oral Complement Factor D Inhibitor, Targeting Alternative Pathway-Mediated Diseases Including Paroxysmal Nocturnal Hemoglobinuria (PNH)

Liu, Q.

1454 - Mobilization of Auto-Stem Cells in the Thalassemia Major and Relationship with Iron Overload
1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors

Liu, R.

2973 - Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Liu, R.

1541 - CoupledCAR^TM Technology for Treating Thyroid Cancer

Liu, R.

1354 - Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data

Liu, R.

1979 - Induced CD25⁺CD127^dim Γδ Tregs in Acute Myeloid Leukemia Suppress the Activity of Normal Αβ T Cells

Liu, S.

897 - Effective Erythropoiesis from Human iPSC-Derived RBC in Immunodeficient Mice

Liu, S.

1672 - Efficient Enucleation and In Vivo Circulation of Differentiated Human Erythroblasts Derived from Peripheral Blood Mononuclear Cells after Extensive Expansion

Liu, S.

86 - Characteristics of in Vitro Differentiated Erythrocytes Derived from Human Bmi-1 Extensively Expanded Erythroblasts (E3)

Liu, S.

222 - Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension

Liu, S.

254 - Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Liu, S.

714 - Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms

Liu, S.

1559 - The Quick Antigen Identification By Tissue Flow Cytometry for CAR-T Therapy in Relapsed/Refractory B-Cell Malignancies without Bone Marrow Involvement or Serous Cavity Effusions
2464 - CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy

Liu, S.

27 - Phase 3, Multicenter, Open-Label Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3^mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy

Liu, S.

1627 - Mortality Among Veterans with a Diagnosis of Pyruvate Kinase (PK) Deficiency: A Real-World Study Using US Veterans Health Administration Data

Liu, S.

1229 - Ctdna Monitoring in Predicting Relapse of Primary Mediastinal B-Cell Lymphoma

Liu, S.

251 - Comprehensive RNA Editome Reveals Azin1 As a Functional Regulator in Hematopoietic Stem and Progenitor Cells

Liu, S.

722 - Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma
1983 - Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis

Liu, T.

1116 - Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Liu, T.

1116 - Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action
1140 - Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
1320 - Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
2048 - Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Liu, T.

592 - Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Liu, T.

2891 - Distinct Genomic Landscape of Chinese Pediatric Acute Myeloid Leukemia

Liu, T.

1174 - Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models
1180 - Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Liu, T.

407 - Mutant TRP53-R172H Has Gain-of-Function or Dominant-Negative Effects in Response to Different Hematopoietic Stressors in Mice

Liu, W.

128 - Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study
279 - Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma
1509 - Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies
2349 - Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
2949 - Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Liu, W.

793 - Reconstruction of Sickle Cell Disease with Circulating Sickling Red Blood Cells in Novel Humanized Cytokines and Liver Mistrg Mice

Liu, W.

154 - Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

Liu, W.

2290 - Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Liu, W.

2083 - Clinicopathology, Disease Progression/Transformation and Genomic Alterations of Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract

Liu, W.

2466 - Metagenomics Next-Generation Sequencing for Identifying Pathogens in Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation

Liu, X. S.

2433 - Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation

Liu, X.

1107 - Genetic Mutations of Tim-3 Ligand, and Exhausted Tim-3⁺CD8⁺ T Cells and Survival in Diffuse Large B Cell Lymphoma
2031 - Associations of OX40 and Tumor Microenvironment with Outcomes in Diffuse Large B-Cell Lymphoma

Liu, X.

72 - Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation
733 - Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR⁺ and αvβ3⁺ Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT
3313 - PGE₂ Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD

Liu, X. J.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Liu, X.

1002 - Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia

Liu, X.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Liu, X.

1737 - Effects of MiR-451a on the Phagocytosis and Polarization of Macrophages

Liu, X.

2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution
2926 - VAV1-GFP Fusion Protein Generated By Intron-Based Genome Editing through CRISPR/Cas9 Leads to Spontaneous Activation in TCR Signaling

Liu, X.

1454 - Mobilization of Auto-Stem Cells in the Thalassemia Major and Relationship with Iron Overload
1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors

Liu, X.

1018 - Safety of Palbociclib in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoma: A Children’s Oncology Group Pilot Study

Liu, X.

569 - Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Liu, X.

916 - TWIST1 Preserves Hematopoietic Stem Cell Function Via Repression of Cacna1b Expression

Liu, X.

2415 - Autologous Stem Cell Transplantation (ASCT) for T-Cell Non Hodgkin Lymphoma (T-NHL) Patients Who Achieve Complete Remission with First-Line Treatment: A Systematic Review and Meta-Analysis

Liu, X.

260 - Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

Liu, X.

1541 - CoupledCAR^TM Technology for Treating Thyroid Cancer

Liu, X.

2751 - A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)

Liu, X.

644 - Anti-PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single-Arm, Phase Ib/II Trial (SCENT)

Liu, X.

1454 - Mobilization of Auto-Stem Cells in the Thalassemia Major and Relationship with Iron Overload
1497 - Mixed Chimerism after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with β Thalassemia: Impact on Outcome and Risk Factors

Liu, X.

2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution
2926 - VAV1-GFP Fusion Protein Generated By Intron-Based Genome Editing through CRISPR/Cas9 Leads to Spontaneous Activation in TCR Signaling

Liu, Y. L.

3314 - Comparison of Fixed Vs ALC-Based Doses of Thymoglobulin^® (ATG) in Pediatric Patients with Acute Leukemia Given Αβhaplo-HSCT: Impact on Immune Reconstitution at Day 90

Liu, Y.

Liu, Y.

274 - Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts

Liu, Y.

2406 - Lung Function Monitoring in Allogenic Hematopoietic Cell Transplant (A-HCT) Patients

Liu, Y.

2463 - Comparative Analysis of Flow Cytometry and Real-Time Quantitative Polymerase Chain Reaction for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia before Hematopoietic Stem Cell Transplantation

Liu, Y.

2143 - A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Liu, Y.

2678 - Binding of Gpibα to VWF A2 Domain Alters Mechanical Unraveling of the A2 Domain

Liu, Y.

285 - IL-6 Deficiency Reverses Leukemic Transformation in an MDS Mouse Model

Liu, Y.

1223 - Impact of Evidence-Based Chemotherapy Regimens on Health Outcomes, Utilization and Cost for Diffuse Large-b-Cell Lymphoma (DLBCL) Patients

Liu, Y.

579 - Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
1261 - Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults
2856 - Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial

Liu, Y.

3060 - Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Liu, Y.

2891 - Distinct Genomic Landscape of Chinese Pediatric Acute Myeloid Leukemia

Liu, Y.

1541 - CoupledCAR^TM Technology for Treating Thyroid Cancer

Liu, Y.

3059 - Preliminary Exploration of Ibrutinib Combined with Methotrexate, Ifosfamide, Liposomal Doxorubicin and Methylprednisolone in the Treatment of Relapsed/Refractory Primary CNS Lymphoma

Liu, Y.

162 - CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia
601 - Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Liu, Y.

270 - A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)

Liu, Y.

2891 - Distinct Genomic Landscape of Chinese Pediatric Acute Myeloid Leukemia

Liu, Y.

2901 - BCOR Mutations in Acute Myeloid Leukemia: Clonal Evolution and Prognosis

Liu, Y.

2294 - Real World Data (RWD) Treatment Patterns and Sequencing of Patients with Multiple Myeloma (MM)

Liu, Y.

478 - CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
579 - Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis

Liu, Y.

260 - Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

Liu, Z.

523 - Transcriptional Control of HP1a By the RNA Binding Proteins Rbmx/L1 Maintain Chromatin State in Myeloid Leukemia

Liu, Z.

937 - The Role of Lncrna-AF117829.1 in the Immunopathogenesis of CD8+ T Cells in Patients with Severe Aplastic Anemia
1345 - Bone Marrow-Derived Mesenchymal Stem Cells Inhibit CD8⁺t Cell Immune Responses Via PD-1/PD-L1 Pathway in Multiple Myeloma
2576 - The Study of Proliferation Relative Long Non-Coding RNA FAM157C in CD59^-cell from Paroxysmal Nocturnal Hemoglobinuria Patients

Liu, Z.

1083 - Fusion Gene Map of Acute Myeloid Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 400 Cases in a Single Center
2915 - Fusion Gene Map of Acute Lymphoblastic Leukemia Revealed By Transcriptome Sequencing of a Consecutive Cohort of 350 Cases in a Single Center

Liu, Z.

162 - CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Liu, Z.

1163 - Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial

Liu, Z.

1272 - Prognostic Prediction Clinical-Molecular Model for Allogeneic Transplant Outcomes in Patients with Myelodysplastic Syndrome

Livak, K. J.

659 - Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter’s Syndrome
941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model
1297 - Genetic Determinants and Evolutionary History of Richter's Syndrome
1304 - IKZF3 Overexpression Phenocopies Gain-of-Function Mutation in Chronic Lymphocytic Leukemia
2433 - Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation

Livingston, M.

2512 - Comparing Effectiveness of Nitrous Oxide, Propofol, and Midazolam-Assisted Lumbar Punctures in Childhood Acute Lymphoblastic Leukemia

Livnat, T.

575 - The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Livneh, I.

2885 - RNF5 Defines Acute Myeloid Leukemia Growth and Susceptibility to Histone Deacetylase Inhibitors

Liyanage, P. Y.

2092 - R-Nanochop Incorporating a TFR1-Targeted Doxorubicin Nanocarrier Is Superior to R-CHOP in a PDX Model of Diffuse Large B-Cell Lymphoma

Lizarraga, S.

1825 - Supplementation of Barium to Cold-Stored Platelets Improves Platelet Quality over 7 Days of Storage

Ljungman, P.

2384 - COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)

Ljungström, V.

2215 - Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy

Llamas, C.

1914 - Real-World Treatment Patterns and Clinical Outcomes in Unfit Patients with AML Receiving First-Line Systemic Treatment or Best Supportive Care (CURRENT): Final Analysis
3145 - A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Llamas, P.

2411 - Impact of Sars-Cov-2 Infection in Hematopoietic Transplant Patients: Experience from the Madrid Group

Llanos, L.

2446 - Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Llanos, M.

2923 - Diffuse Large B Cell Lymphoma Genetic Classification By Targeted Sequencing and Associations with Immunochemotherapy-Treated Patients’ Clinical Outcome

Llavata Martí, L.

2489 - Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival

Lledo, L.

2224 - Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Llewellyn, M. J.

2447 - Multiplex CRISPR/Cas9 Genome Editing Targeting the BCL11A/HBG Axis Maximizes Fetal Hemoglobin Reinduction but Generates Chromosomal Translocations Which Persist In Vivo

Llobera Rius, L.

2489 - Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival

Lo, A. C.

2067 - Cardiac Morbidity in Adolescents and Young Adult Survivors of Hodgkin Lymphoma

Lo, C.

680 - Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant

Lo, F. Y.

1985 - Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia

Lo, M.

1649 - Digital Life Coaching for Myeloma Patients Undergoing Transplantation
2352 - Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy
2353 - Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes
3454 - Direct Oral Anticoagulants (DOACs) Vs. Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) in Patients with Primary Brain Tumors or Secondary Brain Metastases

Lo Nigro, L.

399 - Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Lob, H. E.

2606 - Anti-GDF11Treatment of β-Thalassemia Intermedia Mice Does Not Improve Erythropoiesis

Lobbes, H.

2589 - Pure Red Cell Aplasia in Systemic Lupus Erythematosus, a Nationwide Retrospective Cohort and Review of the Literature

Lobner, K.

1845 - JAK2 V617F Prevalence Study: Associations in the General Population and Vascular Disease Populations

Locatelli, F.

4 - Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9–Modified CD34+ Hematopoietic Stem and Progenitor Cells
77 - Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study
138 - Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Analysis of a Multinational, Prospective, Observational Registry Study
153 - Long-Term Efficacy and Safety of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia: Results in Patients with up to 6 Years of Follow-up
154 - Favorable Outcomes in Pediatric Patients in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia
164 - A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study
268 - Superior Event-Free Survival with Blinatumomab Versus Chemotherapy in Children with High-Risk First Relapse of B-Cell Precursor Acute Lymphoblastic Leukemia: A Randomized, Controlled Phase 3 Trial
399 - Clinical Implications of Minimal Residual Disease Detection in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol
560 - Outcome of Children with Different Non-Malignant Disorders Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
776 - Improvement in Erythropoiesis Following Treatment with Betibeglogene Autotemcel Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia in the Phase 3 Hgb-207 Study
977 - Blinatumomab in Children with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R-ALL): Final Results of 110 Patients Treated in an Expanded Access Study (RIALTO)
1008 - Efficacy, Safety, and Pharmacokinetics (PK) of Azacitidine (AZA) in Children and Young Adults with Acute Myeloid Leukemia (AML) in the Phase 2 AZA-AML-004 Trial
1076 - Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
1093 - Incidence and Therapeutic Implications of Germline TP53 Mutations in Hypodiploid Childhood Acute Lymphoblastic Leukemia: A Retrospective Analysis of the Italian Cohort
1699 - Response of Patients with Transfusion-Dependent β-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers
2181 - NF1 Tumor Suppressor Gene Inactivation in Juvenile Myelomonocytic Leukemia: New Genetic Evidence and Consequences for Diagnostic Work-up
2892 - Impact of Minimal Residual Disease (MRD) Assessed before Transplantation on the Outcome of Children with Acute Myeloid Leukemia Given an Allograft: A Retrospective Study By the I-BFM Study Group
2907 - Recurrent Genetic Fusions Redefine MLL-Germline Acute Lymphoblastic Leukemia in Infants
3266 - Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH)
3278 - Safety of Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis: Results of the Primary Analysis of the Pivotal Phase 2/3 Study

Lock, E.

1683 - Multiomic Profiling of Iron Deficient Infant Monkeys Detects Biochemical Signatures of Inflammatory and Neural Dysfunction in Blood and CSF Prior to Anemia

Lock, R. B.

1891 - A Novel Engineered Single-Chain Antibody Fragment for Targeting Pediatric Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Locke, F. L.

1120 - One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
1126 - Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
1187 - Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
1200 - Ibrutinib before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results from a Phase 1b Study
1431 - Metabolically Flexible CAR T Cells (mfCAR-T), with Constitutive Expression of PGC-1α Resistant to Post Translational Modifications, Exhibit Superior Survival and Function in Vitro
1451 - Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel
2100 - Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product

Locke, S. C.

2572 - Patient Experiences with Liposomal Daunorubicin and Cytarabine (CPX-351) Versus Conventional Induction Regimens: An Analysis of Patient-Reported Outcomes Data from a Prospective Trial

Lockerbie, O.

1364 - Novel Alkylating Agent Melflufen Displays Potent Efficacy in Plasma Cell Leukemia Samples and Other High-Risk Subtypes of Multiple Myeloma

Lockey, T.

1444 - Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience

Lockmer, S.

1143 - Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Lockwood, B.

2815 - Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Loda, M.

2270 - RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma

Lodi, A.

527 - Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor
2456 - The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells
2860 - Dual Targeting of Mitochondrial Vulnerability Using Complex I Inhibitor Iacs-010759 with Bcl-2 Inhibitor Venetoclax and Azacitidine in Pre-Clinical Acute Myeloid Leukemia (AML) Models

Lodie, T.

63 - Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Loeb, A.

1959 - Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Loeb, D.

1658 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease

Loeb, L. A.

963 - Co-Occurring Mutation Clusters Predict Drug Sensitivity in Acute Myeloid Leukemia

Loewecke, F.

1768 - Novel Splice-Site Mutation in RASGRP2 Leading to Caldag-GEFI Deficiency

Löffner, K.

627 - Targeting Protein S Using Small Interfering RNA Is Well Tolerated and Protects Mice with Hemophilia a from Acute Hemarthrosis

Loftus, J. P.

699 - DYRK1A Is Required to Alleviate Replication Stress in KMT2A-Rearranged Acute Lymphoblastic Leukemia

Logan, A. C.

1526 - Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

Logan, B.

75 - A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
186 - Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT)
297 - Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative
563 - Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation
2341 - BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
2385 - Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation
3305 - Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Logan, E.

2856 - Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in a Phase 1 Clinical Trial

Loges, S.

1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Loggers, E.

3485 - Patient-Reported Outcomes at Time of CAR-T Cell Therapy

Loghavi, S.

29 - Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies
332 - Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
335 - Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I Versus Type II FLT3-Inhibitors (FLT3i’s)
590 - Response Patterns and MRD By Flow Cytometry and NGS in Patients with Mutant-IDH Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents
1079 - Development of TP53 Mutations over the Course of Acute Myeloid Leukemia Therapy
1089 - Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with NPM1-mutated Acute Myeloid Leukemia
1092 - Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens
1119 - Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression
2147 - Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia
3071 - Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Loginova, A.

3299 - Total Body Irradiation Among Recipients of Tcrαβ /CD19- Depleted Grafts in a Cohort of Children with Hematologic Malignances: Single Center Experience

Loglisci, G.

1238 - Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study
3077 - Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the “Registro Italiano LMC & Campus CML”

Logtenstein, R.

2452 - A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing

Loguinov, A.

670 - Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Loh, M.

3490 - Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML)
3491 - Decisional Involvement, Information Preferences, and Prognostic Optimism Among Patients with Hematologic Malignancies
- Session Introduction

Loh, M. L.

Loh, Y. S. M.

3306 - HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-Αβ and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies: Three-Year Follow-up of Multicenter Study in Singapore

Lohmeyer, J. K.

2329 - RNA and TCR Sequencing Shed Light on Mechanisms of Treg Suppression in a Murine Model of Acute GvHD
3255 - Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet

Lohrmann, E.

3028 - A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase

Loiseau, C.

2857 - Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Loiselle, C.

464 - Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study
1014 - Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Lok, A.

3300 - Absence of Influence of the Pre-Transplant Immune Status of Recipients on Survivals and Gvhd after Allogeneic Stem Cell Transplantation: A Retrospective Study of 195 Cases

Loken, M. R.

593 - Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol
1959 - Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Lokhandwala, P.

2634 - Low Rates of Transfusion Transmitted Infection Screening in Chronically Transfused Adults with Sickle Cell Disease

Lokhnygina, Y.

505 - Renal Function Is Preserved after Hematopoietic Stem Cell Transplantation for Sickle Cell Disease

Lomaia, E.

LBA-4 - Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Lomazzi, S.

36 - Large-Scale Proteomics Identifies Distinct Signatures for Richter Syndrome and De Novo Diffuse Large B-Cell Lymphoma: A French Study from the Filo Group
1300 - Clinico-Biological, Molecular and Prognostic Features of Patients with Diffuse Large B-Cell Lymphoma-Variant of Richter Syndrome: A Multicenter Retrospective Study of the French Innovative Leukemia Organization

Lombardi Story, J.

1261 - Evaluation of a Pan-Lysyl Oxidase Inhibitor, Pxs-5505, in Myelofibrosis: A Phase I, Randomized, Placebo Controlled Double Blind Study in Healthy Adults
1935 - Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults
1952 - A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies

Lombardi Story, J.

994 - Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
1955 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Lombardo, A.

2984 - Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System
3484 - Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Londregan, J.

98 - Stromal Notch Ligands Drive Notch2-Dependent Transdifferentiation of Follicular B Cells into Marginal Zone-like B Cells in Lymphopenic Environments

Lone, W. G.

643 - DNMT3A Mutations Identify a Prognostic Subgroup in Peripheral T-Cell Lymphoma
2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution

Lonez, C.

990 - First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
993 - Results from the Phase I Clinical Studies Evaluating Cyad-01, a First-Generation NKG2D CAR T-Cell Product in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
1428 - Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed or Refractory Multiple Myeloma

Long, B.

1422 - Ruxolitinib, a JAK1/2 Inhibitor, Is Efficacious in a Novel Humanized GvHD Model Characterized By Enhanced NK, NK-T and T-Cell Engraftment

Long, G. D.

74 - Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant

Long, J. B.

308 - Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes

Long, L.

- Building a Contemporary Pain Management Strategy for SCD Patients in Your Practice in 2021

Long, M. J.

1074 - P53 Downregulation-Based Strategy to Protect Genomic Integrity from Radiation Therapy

Long, S. R.

641 - Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination
1144 - Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Long, T.

2528 - Incidence of Vascular Thromboembolic Events in Outpatients with Mild COVID-19

Long-Boyle, J. R.

1424 - 5-Azacytidine Depletes Hematopoietic Stem Cells and Synergizes with an Anti-CD117 Antibody to Augment Engraftment of Donor Stem Cells in Immunocompetent Mice
1457 - First Report of Non-Genotoxic Conditioning with JSP191 (anti-CD117) and Hematopoietic Stem Cell Transplantation in a Newly Diagnosed Patient with Severe Combined Immune Deficiency

Longarón, R.

2161 - Molecular Characterization and Clinical Outcomes of Young Adult Patients (≤45 years old) with Philadelphia-Negative Myeloproliferative Neoplasms

Longhitano, L.

2175 - Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients

Longley, R. M.

3493 - Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Longo, F.

778 - COVID 19 and Hemoglobinopathies: Update of the Italian Experience

Longoria, J.

1720 - Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease

Longval, T.

931 - Impact and Dynamics of TP53 Mutated Clones in Shwachman Diamond Syndrome in a Series of 80 Patients

Lonial, S.

Lonshteyn, A.

2627 - Real-World Effectiveness of Voxelotor for Treating Sickle Cell Disease in the US

Lontos, K.

1988 - Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Loo, S.

657 - Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
2192 - Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

Loo, S.

591 - Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Looney, T.

2467 - Characterization of the Immunoglobulin Heavy- and Light-Chain Repertoires in a Single Reaction

Loor Morán, Y.

898 - Use of Convalescent Plasma in COVID-19 Patients: Guayaquil, Ecuador Experience.

Loos, R.

779 - RAP-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia

Loos, R.

57 - Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study

Loperfido, M.

3283 - A Comprehensive High Resolution Scrna-Seq Analytical Platform for Characterizing Human Hematopoietic Stem/Progenitor Cells States in Ex Vivo Drug Products

Lopes, A. A.

3399 - A Real World Longitudinal Analysis of Anemia Treatment Prescriptions in Non-Dialysis-Dependent Chronic Kidney Disease Patients, a CKDopps Study

Lopes, C.

1006 - Disseminated Intravascular Coagulation Score Evolution in 48 Hours Predicts Early Death in Newly-Diagnosed Chemotherapy-Treated Acute Promyelocytic Leukemia Patients

Lopes de Menezes, D.

692 - CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial
779 - RAP-536 Induces Reticulocyte Maturation in Wild-Type Mice, Increases Survival of Beta-Thalassemic Reticulocytes, and Increases Red Blood Cells in a Mouse Model of Alpha-Thalassemia
2887 - CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells

Lopes, G. S.

1601 - Comparison of Clinical and Laboratory Features, Drug Availability, and Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil: A Retrospective Analysis of the Brazilian Registry of CLL

Lopez, A. L.

57 - Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study
489 - Waldenström’s Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

López Cadenas, F.

536 - Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
1274 - Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the “Sintra-REV” Clinical Trial
2763 - Germline GATA2 Mutations (R986Q and R398W) Inhibit Endothelial Development and Augment Myeloid Differentiation during Early Human Hematopoiesis

Lopez Corral, L.

2117 - Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

López, C.

1104 - Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

López, F.

3099 - Myelodysplastic Syndromes with 20q Deletion: Incidence, Prognostic Value and Impact on Response to Azacitidine of ASXL1 Chromosomal Deletion and Genetic Mutations

Lopez Jimenez, J.

1063 - Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia
1226 - Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma NOS Diagnosis: Comparative Study between PET, Histology and Flow Cytometry
1590 - Worldwide Examination of Patients with CLL Hospitalized for COVID-19
2883 - Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

López Jiménez, J.

312 - Impact of Sars-CoV2 Infection on 491 Hematological Patients: The Ecovidehe Multicenter Study
2384 - COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
2972 - Nodal Peripheral T-Cell Lymphoma with T Follicular-Helper Phenotype: A Different Entity? Results of the Spanish Retrospective Real-T Study

Lopez, J.

522 - A Synthetic Lethal Approach to Eradicate AML Via Synergistic Activation of Pro-Apoptotic p53 By MDM2 and BET Inhibitors

Lopez, J. A.

247 - Targeted Proteomics Reveals That the Dominant Mechanism of Gpibα Loss during Platelet Storage Depends on Temperature of Storage
1761 - Plasma Proteomic Profile Associated with Platelet Dysfunction after Trauma

López, J. A.

2722 - Human Platelets Stored at Room Temperature Demonstrate Diminished Resistance to Oxidative Stress Compared to Those Stored at 4°C

López Lorenzo, J. L.

85 - Correction of the Energetic Defects in Pyruvate Kinase Deficiency through Genome Editing in Hematopoietic Stem and Progenitor Cells
2446 - Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Lopez Lorenzo, J. L.

1082 - Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial
2384 - COVID-19 and Stem Cell Transplantation; Results from the Prospective Survey By the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
2805 - Impact of Sars-Cov-2 Infection in Acute Myeloid Leukemia Patients: Experience of the Pethema Registry

Lopez, M.

557 - Loss of TET2 Uncouples Proliferative and Effector Functions in CAR T Cells

Lopez, N.

578 - Filter Clotting with Continuous Renal Replacement Therapy in COVID-19

Lopez, N. H.

90 - Salubrinal Mediated Fetal Hemoglobin Induction through the eIF2α-ATF4 Signaling Pathway

Lopez Pascua, L.

2120 - Interim Cell-Free Circulating Lymphoma DNA Analysis of the Phase 2 Accept Trial

Lopez Prieto, C.

1226 - Bone Marrow Infiltration at Diffuse Large B-Cell Lymphoma NOS Diagnosis: Comparative Study between PET, Histology and Flow Cytometry

Lopez, R. D.

74 - Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant

Lopez, R.

3484 - Older Age and Increased Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms and COVID-19 Patients

Lopez Rubio, M.

1676 - Evans’ Syndrome in Adults: An Observational Multicentre Study

Lopez-Anglada, L.

2252 - Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma

López-Diaz de Cerio, A.

824 - Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance

López-Flores, N. J.

1766 - Low Dose Rituximab Plus High Dose Dexamethasone As First-Line Treatment for Autoimmune Hemolytic Anemia

Lopez-Guerra, M.

986 - Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Lopez-Guillermo, A.

1823 - Hemorrhage Is a Major Cause of Blood Transfusion in COVID-19 Patients
2098 - Final Analysis of the International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL in Response after R-CHOP, the Remarc Study from Lysa

López-Muñoz, N.

1968 - Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

López-Pavía, M.

634 - Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry

Lorand-Metze, I.

1075 - Developing a Simple Algorithm Based on Multiparameter Flow Cytometry for Fast Screening of Acute Promyelocytic Leukemia

Lörch, T.

195 - Machine Learning (ML) Can Successfully Support Microscopic Differential Counts of Peripheral Blood Smears in a High Throughput Hematology Laboratory
197 - Artificial Intelligence Substantially Supports Chromosome Banding Analysis Maintaining Its Strengths in Hematologic Diagnostics Even in the Era of Newer Technologies

Lord-Bessen, J.

1611 - Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Study

Loren, A. W.

41 - Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis
2224 - Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells
2495 - Using Virtual Reality to Promote Mindfulness Among Medical Trainees; A Study of Feasibility and Acceptance
- Leading Others

Lorens, J. B.

1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Lorens, K.

1908 - The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Lorentz, C. U.

237 - Safety and Efficacy of the Contact Activation Inhibitor AB023 in Patients with End-Stage Renal Disease on Chronic Hemodialysis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial

Lorentz, F.

2403 - Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Lorentzian, A.

2011 - MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential

Lorenz, S.

685 - Systems-Level Analysis of the Immune Repertoire in Neutropenia Reveal Arrested NK Cell Differentiation and Exhaustion
2029 - Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Lorenzi, L.

2131 - Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with MYC and BCL-2 and/or BCL-6 Gene Rearrangements or Increase Copy Number
3091 - Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Lorenzi, P.

527 - Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor
2799 - Population Pharmacokinetics of Eryaspase in Patients with Acute Lymphoblastic Leukemia or Pancreatic Adenocarcinoma

Lorini, L.

446 - Extensive Characterization of the Hemostatic Derangement Occurring in COVID-19 Patients Admitted to the Bergamo Hospital

Loron, S.

462 - Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively
496 - Viral Reactivation in Acute Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation in Complete Remission: Stimulation of the Immune System

Loschi, F.

190 - Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Loschi, M.

140 - Risk Factors for Severe Form of COVID-19 after Allogeneic Hematopoietic Stem Cell Transplantation: A SFGM-TC Multicentre Cohort Study
422 - Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use/Expanded Access Treatment Program

Loschirico, M.

1235 - Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study)

Loseto, G.

2030 - Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial

Losman, J. A.

445 - Rare Inherited Defects of the Complement System in Purpura Fulminans

Lossos, A.

2141 - Rituximab, Methotrexate, Procarbazine and Lomustine (R-MPL) for the Treatment of Primary CNS Lymphoma

Lossos, I. S.

338 - Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
705 - The Burkitt Lymphoma International Prognostic Index (BL-IPI)
706 - Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis
1209 - Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis
1210 - Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma
2050 - Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis
2097 - Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Lott, L. L.

593 - Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol

Lou, C. H.

2921 - Single-Cell Transcriptomics of Human TET2 Knockout CD4 T-Cells and Their Clonal Evolution

Lou, F.

1272 - Prognostic Prediction Clinical-Molecular Model for Allogeneic Transplant Outcomes in Patients with Myelodysplastic Syndrome

Lou, F.

1067 - A Risk Score Combined Clinical and Molecular Profiles Identifies a High-Risk Subgroup within AML1-ETO-Positive Acute Myeloid Leukemia

Lou, J.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials

Lou, Y.

1580 - Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors

Loubert, A.

2278 - DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Loughran, Jr., T. P.

278 - Analysis of Genomic Landscape of Large Granular Lymphocyte Leukemia Reveals Etiologic Insights
2770 - Recurrent Mutations of the C-C Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK)

Louis, C. U.

1617 - Changing Molecular Diagnostic Testing Patterns for Patients (Pts) with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) in the Connect^® MDS/AML Disease Registry
2523 - Post-Remission Treatment (Tx) Patterns for Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the Connect^® MDS/AML Disease Registry

Louis, S.

2982 - Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin’s Lymphoma Patients to First Line Therapy at Point of Diagnosis

Louissaint, Jr., A.

521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis

Lourenço, A. L.

1240 - COVID-19 in Chronic Myeloid Leukemia Patients – Brazilian Experience

Lourenço, F.

1006 - Disseminated Intravascular Coagulation Score Evolution in 48 Hours Predicts Early Death in Newly-Diagnosed Chemotherapy-Treated Acute Promyelocytic Leukemia Patients

Lousada, I.

1585 - Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments

Loustau, V.

840 - Risk Factors of Neonatal Immune Thrombocytopenia in Pregnant Women Previously Diagnosed with ITP: Results from a French Nationwide Prospective Study
2664 - Outcome of Immune Thrombocytopenia in Pregnancy: A French Nationwide Prospective Multicenter Observational Case-Control Study

Louw, A.

1673 - Lyn Kinase Activity Is Required for Akt Mediated Erythroleukemia Cell Differentiation

Louzada, M. L.

725 - Part 1 Results of a Dose Finding Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)
1607 - Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
2417 - Is Tandem ASCT Needed in MM Patients with High Risk Cytogenetics in the Era of Maintenance Therapy? Results from the Canadian Myeloma Research Group (CMRG) Database

Love, T.

1654 - Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study

Lovejoy, A.

1208 - Risk Profiling of De Novo DLBCL Patients By Measuring Circulating Tumor DNA

Lovelace, W.

129 - Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Lovitch, S. B.

521 - Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis
2186 - Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53

Lovrencic, B.

845 - Patients’ Reported Perceptions on Satisfaction with Immune Thrombocytopenia Treatments: Results from the ITP World Impact Survey (I-WISh)
1760 - A Patient’s Perspective on Impact of Immune Thrombocytopenia on Emotional Wellbeing: ITP World Impact Survey (I-WISh)
2668 - Higher Symptom Burden in Patients with Immune Thrombocytopenia Experiencing Fatigue: Results from the ITP World Impact Survey (I-WISh)

Low, J. G. H.

879 - Thrombotic Events in COVID-19 Patients and Its Comparison with Other Non-Sars-Cov-2 Respiratory Viruses

Low, R.

1782 - Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease

Low, S. K.

2549 - Malignant Progression of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review and Meta-Analysis

Lowdell, M. W.

160 - ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Lowe, H.

160 - ALLCAR19: Updated Data Using AUTO1, a Novel Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Lowekamp, B. C.

1106 - Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Lowenberg, B.

331 - Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia
2001 - TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia
2817 - Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab
2878 - Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Lowery, E. M.

205 - Real World Outcomes of Sars-Cov-2 Thrombosis Rates across Three University Health Systems in the Chicago Metropolitan Area

Lowman, G.

2467 - Characterization of the Immunoglobulin Heavy- and Light-Chain Repertoires in a Single Reaction

Lowman, H.

701 - A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Lowney, J.

2216 - Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)
3141 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter’s Syndrome

Lownik, J.

37 - Modeling Marginal Zone Lymphomagenesis

Lowsky, R.

354 - Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants
495 - Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis
736 - CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
975 - Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study
1507 - Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma
1788 - Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity
3322 - Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant
3332 - Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation

Loy, K.

3064 - Analysis of Mechanisms of Blast Crisis in Chronic Myeloid Leukemia By Whole Genome Sequencing

Lozano, M.

2673 - Caplacizumab As New Paradigm-Changing Therapy for Patients with Autoimmune Thrombotic Thrombocytopenic Purpura (aTTP): Real-World Data from TTP Spanish Registry

Lozanski, G.

1305 - Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
1312 - Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Lozier, J. N.

678 - Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis
2679 - Characterization of Protein Unable to Bind Von Willebrand Factor in Recombinant Factor VIII Products: Can We Reduce Their Immunogenicity?

Lozinsky, K.

1054 - A Phase II Study of Bisantrene in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Lozinsky, Y.

1106 - Integration and Iteration: Using Advanced, High-Content Imaging and Single-Cell Gene Expression Analysis to Uncover Unique Aspects of Follicular Lymphoma Biology

Lu, B.

2004 - FLT3 Inhibitors Induce Instability of p53 By Mir-181 Mediated Downregulation of Deubiquitinase YOD1 in Acute Myeloid Leukemia

Lu, C.

548 - Treatment of High Risk (HR) Smoldering Multiple Myeloma (SMM) with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed By Lenalidomide Maintenance (-R): A Phase 2 Clinical and Correlative Study
3159 - The Role of ¹⁸f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

Lu, D.

1434 - Multiplexed Engineered, Off-the-Shelf T Cells Carrying Three Tumor-Associated Antigen-Targeting Modalities: CAR + Pan-Tumor Targeting TCR + CD16 Fc Receptor
3263 - Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Lu, E.

739 - Preliminary Results of the First-in-Human Study of Nexi-001, a Multi-Antigen Specific CD8+ T Cell Product, in Acute Myeloid Leukemia (AML) Patients with Relapsed Disease after Allogeneic Hematopoietic Cell Transplantation (Allo-HSCT) Demonstrate Early Signs of Safety, Tolerability and Robust Immune Responses

Lu, G.

892 - Validation of a Modified Anti-FXa Assay on STA-Compact Analyzer for Measuring FXa Inhibitor Levels in the Presence of Andexanet Alfa

Lu, H.

2229 - Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies

Lu, J.

552 - Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda
1409 - Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study
1640 - Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study
2290 - Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Lu, J.

178 - Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Lu, J.

31 - Identification of Chemo-Resistant Residual Cell Population in Pediatric AML of Complete Remission By Single Cell RNA Sequencing

Lu, J.

350 - The IGLV3-21^R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome
565 - Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Lu, K.

2210 - CTP Synthase 2: A Novel Prognostic Biomarker and Potential Therapeutic Target in Chronic Lymphocytic Leukemia

Lu, L. C.

3057 - Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Lu, L.

2074 - Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Lu, M.

713 - Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Lu, M.

651 - Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
2153 - Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)
2164 - Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy

Lu, P.

159 - Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients
182 - An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma
200 - Detecting 24 Kinds of Cytokines Via Flow Cytometry Aimplex Kit Is an Effective Way to Monitor CRS after CAR-T Cells Infusion
270 - A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL)
1445 - Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant
1495 - Peripheral Blood Monoclonal B-Cell and/or Plasma Cell Detection By Flow Cytometry in Screening and Monitoring EBV-Positive Post-Transplant Lymphoproliferative Disorders
1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
2465 - One Tube 24 Color Full Spectral Flow Cytometry and Multi-Dimensional Software to Study the Maturation Pattern and Antigen Expression of the Myeloid
2821 - CD69 Is a Very Useful Marker for Minimal Residual Disease and Related Mast Cell Assessment of Acute Myeloid Leukemia

Lu, Q.

24 - A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results
334 - Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib
995 - Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia

Lu, S.

9 - A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription

Lu, S. X.

436 - Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients
518 - ZRSR2 Mutation Induced Minor Intron Retention Drives MDS and Diverse Cancer Predisposition Via Aberrant Splicing of LZTR1
1369 - Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study
2307 - A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)
3204 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study

Lu, T.

2091 - Discovery of JNJ-67856633: A Novel, First-in-Class MALT1 Protease Inhibitor for the Treatment of B Cell Lymphomas

Lu, V.

48 - Outcome By Mutation Status and Line of Treatment in Optic, a Dose-Ranging Study of 3 Starting Doses of Ponatinib in Patients with CP-CML
647 - Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
2842 - A Phase 1/2 Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome–Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
3200 - In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Lu, V.

501 - Novel CoupledCAR^TM Technology for Treating Colorectal Cancer

Lu, W.

1941 - CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Lu, X.

1654 - Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study

Lu, X.

2882 - Hyperglycemia Cooperates with Tet2 Heterozygosity to Induce Leukemia Driven By Pro-Inflammatory Cytokine Induced Lncrna Morrbid

Lu, X.

1341 - Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma
3236 - Integrative Analysis of the Genomic and Transcriptomic Landscape of Relapsed/Refractory Multiple Myeloma Patients Treated With Venetoclax in Combination With Bortezomib and Dexamethasone: Biomarker Analyses From the Phase 3 BELLINI Study

Lu, X. A.

161 - Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (b-all) Patients

Lu, X.

1898 - Factors Predicting Long-Term Survival Following CD19 CAR T-Cell Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Lu, X.

2456 - The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Lu, X.

416 - Circularly Permuted TRAIL (CPT) Combined with Thalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (CPT-MM301)

Lu, Y. C.

326 - Cell Cycle Regulates Phosphorylation of RUNX1 to Modulate Megakaryocyte-Erythroid Progenitor Fate Specification

Lu, Y.

4 - Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9–Modified CD34+ Hematopoietic Stem and Progenitor Cells

Lu, Y.

459 - Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial

Lu, Y.

1445 - Significant Long-Term Benefits of CAR T-Cell Therapy Followed By a Second Allo-HSCT for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Who Relapsed after an Initial Transplant

Lu, Y.

1882 - Cigarette Smoke or Cigarette Condensate Exposure Enhances Growth of FLT3-ITD AML Models and Alters DNA Methylation and Leukemic Gene Expression

Lu, Z.

1831 - YY1 Promotes SCF/c-Kit Signaling and HSC Self-Renewal in Fetal Hematopoiesis
2738 - A Lineage-Specific Requirement for YY1 Polycomb Group Protein Function in Early T Cell Development

Lu, Z.

1140 - Pooled Analysis of Safety Data from Clinical Trials of Orelabrutinib Monotherapy in Hematologic Malignancies
2048 - Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study

Lu, Z.

1989 - Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Luan, D.

348 - Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK^C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia
1205 - Evaluation of the Prognostic Utility of Bone Marrow Biopsy in Diffuse Large B-Cell Lymphoma: A SEER-Medicare Linked Database Analysis
2362 - Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Lubach, G.

1683 - Multiomic Profiling of Iron Deficient Infant Monkeys Detects Biochemical Signatures of Inflammatory and Neural Dysfunction in Blood and CSF Prior to Anemia

Luban, N.

1824 - Impact of Universal Irradiation on Chronic Transfusion for Sickle Cell Disease

Lubega, J.

1084 - Effects of Race and Ethnicity on Clinical Features, Tumor Genetics and Outcome in Children with KMT2A Rearranged Acute Myeloid Leukemia

Lubetsky, A.

575 - The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease

Lubowitzki, S.

359 - Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial

Lucas, A. N.

2110 - Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma
3025 - Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Lucas, A.

3249 - Tissue-Derived IL-33 Is a Critical Local Signal That Targets Th1 Cells in the Small Intestine to Sustain Graft Versus Host Disease in the Absence of IL-12

Lucas, C. L.

SCI-45 - Human PI3K Mutations: Immunodeficiency and Malignancy

Lucas, F.

941 - RPS15 and TP53 Co-Mutation Drives B Cell Malignancy through Altered Translation and MYC Activation in a Murine Model

Lucas, L. F.

1352 - Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results
2416 - Preliminary Results of Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone: A Quadruplet Intensified Treatment for Newly Diagnosed Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients

Lucas, S.

3459 - A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Lucas, T. L.

868 - Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices

Lucas-Alcaraz, D.

450 - In Situ Fate Mapping of Native and Stress Myelopoiesis Reveals a Unique Niche for Mono- and Dendritic Cell –Poiesis
906 - Complete Spatial Mapping of Steady-State and Stress Erythropoiesis

Lucchesi, A.

652 - Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Lucco Navei, G.

1554 - Minimal Residual Disease (MRD) at 10^-6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication)

Luce, J.

722 - Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma

Lucero, K. T.

2562 - Population Based Analysis of Mantle Cell Lymphoma in Texas: Are Outcomes Any Different in Hispanics?

Luchkin, A. V.

2542 - Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry
2759 - Stromal Precursors in the Bone Marrow of Untreated Patients with Severe and Non-Severe Aplastic Anemia Differ in the Proliferative Potential

Luchtman-Jones, L.

3408 - Assessing Barriers to Medication Adherence in Pediatric and Adolescent and Young Adult (AYA) Patients on Anticoagulation

Luciani, M.

236 - Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Paediatric Patients: Combined Data from Five Paediatric Clinical Trials
239 - Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial
889 - Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia
891 - Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Pediatric Patients with Venous Thromboembolism

Luciano, L.

50 - Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study
2156 - Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Lucidarme, O.

2462 - The Role of PET-MRI in Multiple Myeloma Patients

Lucio, P.

3238 - Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone

Luck, Jr., J. V.

1790 - PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Luckevich, M.

1566 - Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch

Luckhurst, C. M.

2714 - A Low Dose Heparinized Saline Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Ludewig, B.

98 - Stromal Notch Ligands Drive Notch2-Dependent Transdifferentiation of Follicular B Cells into Marginal Zone-like B Cells in Lymphopenic Environments
731 - MHC Class II on Ccl19⁺ Reticular Cells Mitigates Graft-Versus-Host Disease Via Maintenance of Regulatory T Cells

Ludkovski, O.

2982 - Three-Dimensional Telomere Analysis Using Teloview® Technology Predicts the Response of Classic Hodgkin’s Lymphoma Patients to First Line Therapy at Point of Diagnosis

Ludvigsen Al-Mashhadi, A.

2985 - Outcome of Limited Stage Peripheral T-Cell Lymphoma after CHOP(-like) Therapy: A Population Based Study of 251 Patients from the Nordic Lymphoma Epidemiology Group

Ludvigsen, M.

71 - Clonal Hematopoiesis Drives Therapy-Related Myeloid Neoplasms Following Autologous Stem Cell Transplantation and Propagates during Disease Evolution

Ludwig, C.

1603 - Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Ludwig, D.

2875 - Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study

Ludwig, H.

57 - Longitudinal Immunogenomic Profiling of Tumor and Immune Cells for Minimally-Invasive Monitoring of Smoldering Multiple Myeloma (SMM): The Immunocell Study
142 - Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study
550 - Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)
2292 - Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the ‘Use Via Early Access to Ixazomib’ (UVEA-IXA) Study
3225 - Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)
3226 - Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Lue, J. K.

3013 - Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

Luebbert, M.

275 - Next-Generation Sequencing (NGS)-Based Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication (FLT3-ITD⁺ AML) Treated with Additional Midostaurin
654 - Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial
2807 - Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial
2896 - Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Luff, S. A.

253 - Generation of Retinoic Acid-Dependent Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells

Lufkin, J.

1726 - Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Luft, T.

3262 - Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Luger, S. M.

388 - Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
433 - Factors Associated with High Healthcare Utilization at the End-of-Life (EOL) for Patients with Acute Myeloid Leukemia
1958 - Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation
2148 - Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
3493 - Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)

Luger, T.

537 - DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents
1273 - Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Lugtenburg, P. J.

402 - Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
535 - ¹⁸f-FDG PET/CT Baseline Rdiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients

Lugthart, S.

1726 - Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Luider, T.

3156 - Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Luis, H. C.

1769 - Characterization of the Platelet Phenotype Caused By a Germline RUNX1 Variant in a CRISPR/Cas9-Generated Murine Model

Luk, A.

102 - COVID-19 Convalescent Plasma Decreased Oxygen Requirement and Hospital Stay in COVID-19 Hospitalized Patients Including Those with Hematological Malignancies: A Report of 16 Patients
313 - COVID-19 in Patients with Hematological Malignancies: High False Negative Rate with High Mortality

Lukasik, B.

1456 - Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases

Lulla, P.

609 - Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study
612 - Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Lulla, S.

612 - Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Lumbreras, E.

1274 - Sequential Study By RNA-Seq Shows a Reduction in Inflammation and a Cell Cycle Activation in T-Lymphocytes from Myelodysplastic Syndrome with Del(5q) after Lenalidomide Treatment in Patients Included in the “Sintra-REV” Clinical Trial

Lumbreras, E.

536 - Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Luminari, S.

2026 - Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma
2124 - IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study

Lummertz da rocha, E.

1986 - Mechanisms of Leukemia Stem Cell Plasticity Revealed By Single Cell Analysis
2730 - Single Cell Resolution Mapping of Hematopoietic Stem and Progenitor Cell States throughout Human Life

Luna, A.

1063 - Prognosis Impact of Positive Minimal Residual Disease By Flow Cytometry Prior to Transplant According to the Cut-Off Threshold in Patients with Acute Myeloid Leukemia
1241 - Safety and Efficacy Profile of Asciminib As Treatment in Chronic Myeloid Leukemia Patients after Several Tyrosine-Kinase Inhibitors Failure
2883 - Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes According to the Different Subgroups of the WHO 2016 Classification in Patients Candidates to Intensive Chemotherapy

Luna-Gonzalez, M.

2430 - Survival in Patients Who Underwent HLA-Haploidentical Stem Cell Transplantation in Two Centers in Colombia

Lund Hansen, D.

1676 - Evans’ Syndrome in Adults: An Observational Multicentre Study

Lund, J. L.

1645 - Prognosis of Older Adults with Chronic Lymphocytic Leukemia By Comorbidity and Frailty: A SEER-Medicare Cohort Study
3448 - Venous Thromboembolism Incidence and Impact on Survival in Patients with Brain Metastases

Lundberg, L.

403 - Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
1198 - Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing

Lundh, S. M.

351 - B-CLL Mediated Resistance to CAR T Cell Therapy Via Insufficient Activation Is CAR-Independent

Lundin, V.

11 - An Essential Role for the RNA Editor-Exonuclease Axis in Terminal Erythroid Differentiation

Lundquist, A. L.

578 - Filter Clotting with Continuous Renal Replacement Therapy in COVID-19

Lunec, J.

697 - Preclinical Investigation of the p53-MDM2 Antagonist Idasanutlin (RG7388) Demonstrates Significant Activity in High Risk Adult Acute Lymphoblastic Leukemia

Lunghi, M.

1927 - A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Lunkad, N.

2906 - Monosomy 7 and Co-Occurrent Genomic Aberrations Determine Chemotherapy Response in Acute Myeloid Leukemia (AML) Patients Using the Cellworks Omics Biology Model (CBM): Mycare-021-04

Lunn, M. P.

1782 - Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease
2061 - High-Dose Methotrexate Based Therapy for the Treatment of Bing Neel Syndrome
2948 - Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis

Lunning, M. A.

118 - Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
703 - Safety, Pharmacokinetics and Activity of CA-4948, an IRAK4 Inhibitor, for Treatment of Patients with Relapsed or Refractory Hematologic Malignancies: Results from the Phase 1 Study
705 - The Burkitt Lymphoma International Prognostic Index (BL-IPI)
2945 - A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of a Novel IRAK4 Inhibitor CA-4948 in Combination with Ibrutinib, in Patients with Relapsed or Refractory Hematologic Malignancies
2955 - Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Luo, A.

2461 - Deep Learning for Distinguishing Morphological Features of Acute Promyelocytic Leukemia

Luo, H.

105 - Hottip-Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/b-Catenin Pathway in AML Genome

Luo, J.

2053 - Waldenström’s Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Luo, M.

2859 - Phase I Clinical Trial of Autologous CLL1 CAR-T Therapy for Pediatric Patients with Relapsed and Refractory Acute Myeloid Leukemia

Luo, S.

3451 - Elevated International Normalized Ratio (INR) Did Not Prevent Against Thrombosis in Patients with Chronic Liver Disease (CLD): A Population Based Study

Luo, X.

2376 - Changes of Hepatitis B Immune Status after Allogeneic Hematopoietic Stem Cell Transplantation in HBsAg Negative/Anti-Hbc Positive Patients: A Single Center Observational Study
2392 - Mesenchymal Stem Cells (MSCs) Intensify the Impact of KIR Ligand-Mismatching on Acute Graft-Versus-Host Disease Post HSCT in Patients with Acute Myeloid Leukemia but Not with Acute Lymphocytic Leukemia
2909 - DNA Methylation-Mediated Silencing of Mir-204 Enhances the Occurrence of T-Cell Acute Lymphoblastic Leukemia By Upregulating MMP-2 and MMP-9 through the NF-Κb Signaling Pathway
3295 - Antibodies to Hepatitis B Surface Antigen (HBsAb) Are Acquired after Allogeneic Stem Cell Transplantation in Non-B Hepatitis Virus-Infected Patients but Disappear over Time

Luo, X.

238 - Reversal of Anticoagulation By Ciraparantag: Time to Onset and Duration of Effect
2718 - Design of a Randomized, Controlled Study to Evaluate Reversal of Anticoagulation of Ciraparantag in Healthy Adults: Whole Blood Clotting Time Assessed By Automated and Manual Methods

Luo, X.

1887 - Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4

Luo, X.

3398 - Effectiveness and Safety of Apixaban Vs Warfarin Among Venous Thromboembolism Patients Using Five US Databases: A Subgroup Analysis of Obesity

Luo, Y.

2394 - Salvage Therapy with Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem Cell Transplantation
2398 - Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT

Luo, Y.

501 - Novel CoupledCAR^TM Technology for Treating Colorectal Cancer

Luoma, S.

3217 - Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Luong, H. A.

2772 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia

Luppi, M.

392 - Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol
632 - Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy
2214 - Indoleamine 2,3-Dioxygenase Mediates Survival of Chronic Lymphocytic Leukemia B Cells through Aryl Hydrocarbon Receptor By Inducing Mcl1

Lupsa, N.

1487 - B-T Cell Interactions in GRAFT-Versus-Host Disease

Luptakova, K.

55 - CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, in Combination with Ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis Patients: Update of MANIFEST Phase 2 Study
56 - CPI-0610, Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As “Add-on” to Ruxolitinib, in Advanced Myelofibrosis Patients with Suboptimal Response: Update of MANIFEST Phase 2 Study
2163 - CPI-0610, a Bromodomain and Extraterminal Domain Protein (BET) Inhibitor, As Monotherapy in Advanced Myelofibrosis Patients Refractory/Intolerant to JAK Inhibitor: Update from Phase 2 MANIFEST Study
3079 - The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells
3085 - MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI‑0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients

Luquet, I.

2857 - Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup

Lurain, K.

2105 - Phase I Study of Lenalidomide Combined with Dose-Adjusted EPOCH and Rituximab (EPOCH-R²) in Primary Effusion Lymphoma in Participants with or without HIV (NCT02911142)

Lurienne, L.

3406 - Incidence of CDI in a Cohort of US Patients with Newly Diagnosed Acute Myeloid Leukemia Receiving Intensive Chemotherapy

Lusina, D.

3112 - Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study

Luskin, M. R.

587 - Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials
714 - Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Hematopoietic Stem Cells in JAK2-Mutant Myeloproliferative Neoplasms
1038 - Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML)
1911 - Distinct Clinical and Genetic Factors Predict Early Versus Late Mortality in AML Patients Undergoing Induction Chemotherapy
2810 - Incidence and Risk Factors for Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
3349 - Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Luskin, M. R.

170 - Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings
190 - Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies

Lussana, F.

614 - Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
741 - Donor-Derived CAR T Cells Engineered with Sleeping Beauty Achieve Anti-Leukemic Activity without Severe Toxicity
1081 - Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group

Lust, J. A.

1302 - Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis
1336 - A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders
2244 - MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients
2257 - The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma
2280 - Continued Improvement in Survival of Patients with Newly Diagnosed Multiple Myeloma (MM)
2306 - Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)
3160 - Sequential Comparison of Conventional Serum Immunofixation (IFE) to Mass Spectrometry-Based Assessment (MASS FIX) in Patients with Multiple Myeloma (MM)
3165 - Prognostic Impact of PET Findings Post-Transplant in Multiple Myeloma
3184 - Assessing the Utility of Monitoring IgA Multiple Myeloma Patients with Quantitative Serum IgA Levels
3196 - Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
3228 - Unmet Needs in AL Amyloidosis: Outcomes in the Modern Era Among the Highest Risk, Newly Diagnosed AL Amyloidosis Patients

Lustberg, M.

2815 - Psychological Distress in Young Adults with Acute Myeloid Leukemia Undergoing Induction Chemotherapy

Lustgarten, S.

44 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Lutfi, F.

1216 - Pseudo-Allogeneic CAR-T Therapy after Allogeneic Stem Cell Transplantation in Relapsed/Refractory B-Cell NHL
2351 - Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
3365 - Long-Term Outcomes of Busulfan, Fludarabine and 400 Cgy Total Body Irradiation Versus Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Hematologic Diseases: A Large Single Center Experience

Lütgehetmann, M.

1001 - Challenges in Treatment of Patients with Acute Leukemia and COVID-19 – a Series of 12 Patients

Lüthi, J. M.

3338 - High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

Luthra, R.

1092 - Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens
2201 - Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Lutska, Y.

549 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy
3243 - Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Lutwak, E.

727 - A Novel Therapy-Resistance Transcriptional Signature Based on Single Cell Analysis in Kydar Clinical Trial

Lutz, R.

1326 - The Bone Marrow Microenvironment of Multiple Myeloma Long-Term Survivors at Single Cell Resolution

Lutzko, C.

680 - Early Results from a Phase 1/2 Study of Aru-1801 Gene Therapy for Sickle Cell Disease (SCD): Manufacturing Process Enhancements Improve Efficacy of a Modified Gamma Globin Lentivirus Vector and Reduced Intensity Conditioning Transplant

Lützner, J.

2744 - High Prevalence of Clonal Hematopoiesis in Patients Undergoing Hip Replacement Surgery - Implications for Experimental Models and Association with Autoimmune Disease

Luu, B. W.

508 - Disentangling the Effects of HLA DRB1*15:01 and DQB1*06:02 to Establish the True HLA Risk Allele for Inhibitor Development in the Treatment of Hemophilia A

Luu, B. W.

1785 - N-Linked Glycans on Therapeutic Factor VIII (FVIII) Proteins Attenuate Immunogenicity Potential: Evidence from Independent HLA-Class-II/FVIII (HLAcII/FVIII) Peptidomes

Lux, L.

2714 - A Low Dose Heparinized Saline Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Luzi, D.

2156 - Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib

Luznik, L.

33 - An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia
297 - Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative
2341 - BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
2443 - Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use
2797 - Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2^nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL
2878 - Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia
3350 - Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Lv, F.

1116 - Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action

Lv, L.

2349 - Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Lv, R.

128 - Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Lv, R.

279 - Genomic and Transcriptomic Profiling Reveals Distinct Subsets Associated with Outcomes in Mantle Cell Lymphoma
1509 - Safety and Efficacy of GBC/GBM Conditioning Regimen Followed By Autologous Stem Cell Transplantation in Lymphoid Malignancies
2349 - Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
2949 - Minimal Residual Disease Assessment Is an Independent Prognostic Factor in Splenic Marginal Zone Lymphoma

Lv, X.

182 - An Anti-Bcma CAR T-Cell Therapy (C-CAR088) Shows Promising Safety and Efficacy Profile in Relapsed or Refractory Multiple Myeloma

Lv, X.

9 - A Novel Lncrna, Lncery, Interacts with Wdr82 to Regulate Erythroid Differentiation By Promoting Globin Gene Transcription

Lvova, O.

889 - Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia

Lwin, T.

972 - Pharmaocogenomic Characterization of MCL-1 Inhibitor Response and Resistance in Aggressive B-Cell Lymphomas

Ly, L. C.

156 - ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression

Ly, S.

1978 - AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Lyapichev, K. A.

1119 - Immune Evasion Phenotype Is Common in Richter Transformation Diffuse Large B-Cell Lymphoma and Correlates with CD30 Expression

Lycan, T.

3404 - Just-in-Time Teaching (JiTT) Screencasts: A Randomized Controlled Trial of Asynchronous Learning on an Inpatient Hematology-Oncology Service

Lyden, E. R.

1613 - Early Mortality and Overall Survival in Acute Promyelocytic Leukemia: Do Real-World Data Match Results of the Clinical Trials?
2955 - Thirty-Five Year Follow-up Analysis of Follicular Lymphoma Patients Treated through the Nebraska Lymphoma Study Group: Prognostic Factor Analysis and Outcomes

Lyerly, H.

2455 - Targeting the Glucagon Receptor Signaling Pathway As a Novel Strategy to Counteract PI3K Inhibitor Induced Hyperglycemia While Sustaining Tumor PI3K Inhibition

Lyerly, S.

633 - Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)

Lykon, J.

2852 - Real World Outcomes of Liposomal Daunorubicin and Cytarabine Versus 7+3 in Patients with Secondary Acute Myeloid Leukemia

Lyman, G. H.

204 - Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
1632 - Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Lymp, J.

1196 - Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study
2514 - Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Lynch, A.

2750 - Bone Marrow Stromal Antigen 2 Is Critical for IFNy-Dependent Hematopoietic Stem Cell Activation

Lynch, J. M.

1307 - MRD-Driven Time Limited Therapy with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Previously Untreated Chronic Lymphocytic Leukemia

Lynch, M.

2600 - Proof of Concept for the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non–Transfusion-Dependent Thalassemia: Interim Results from an Ongoing, Phase 2, Open-Label, Multicenter Study

Lynch, R. C.

1632 - Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis
2051 - Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen
2111 - Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
2964 - Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
3048 - Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Lynch, R. C.

2935 - Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
2943 - Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
3038 - Real World Outcomes of Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy: An Updated Analysis

Lynggaard, L. S.

467 - NOR-GRASPALL2016 (NCT03267030): Asparaginase Encapsulated in Erythrocytes (eryaspase) – a Promising Alternative to Peg-Asparaginase in Case of Hypersensitivity
585 - The Association between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in the NOPHO ALL2008 Protocol

Lyons, J. F.

1056 - Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Lyons, R. M.

3200 - In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study
3405 - Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method

Lys, M. J.

3108 - A Revised International Prognostic Scoring System of 3.5 Points Stratifies Patients with Myelodysplastic Syndromes into 2 Risk Categories

Lysak, D.

3140 - Acalabrutinib Vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Ascend Final Results

LYSARC study group, L.

2118 - Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project

Lyski, R.

2089 - SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies

Lyssiotis, C.

2578 - Metabolomic Characterization of Red Blood Cell Differentiation

Lyu, H.

1941 - CD19 CAR-T Cells Treatment Conferred a Sustained Remission in Patients with Chemotherapy-Refractory MRD in B-ALL

Lyu, J.

260 - Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

Lyu, M.

2748 - M2 Macrophages, but Not M1 Macrophages, Support Megakaryopoiesis Via up-Regulating PI3K-AKT Pathway

Lyu, M. A.

3083 - Adoptive Therapy with Allogeneic Cord Blood T Regulatory Cells Show Safety and Early Clinical Signal in Primary Myelofibrosis

Lyu, S.

2747 - Single-Cell Transcriptome of Early Hematopoiesis Guides Arterial Endothelium-Promoted Functional T Cell Generation from Human Pluripotent Stem Cells

Lyu, Z. S.

2748 - M2 Macrophages, but Not M1 Macrophages, Support Megakaryopoiesis Via up-Regulating PI3K-AKT Pathway
3318 - M1 and M2 Macrophages Play Different Roles in the Pathogenesis of Acute Graft-Versus-Host Disease Post-Allotransplant By Modulating Immune Microenvironment

Author Index: L